Vitamin D-tour : cognition and depression: the role of vitamin D and its interplay with glucose homeostasis by Brouwer-Brolsma, E.M.
VITAMIN D-TOUR
Cognition and depression: the role of vitamin D and its interplay with glucose 
homeostasis
Elske Maria Brouwer-Brolsma
 Thesis committee
Promotors
Prof. Dr C.P.G.M. de Groot
Personal chair at the Division of Human Nutrition
Wageningen University
Prof. Dr E.J.M. Feskens
Personal chair at the Division of Human Nutrition
Wageningen University
Co-promotors
Prof. Dr T. Schuurman
Professor in Behavioural and Neurobiology
Wageningen University
Dr W.T. Steegenga
Assistant professor, Division of Human Nutrition
Wageningen University
Other members
Prof. Dr J.M. Dekker, VU University Medical Center Amsterdam
Prof. Dr B. Kemp, Wageningen University
Dr M. van Boxtel, Maastricht University
Dr J.M.T. Klein Gunnewiek, Hospital Gelderse Vallei, Ede
This research was conducted under the auspices of the Graduate School VLAG 
(Advanced studies on Food Technology, Agrobiotechnology, Nutrition and Health 
Sciences). 
VITAMIN D-TOUR
Cognition and depression: the role of vitamin D and its interplay with glucose 
homeostasis
Elske Maria Brouwer-Brolsma
Thesis
submitted in fulfilment of the requirements for the degree of doctor
at Wageningen University
by the authority of the Rector Magnificus
Prof. Dr M.J. Kropff,
in the presence of the
Thesis Committee appointed by the Academic Board
to be defended in public
on Tuesday 14 October 2014
at 11 a.m. in the Aula.
Elske Maria Brouwer-Brolsma
VITAMIN D-TOUR. Cognition and depression: the role of vitamin D and its interplay 
with glucose homeostasis,
215 pages.
PhD thesis, Wageningen University, Wageningen, NL (2014)
With references, with summaries in Dutch and English
ISBN: 978-94-6257-108-2
Contents
Chapter 1 General introduction
 
Chapter 2 Vitamin D. Do we get enough? A discussion between vitamin D  
  experts in order to make a step towards the harmonisation of  
  dietary reference intakes for vitamin D across Europe
 
Chapter 3 Relative importance of summer sun exposure, vitamin D intake 
  and genes to vitamin D status in Dutch older adults: the B-PROOF  
  study 
Chapter 4 Associations of 25-hydroxyvitamin D with fasting glucose, fasting  
  insulin, dementia and depression in European elderly: the SENECA  
  study 
Chapter 5 Serum 25-hydroxyvitamin D is associated with cognitive executive  
  function in Dutch pre-frail and frail elderly: a cross sectional study  
  exploring the associations of 25-hydroxyvitamin D with glucose  
  homeostasis, cognitive performance and depression
Chapter 6 Cognitive performance: is there an interplay between serum 
  vitamin D and glucose homeostasis? 
Chapter 7 Vitamin D-epressed:  Low vitamin D status is associated with more  
  depressive symptoms in Dutch older adults  
Chapter 8 Higher serum 25(OH)D and lower plasma glucose are associated  
  with a higher grey matter volume in Dutch community-dwelling  
  older adults 
Chapter 9  No role for vitamin D or a moderate fat diet in aging induced 
  cognitive decline and emotional reactivity in C57BL/6 mice
 
Chapter 10 General discussion 
  
  Summary
  Samenvatting
  Dankwoord / Acknowledgements / Tankwurd
  About the author
7
29
49
65
81
103
119
135
149
173
197
201
205
209

General introduction
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We are getting older. In 2002, Dutch men and women reached an average age of 76 
and 81 years. Recent estimates of the Dutch National Institute of Public Health and the 
Environment indicate an average life expectancy of 79 years in men and 83 years in women 
[1]. Unfortunately, old age is regularly accompanied by a rise in chronic conditions that may 
result in impairments and hinder an individual from active participation in daily life activities 
[2]. Discovering potentially modifiable environmental factors that impede the functioning 
of an individual is crucial to postpone or slow-down these impairments as long as possible. 
Vitamin D inadequacy has been identified as one of the potential environmental factors 
to target [3]. Associations have been suggested between vitamin D and fall incidence [4], 
fracture risk [5], muscle health [6], cancer [7], hypertension [8], type 2 diabetes mellitus 
[9], mood [10] and cognitive performance [11]. However, there are still many uncertainties 
regarding the causality of these associations and the underlying pathophysiology. To gain 
more insight in the actions of vitamin D, the research described in this thesis addresses the 
potential role of vitamin D in cognitive function and depression in populations aged ≥65 
years, and in a sample of aged C57BL/6 mice. By exploring the hypothetical role of glucose 
homeostasis in the potential relationship between vitamin D and brain health also a possible 
underlying mechanism is addressed. 
1.1. A focus on vitamin D 
The vitamin D chronicle started in the early 20th century when exposure to a mercury-vapor-
quartz lamp and cod liver oil appeared to be effective in the treatment of rachitis [12, 13]. 
Subsequently, vitamin D was identified as being the responsible agent [13]. In 1931 vitamin 
D2 was chemically characterized [14], followed by vitamin D3 in 1936 [15]. Since the 1960s 
knowledge on vitamin D further expanded. In 1968, Blunt and colleagues identified the 
inactive vitamin D metabolite, 25-hydroxyvitamin D (25(OH)D), which is at this moment 
considered to be the best status marker of vitamin D in blood. Nowadays it is known that skin 
exposure to sun, more specifically ultraviolet-B (UV) radiation, can activate the conversion of 
7-dehydrocholesterol into pre-vitamin D3 and subsequently into vitamin D3 [16], and that 
most of the 25(OH)D traced in human blood is formed in response to UV-B radiation [17].
1.1.1 Vitamin D metabolism
Once vitamin D is synthesized in the skin or dietary vitamin D is absorbed in the small 
intestine, it is incorporated in the blood circulation and - attached to vitamin D binding 
protein - transported to the liver. In the liver, vitamin D is converted into 25(OH)D. To 
actually influence biological processes throughout our body, 25(OH)D needs to be converted 
in 1,25(OH)D. This conversion can take place in a variety of tissues, but primarily occurs in 
the kidneys. 1,25(OH)D is the active vitamin D metabolite and acts on vitamin D receptors 
throughout the body [3]. 
1.1.2 Skin synthesis
Sun exposure is considered to be the most important determinant of 25(OH)D in blood. 
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The exact amount of vitamin D synthesized in the skin, however, depends on many factors, 
including melanin pigmentation, age, time of the day, season, latitude, sunscreen use, air 
pollution, type of clothing worn and also gene profile [18]. In view of the scope of this thesis 
(i.e. populations studied mainly include Dutch older adults), the factors season, latitude and 
age are here described in more detail. In the Netherlands, located at a latitude of ± 52°N, the 
average annual vitamin D synthesis has been estimated to be around 6-7 µg vitamin D daily 
[19]. During the Dutch winter period, however, the quality and quantity of ultraviolet-B 
photons is reduced and as such the production of pre-vitamin D3 in response to UV-B is 
largely absent [20]. Older age is also considered a risk factor for low 25(OH)D concentrations. 
This is explained by the age-dependent reduction of 7-dehydrocholesterol in the skin, and 
consequently a reduced capacity to produce vitamin D in response to ultraviolet-B radiation 
[21]. Impaired physical functioning, reduced sun exposure, and a low dietary vitamin D 
intake are furthermore assumed to contribute to low 25(OH)D concentrations at older age 
[22].
1.1.3 Dietary and supplemental vitamin D intake
After sun exposure, dietary factors, such as fatty fish (e.g. 100 grams mackerel provides 6.3 
µg vitamin D3), egg yolk (0.5 µg vitamin D2 or vitamin D3), mushrooms (e.g. 100 grams 
fresh Shiitake mushrooms provides 2.5 µg vitamin D2), and vitamin D supplements are the 
second source of vitamin D [3]. The efficacy of vitamin D intake to influence 25(OH)D 
concentrations is assumed to depend on a variety of factors, like the body’s capacity to absorb 
vitamin D, body composition, use of specific medication, liver and kidney function, and 
genetic make-up [3]. 
1.1.4 Dietary Reference Intakes
During the past years there has been a continuous debate on what the optimal vitamin 
D intake level and blood concentration should be. The Dietary Reference Intakes (DRI) 
formulated by the Institute of Medicine (IOM) range from an Adequate Intake (AI) of 10 µg/
day in infants to a Recommended Dietary Allowance of 20 µg/day in persons aged ≥70 years 
[23]. The daily requirement as set by the Dutch Health Council also ranges from 10-20 µg/
day, where all older adults aged ≥70 years are recommended to use a supplement containing 
20 µg vitamin D per day [24]. 
1.1.5 Optimal 25(OH)D concentrations
According to the Dutch Health Council a 25(OH)D concentration of ≥30 nmol/L can be 
considered sufficient for persons aged 4-70 years [24]. This concentration is primarily based 
on the evidence related to bone health. Currently, the IOM concludes that persons with 
25(OH)D concentrations ≥50 nmol/L are vitamin D sufficient [23]. The Endocrine Society 
considers a concentration of 50 nmol/L suboptimal. Based on data related to fall and fracture 
risk, parathyroid suppression, pathologic osteoid formation, and muscle metabolism, the 
Endocrine Society recommends 25(OH)D concentrations ≥75 nmol/L [25]. Whether these 
concentrations also beneficially relate to outcomes beyond bone health warrants further study.
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1.2  A general introduction to cognitive performance, cognitive decline  
 and dementia
  
1.2.1 Epidemiology
Age-related decrements in cognitive function are regularly observed. In case of 
pathophysiological abnormalities like Alzheimer’s disease (AD), vascular dementia, Lewy 
body dementia or frontotemporal dementia, people are generally faced with more severe 
cognitive deficits. Patients gradually lose the ability to learn, recall previously learned skills, 
and as such their independence. Estimates suggest that worldwide more than 35 million 
persons are affected by dementia [26]. In about 70% of the dementia cases the diagnosis is 
AD [27]. Approximately 20% of the patients is diagnosed with vascular dementia [28]. In 
practice, however, patients often have AD pathology as well as vascular injuries [27].
1.2.2 Biological underpinnings 
The aetiology of dementia and cognitive decline is complex. Necropsy studies in dementia 
patients have pointed towards the presence of amyloid plaques and neurofibrillary tangles, 
vascular damage and brain atrophy as the pathological processes to target. Amyloid plaques 
are made of the protein amyloid-β (Aβ). ‘Normal’ synaptic Aβ levels are thought to prevent 
neuronal hyperactivity. Too high levels of Aβ, however, can result in Aβ accumulation and the 
deposition of amyloid plaques. Amyloid deposits are predominantly located between brain 
neurons. Neurofibrillary tangles are made of the phosphorylated protein tau [27]. Tau plays 
an important role in the stability of axonal microtubules. However, in AD, the structure of 
tau is altered, resulting in the formation of neurofibrillary tangles in axonal microtubules 
[27]. There is increasing evidence that amyloid plaques and neurofibrillary tangles may be 
related to synaptic failure, and hence cognitive decline [27, 29]. Vascular dementia typically 
arises from problems with the cerebral blood supply resulting in infarcts and/or white matter 
lesions [30]. An overlapping characteristic of the different types of dementia is that they are 
generally accompanied by relatively severe neurodegeneration; demonstrated by thinning of 
the cerebral cortex, shrinkage of subcortical structures and increasing ventricle volumes [31, 
32]. 
1.2.3 Predisposing factors
Several risk factors for cognitive decline and dementia have been identified. To date, just a 
few of these factors are considered unequivocally established predisposing factors, including 
having the apoE4 allele [33], increasing age [34], and being woman [35]. Other proposed 
risk factors include high blood pressure, diabetes, metabolic syndrome, high body weight, 
dyslipidaemia, smoking, physical inactivity, intellectual inactivity [33], high saturated fat 
intake [36], excessive alcohol consumption [37], and depression [38]. Studies have also 
suggested that specific nutrient deficiencies may relate to cognitive decline, including 
B-vitamins [36, 39, 40], vitamin D [11, 41], omega-3 fatty acids [36, 40], zinc [42], and 
selenium [43]. 
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1.2.4 Treatment
To date, treatment options for dementia are limited. The commonly prescribed 
pharmacological agents mainly target the observed neurotransmitter disturbances in cognitive 
decline and dementia, specifically acetylcholinesterase inhibitors and N-methyl-D-aspartate 
receptor (NMDA) receptor antagonists [44]. Unfortunately, the observed treatments effects 
are relatively small [45, 46]. 
1.2.5 Assessing cognitive performance, cognitive decline and dementia
To assess cognitive functioning and to acquire information on the affected brain regions 
in cognitive decline, neuropsychological testing can be performed, which has been defined 
as “(..) the intensive study of behaviour by means of interviews and standardized scaled 
tests and questionnaires that provide relatively precise and sensitive indices of behaviour” 
[47]. Numerous of these neuropsychological tests have yet been developed, targeting global 
cognitive function as well as more specific cognitive functions. Table 1 provides an overview 
of the cognitive tests used in this thesis, their properties and a real life example. During the 
past decade also imaging techniques gained ground in behavioural brain research. Structural 
Magnetic Resonance Imaging (MRI) is one of these techniques, and provides information 
on amongst others total brain volume and integrity of grey matter and white matter brain 
structures. However, despite these relatively new techniques, still not all theories on brain 
function can be studied in humans. In these cases, the scientific community regularly uses 
mouse and rat models to gain more insight in potential behavioural and physiological 
processes. Table 2 and Figure 1 provide an overview of the behavioural tests used in the 
animal trial that was conducted for this thesis.
 
1.3 A general introduction to depression
1.3.1 Epidemiology
By affecting about 4-20% of the people at least once in their lifetime, depression is the 
most commonly diagnosed psychiatric disorder worldwide [48]. Estimates indicate that 
about 8-16% of older men and women aged ≥65 years have clinically significant depressive 
symptoms, and that these symptoms are more likely to occur in the oldest old [49]. Depression 
is frequently accompanied by a depressed mood or irritability, decreased interest or pleasure, 
significant weight change or change in appetite, insomnia or hypersomnia, psychomotor 
agitation or retardation, fatigue or loss of energy, feelings of guilt or worthlessness, 
concentration problems, indecisiveness and/or suicide [50].
1.3.2 Biological underpinnings
There are several pathophysiological hypotheses on the development of depression, 
including monoamine depletion, hypothalamic pituitary adrenal (HPA)-axis hyperactivity, 
decreased activity of specific brain regions and genetic predisposition [51]. To start with 
the first hypothesis, there is the monoamine hypothesis. This hypothesis posits that 
depression is caused by depletion of noradrenaline, serotonin and/or dopamine levels. 
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Currently, most of the prescribed antidepressants target this monoamine system [51]. 
Secondly, in case of depression there is often hyperactivity of the HPA-axis. In response 
to stress the hypothalamus starts to secrete corticotropin-releasing hormone (CRH) and 
vasopressin. CRH and vasopressin on their turn stimulate the pituitary gland to secrete 
adrenocorticotropic hormone (ACTH). ACTH subsequently acts on the adrenal cortex, 
which results in the production of glucocorticoids, mainly cortisol. In a normal situation 
these hormones are helpful to deal with stressful situations, where there is a negative 
feedback cycle in which high levels of glucocorticoids suppress the secretion of CRH and 
vasopressin. However, when this negative feedback cycle does not function adequately, HPA-
hyperactivity may result in depression and even hippocampal atrophy [51]. Depression has 
furthermore been associated with an increased activity of the amygdala, orbitofrontal cortex, 
and a decreased activity of the subgenual cingulate and the ventral stratium [51]. Finally, 
neurodegeneration and vascular injury may be involved in the development of depressive 
symptoms [52]. 
Figure 1. Visualisation of the behavioural tests used in the animal study presented in this thesis.
1.3.3 Predisposing factors
Biological, psychological and social factors have been suggested to form the basis for depression 
[52]. First of all, genetic predisposition may play a role in the development of depression 
[51]. Depression in older adults has furthermore been associated with being woman, medical 
           Open Field Test          Elevated Plus Maze  
      Object Recognition Test         Morris Water Maze  
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illness, functional disability, sleep disturbance, stressful life events, bereavement, being 
unmarried, small social network, and a poor-perceived health [52, 53]. Nutritional factors 
that have been associated with depression include omega-3 fatty acids [40], B-vitamins [40], 
vitamin D [10], zinc [54] and magnesium [55]. 
1.3.4 Treatment
Depression is commonly treated with antidepressants, which primarily act via the 
enhancement of neurotransmission in the brain by increasing the availability of serotonin 
and noradrenalin [49, 56]. However, for many patients treatment with anti-depressants is 
suboptimal (e.g. relapse), not effective and/or coincides with unwanted side-effects [57]. 
Alternative treatment possibilities include psychotherapy, light therapy, physical exercise and 
in severe depression, electroshock therapy [49]. 
1.3.5 Assessing depression
Epidemiological studies often use brief self-administered symptom checklists to assess 
mood [58, 59]. In this thesis the Geriatric Depression Scale-15 (GDS) and Centre for 
Epidemiologic Studies Depression scale (CES-D) were used to assess depressive symptoms, 
where higher scores reflect more depressive symptoms. The GDS is a depression-screening 
tool that has been specifically developed for population of older adults [60]. The CES-D 
has been specifically developed to identify persons at risk for clinical depression in a general 
population [61]. Many studies have attempted to estimate the cut-off value for clinical 
depression presenting varying results. Suggested cut-off values for clinical depression include 
amongst others ≥5 for the GDS [60] and ≥16 for the CES-D [62]. 
1.4 Vitamin D, the brain and how they relate
1.4.1 Vitamin D-mediated processes in the brain
Several in vitro studies and molecular studies have demonstrated a role of vitamin D in brain 
function. The clearest biological evidence for a role of vitamin D in brain function is the 
localization of vitamin D receptors (VDR) on various brain structures and 1,25-α-hydroxylase, 
the enzyme that catalyses the conversion of 25(OH)D in the active form of vitamin D, 
in cerebrospinal fluid [63]. Treatment with 1,25(OH)D has furthermore been shown to 
stimulate choline acetyltransferase activity [64], promote the synthesis of neurotrophins [65], 
exert anti-excitotoxic properties by decreasing L-type voltage-dependent calcium channel 
expression [66] and to have anti-oxidative properties by regulating glutathione concentrations 
[67]. In addition, Aβ-PP transgenic mice (i.e. mice that are prone to develop amyloid plaques) 
on a vitamin D enriched diet have been shown to have less amyloid plaque deposition, 
when compared to non-treated counterparts [68]. Vitamin D adequacy may furthermore 
prevent cerebrovascular disease by beneficially affecting several vascular risk factors [69]. The 
observation of a crosstalk between the glucocorticoid receptor and VDR in hippocampal cells 
resulted in the hypothesis that vitamin D may ameliorate the progression of neuronal atrophy 
that is caused by high glucocorticoid levels during depressive episodes [70].
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1.4.2 Experimental evidence from rodent experiments
Several animal studies have investigated the effect of vitamin D on behaviour and brain 
function (reviewed in [71, 72]). Many of these studies were conducted in vitamin D receptor 
knockout mice or mice that had a prenatal vitamin D deficiency. However, the behavioural 
effects examined in these ‘early life’ models may substantially differ from the effects of a 
vitamin D deficiency developed later in life. Studies examining the effect of an adult vitamin 
D deficiency on behaviour are sparse and heterogeneous in their experimental design (Table 
3) [68, 73-76]. Due to these experimental differences - that is, the animal models used, study 
duration, treatment type, age of testing and testing procedures - these studies do not provide 
a clear-cut answer on the role of vitamin D deficiency in brain function in aging rodents. 
1.4.3 Evidence from studies in older adults
Cognitive performance, cognitive decline and dementia
Up to now, there have been several human studies examining the potential relation between 
vitamin D and cognition [77-100]. Most of these studies have been cross-sectional and used 
a global screening tool, such as the MMSE [77-83, 85-87, 89-91, 93-96]. The majority of 
the most recent studies, however, also assessed domain-specific cognitive functions, including 
declarative memory, working memory, attention, information processing speed, visuospatial 
abilities and/or executive functioning [80, 84, 86, 88, 90, 92, 94, 95]. Some of these studies 
used clusters of tests to study a cognitive domain [80, 90, 92]. In the NAME study, including 
up to 1050 black and non-black older adults, fully adjusted models showed significant 
associations between serum 25(OH)D and the domains attention/processing speed (β 0.01, 
SE 0.003, P<0.01) and executive function (β 0.01, SE 0.003, P<0.01), but not with the 
domain memory (β -0.004, SE 0.004, P<0.54) [80]. In the ISAAC study, conducted among 
159 men and women ≥70 years, linear regression analyses adjusted for age, sex and level 
of education did not point towards an association between 25(OH)D concentrations and 
attention (β 2.68, P=0.12), working memory (β 2.30, P=0.10) or executive function (β 1.73, 
P=0.27) [90]. In the ZENITH study a significant association was found between 25(OH)
D status and measures of spatial working memory [92]. Prospective studies have largely 
focussed on tests measuring executive functioning, particularly the Trail Making Test-B 
(TMT-B) [86, 94, 95]. Only in the InCHIANTI study the association between 25(OH)D 
concentration and TMT-B performance was significant, indicating that older adults with serum 
25(OH)D concentrations <25 nmol/L had a 31% increased probability of developing cognitive 
impairment when compared to those with concentrations ≥75 nmol/L, after an average follow-
up time of 5.2 years [86]. A complete overview of the results of all the identified studies is 
provided in Figure 2.  Overall, it may be concluded that results are inconclusive.
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Figure 2. Schematic overview of the observational studies that examined the association between 25(OH)D 
concentration and cognitive performance. * Prospective study.
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Depression
Six observational studies have been published that examined the association between 
25(OH)D status and depression in populations aged ≥60 years [81, 101-105] (Table 4). 
Data of the Longitudinal Aging Study Amsterdam (LASA) and the Health Survey for England 
(HSE) both showed a significant association between lower 25(OH)D concentrations and 
more depressive symptoms [101, 104]. Likewise, the Os Study, including 883 Chinese men, 
showed an association between 25(OH)D and depressive symptoms at baseline (i.e. OR 0.46 
(95% CI 0.22-0.98) in the highest 25(OH)D quartile with the lowest quartile serving as the 
reference), but not after 4-years of follow-up [81]. Longitudinal findings of the InCHIANTI 
study indicated that women with 25(OH)D concentrations <50 nmol/L were significantly 
more likely to report increases in CES-D scores than women with 25(OH)D concentrations 
≥50 nmol/L, specifically 2.05 (0.9) and 2.19 (1.1) points higher after 3 and 6 years, 
respectively [103]. Accordingly, a statistically significant higher percentage of depression in 
persons with 25(OH)D levels <25 nmol/L, when compared to those with concentrations 
≥25 nmol/L, was shown in the Older Americans Act Nutrition Program (OAANP) [102]. 
In a population of geriatric primary care patients those with 25(OH)D concentrations <25 
nmol/L were twice as likely to be diagnosed with depression than those with 25(OH)D 
concentrations ≥25 nmol/L [105]. However, although these studies suggest an association 
between 25(OH)D concentration and depression in older adults, these associations should 
be interpreted cautiously as residual confounding is likely. To date, only a few well-designed 
RCTs have been conducted to investigate the effect of vitamin D treatment on depression, 
and results are uncertain [106]. 
1.5 Glucose homeostasis: a potential indirect pathway linking vitamin D 
 with cognitive performance and depression?
The aetiology of cognitive decline and depression is in all probability a complex interplay 
between a variety of factors, and it is unlikely that vitamin D deficiency alone results in 
cognitive decline and depression. It has amongst others been proposed that vitamin D 
deficiency may render the brain more susceptible to other stressors. Glucose intolerance may 
be considered to be such a stressor [107, 108]. Based on this theory it is hypothesized that 
the magnitude of the association between vitamin D and cognitive performance/decline and 
depression differs between persons with a normal glucose tolerance and persons with impaired 
glucose tolerance. Baron and Kenny (1986) defined such a factor (glucose intolerance) that 
affects the strength of the association between a predictor (vitamin D) and an outcome variable 
(cognitive performance/depression) as being an effect modifier [109]. In several chapters 
in this thesis the potential modification effect of impaired glucose tolerance is examined. 
The hypothesis of effect modification is considered to be supported when the interaction 
term between the exposure (vitamin D) and the suggested modifier (glucose intolerance) 
is significant (Figure 3) [109], thus, when the magnitude of the association significantly 
differs between the examined groups, which are defined based on the hypothesized modifier.
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Figure 3. Visualisation of the hypothesized interaction between vitamin D and glucose homeostasis in the 
association with cognitive performance and depression.
However, given the proposed beneficial effects of vitamin D on insulin secretion and 
action [9, 110], it may also be that glucose intolerance acts as an intermediate in the 
pathway linking vitamin D to cognitive performance/decline and depression (Figure 4). 
Figure 4. Visualisation of the hypothesized mediatory role of glucose homeostasis in the association of vitamin 
D with cognitive performance and depression. 
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To determine whether a factor is an actual mediating factor, several pathways have to be 
explored: 1) the pathway between the exposure (vitamin D) and the outcome (cognitive 
performance/depression); 2) the pathway between the exposure (vitamin D) and the 
mediator (glucose intolerance); 3) the pathway between the mediator (glucose intolerance) 
and the outcome (cognitive performance/depression); and 4) the pathway between the 
exposure (vitamin D) and the outcome (cognitive performance/depression) controlled for the 
hypothesized mediating factor (impaired glucose tolerance). According to Baron and Kenny 
(1986) a factor can be considered a mediator when it: 1) is ‘influenced’ by the exposure, 2) 
‘affects’ the outcome, and 3) significantly reduces the association between the exposure and 
the outcome when controlled for [109].
1.6 To wrap up….
It may be clear that there is quite some scientific evidence suggesting a link between 
vitamin D and brain function, but the exact role of vitamin D and its specific pathway 
is far from well defined. To complement to the scientific literature, we conducted several 
studies on the possible relationship of vitamin D with cognitive performance and depression. 
In chapter 2 we start off with a report of a discussion between vitamin D experts that 
was held to make a step towards the harmonization on the formulation of optimal intake 
and serum 25(OH)D concentrations across Europe. In chapter 3 we explore how well 
a population of community-dwelling Dutch older adults adheres to the in chapter 2 
formulated recommendations, followed by the identification of potential intervention targets. 
Subsequently, the cross-sectional association of vitamin D with global cognitive performance 
and depression is examined in an apparently healthy sample of European older adults aged 
70-75 years (chapter 4). Next, the potential role of vitamin D in domain-specific cognitive 
performance and depression is studied in Dutch pre-frail and frail older adults aged ≥65 
years (chapter 5). Associations of vitamin D with domain-specific cognitive performance 
(chapter 6), depression (chapter 7) and brain volume (chapter 8) are also explored in a 
relatively large group of seemingly healthy Dutch community-dwelling older adults aged ≥65 
years. Finally, the results of a proof of principle study on the effect of a vitamin D deficient 
diet on behaviour in old C57BL/6 mice are reported (chapter 9). In most chapters also 
the potential interplay between vitamin D and glucose homeostasis is further explored. In 
chapter 10 an overall reflection is given on the studies that are presented in chapter 2-9. 
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V I TA M I N  D . D O  W E  G E T  E N O U G H ?
Abstract
Several groups at risk for developing vitamin D insufficiency have been identified. 
Accordingly, reviews indicate that a significant percentage of the population worldwide 
have serum 25-hydroxyvitamin D (25(OH)D) concentrations <50 nmol/L. In addition 
to the role of vitamin D in bone health, recent studies suggest that it may play a pivotal 
role in other systems, for instance the cardiovascular system, pancreas, muscle, immune 
system and brain. Most evidence, however, is obtained from observational studies and yet 
inconclusive. To exchange and broaden knowledge on the requirements for vitamin D and 
its effect on various health outcomes, a workshop entitled “Vitamin D Expert Meeting: 
Do we get enough?” was organized. Acknowledged experts, mainly European, in the field 
of vitamin D were brought together in order to discuss the recent advances. Despite 
low 25(OH)D concentrations worldwide, consensus on the definition of deficiency 
is not yet reached. In order to define cut-off points for vitamin D while taking into 
account extraskeletal health effects, randomized controlled trials (RCTs) in these fields 
are warranted. The experts do emphasize that there is evidence to suggest an important 
role for vitamin D in the maintenance of optimal bone health at all ages and that vitamin 
D supplementation, in most studies co-administered with calcium, reduces fracture risk 
in the senior population. To reach a serum 25(OH)D concentration of 50 nmol/L older 
adults aged ≥65 years are therefore recommended to meet a mean daily vitamin D intake 
of 20 µg (800 IU), which is best achieved with a supplement. 
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2.1 Introduction
Studies from all over the world clearly report that an inadequate vitamin D status is a global 
issue, both in the developed as well as in the developing world. Individuals at risk for vitamin 
D deficiency are infants, young children, veiled women, persons with a coloured skin, older 
adults and persons who live at high latitudes [1, 2]. In some studies 40% up to 100% of the 
older adults have been diagnosed with an insufficient 25(OH)D status [2, 3]. In hip fracture 
patients aged ≥65, 80% appeared to have 25(OH)D concentrations <50 nmol/L. Less than 
5% reached a serum concentrations ≥75 nmol/L, considered by some as optimal fracture 
reduction [4, 5]. 
Vitamin D is best known for its role in calcium metabolism and bone health, but recent 
studies suggest a much broader role of vitamin D [6]. Evidence from clinical trials among 
older adults suggest a benefit of vitamin D supplementation in both musculoskeletal function 
and fall prevention, but evidence is inconclusive (reviewed in [7-9]). Vitamin D has also 
been associated with glucose and fat metabolism, cognitive functioning, immune function, 
cancer, and cardiovascular disease (reviewed in [2, 10-15]). In addition, two meta-analysis of 
prospective cohort studies showed that lower 25(OH)D concentrations were associated with 
a higher mortality risk [16, 17]. On the other hand, Zittermann and colleagues do mention 
that two of the studies included in their meta-analyses suggest that overabundant 25(OH)D 
concentrations may also increase mortality risk [16]. 
Although vitamin D can be obtained from food, its main source is not the diet. In fact, 
nutritional sources are rare and largely limited to fatty fish, such as salmon. Vitamin D is 
synthesized in the skin when ultraviolet-B (UV-B) radiation targets the skin at a wavelength 
between 290-315 nm. However, at latitudes above 33°N (all of Europe) UV-B radiation is 
only effective during the summer months. The effectiveness of UV-B depends furthermore 
on the time of the day. During the summer early morning and late afternoon UV-B radiation 
is also not strong enough to activate vitamin D production. Furthermore, the production of 
vitamin D in the skin decreases with age [18]. Skin protection, which is broadly practiced, may 
further reduce skin production of vitamin D [19]. Accordingly, studies suggest that in many 
countries 25(OH)D concentrations are <50 nmol/L, especially during the winter months 
(summarized in [1, 8]). Consensus on the optimal dietary intake is, however, not yet reached 
(Table 1) [8, 20-24]. Doets et al. (2008) summarized the current recommended vitamin D 
intakes across Europe and showed that there is a large variation in these recommendations, 
for instance the recommendation for Russian men ≥70 years, last updated in 1991, is set at 
2.5 µg/day, whereas this is 15 µg/day in Iceland and Spain, which were updated in 2006 and 
2007, respectively [25]. 
Circulating 25(OH)D has the longest half-life (3-6 weeks) of the vitamin D metabolites 
and represents both sunshine and dietary sources, and is therefore considered to be the 
best biomarker of vitamin D status. Although there is no unanimity yet on the optimal 
concentrations of serum 25(OH)D, current evidence discussed by the Institute of Medicine 
(IOM) suggests a serum 25(OH)D concentration >50 nmol/L as being sufficient [8]. 
Guidelines as provided by the International Osteoporosis Foundation (IOF) [26] and 
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Endocrine Society (ES) [22] suggest that for optimal fracture prevention at older age a 
threshold of 75 nmol/L is desirable. 
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2.2 Meeting
To exchange new scientific insights on vitamin D and the resulting implications for the 
requirements of vitamin D, considering vitamin D’s broader effect on human health, a 
conference entitled “Vitamin D Expert Meeting: Do we get enough?” was held on September 
29th, 2011 in Ede. Acknowledged experts in the field of vitamin D were brought together in 
order to discuss the recent scientific advances in the field. This expert meeting was organized 
by Wageningen University and Research Centre in close collaboration with DSM. Invitations 
were primarily send to European experts. Attendees were selected according to their 
specialisation/health outcome and their availability at the time of the meeting. The Institute 
of Medicine (IOM) was invited to take US’s reflections on board. The program included 
presentations about the Dietary Reference Intake (DRI) in North America by CJCG, global 
vitamin D status by ES, insights from epidemiological studies by EH, the possible relation 
with various metabolic processes and diseases by HAB-F, EJMF, DJL, and LCPGMdG, and 
the interaction between diet, sunlight and 25(OH)D by SL-N. Furthermore, the question 
“How to close the gap” was addressed by RB. Sessions were chaired by RB and EJMF.
2.3 The DRI for vitamin D for North America
In November 2010 the IOM presented revised DRI’s for calcium and vitamin D, which 
were last updated in 1997 [8]. Recently, the ES published their views on the treatment and 
prevention of vitamin D deficiency [22]. When compared to the recommendations as set by 
the IOM, the ES advocates higher intake levels in pregnant and lactating women, persons with 
obesity and those using specific medications. According to one of the workshop participants 
screening all the individuals ‘at risk’ according to the ES guidelines would involve about 50 
million individuals, just in the USA. During the meeting an overview of the similarities and 
differences of the two reports was given and inconsistencies were discussed. For instance, the 
IOM focussed its conclusions on RCTs and considers 25(OH)D concentrations ≥50 nmol/L 
to be sufficient for more than 97.5% of the population. Based on the effects of vitamin D 
on fracture and fall reduction, serum parathyroid hormone (PTH) and pathologic osteoid 
formation the ES advocates for a concentration ≥75 nmol/L. 
The individual effect of vitamin D on fracture risk is difficult to assess, as most fracture trials 
that gave a higher dose vitamin D (20 µg/day) also provided calcium supplements. Of three 
double-blind placebo-controlled trials that provided vitamin D alone, one that gave 2500 µg 
in a four monthly interval for five years showed significant fracture reduction [27], one at the 
same dose level annually (12500 µg) suggested an increased fracture risk [28], and one that 
gave 7500 µg intra-muscularly showed no benefit regarding fracture risk  [29]. In one meta-
analysis of double-blind RCTs, the authors compared at the higher intake level (>10 µg/
day) the main effect of vitamin D to the combination of vitamin D plus calcium compared 
to placebo, and found that both pooled effects showed significant non-vertebral fracture 
reduction of 20% [30]. 
One of the factors associated with fracture risk is PTH, as it stimulates calcium release from 
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bone. Low 25(OH)D concentrations have been shown to increase PTH secretion by the 
parathyroid glands, whereas PTH synthesis is suppressed when low 25(OH)D concentrations 
are restored. A recent literature review of 70 papers showed that several studies did not 
identify a ceiling effect for serum PTH with increasing 25(OH)D concentrations. Serum 
25(OH)D concentrations varied, however, from 25-125 nmol/L and therefore no specific 
upper limit could be specified [31]. 
One large cross-sectional study investigated bone mineral density (BMD) as an endpoint for 
bone health with respect to 25(OH)D status in both younger and older adults and suggested 
a positive correlation between 25(OH)D concentrations and hip BMD with optimal 
concentrations occurring between 75-100 nmol/L [32]. On the other hand, intervention 
studies showed little increase in BMD in vitamin D-replete participants [33]. 
2.4 Global Vitamin D Status - The Map
Figure 1. Serum 25(OH)D status across Europe. Based on representative data (full coloured countries) and 
smaller studies in older adults (number displayed in square).
Vitamin D insufficiency appears to be a common health issue all over the world. Therefore, a 
global map of 25(OH)D status in the different regions of the world has been launched (2012) by 
DSM, in partnership with the IOF [34]. During this meeting preliminary results of a European 
map illustrating the 25(OH)D status within different European countries was presented 
(Figure 1). A literature study resulted in a selection of 80 peer-reviewed papers. A paper was 
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considered eligible when it contained information on 25(OH)D status either in a representative 
population based study or in a representative specific age group such as postmenopausal women 
or older adults. For the general population mean 25(OH)D concentrations between 50-75 
nmol/L were observed in Norway, France and Corsica whereas in the Netherlands, Germany, 
Switzerland, Finland and Estonia the serum 25(OH)D concentrations were in the range of 25-
50 nmol/L, revealing insufficiency. These values are below those recommended by the IOM. 
Data on postmenopausal women were only available of residents of the United Kingdom and 
Spain, showing average concentrations of 50-75 nmol/L. Mapping of the 25(OH)D status of 
older adults suggest that this group is at an increased risk for low 25(OH)D concentrations.
2.5 Vitamin D and Health
2.5.1 Insights from epidemiological studies
Interest in the possible health benefits of vitamin D is rapidly growing and has led to an 
increasing number of papers on the association of 25(OH)D status with several non-skeletal 
health outcomes. The results of meta-analyses performed within various epidemiological 
cohort studies were presented. It is clear that environmental factors such as sunlight induced 
synthesis, oily fish and supplement intake are of importance. However, also genetic make-
up has been shown to affect 25(OH)D status. Meta-analyses by the Sunlight Consortium 
demonstrated a 2.5 increased risk of vitamin D inadequacy for individuals in the top 
compared to lowest quartile, based on the polymorphisms of a number of genes of the vitamin 
D pathway, namely those coding the vitamin D binding protein (GC), 25-hydroxylase 
(CYP2R1) and an enzyme involved in the metabolism of 7-dehydrocholesterol (DHCR7), 
which is a precursor of vitamin D [35]. Epidemiological studies have provided support for 
an association between perinatal vitamin D supplementation and the later risk of type 1 
diabetes [36], with recent genetic studies suggesting a causal relation [37]. Analyses from 
epidemiological cohort studies such as the 1958 British Birth Cohort, suggest a link between 
25(OH)D status and a wide-range of outcomes including the metabolic syndrome [38], 
lung function and respiratory infections [39]. However, whether these associations are causal 
has yet to be demonstrated. Recent published data of an RCT in 182 patients with chronic 
obstructive pulmonary disease (COPD) showed no effect of vitamin D in the entire cohort, 
whereas COPD exacerbations were significantly reduced with vitamin D supplementation in 
patients with baseline 25(OH)D concentrations <25 nmol/L [40]. 
2.5.2 Falls – evidence from intervention studies
Most evidence suggests a favourable effect of vitamin D in relation to bone health. Therefore, 
also the latest studies on the possible relation of vitamin D with fall rate and fracture risk were 
presented during the meeting. Currently, there is disagreement regarding the interpretation 
of the scientific evidence on vitamin D and falls. Bischoff-Ferrari et al. (2009) state that 
scientific evidence clearly supports the use of vitamin D in the prevention of falling [7]. 
However, the IOM strongly disagrees with this point of view. According to the IOM [41] the 
inclusion procedure of the meta-analyses of eight double-blind RCTs (n=2426) as performed 
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by Bischoff-Ferrari and colleagues [7] was questionable, the statistical analyses incorrect 
and data inappropriately presented. Bischoff-Ferrari and colleagues did not agree on the 
incorrect inclusion of RCTs, but did reanalyse the data in order to account for the stochastic 
dependencies (correlations) [42] between the corresponding risk ratios in the multiple dosing 
trial by Broe and colleagues [43], and found a reduction in the odds of falling overall for 
dose of <17.5 µg/day versus 17.5-25 µg/day, OR 0.73 (95% confidence interval (CI) 0.62 
to 0.87). The IOM re-analysed the data of this meta-analysis [8] and concluded that there 
is lack of sufficiently strong evidence for the formulation of DRIs for vitamin D regarding 
fall prevention according to their final meta-regression of RCTs showing a relative risk (RR) 
of 0.95 (95% CI 0.89-1.02) per 2.5 µg/day increase in vitamin D intake [8]. One of the 
included RCTs even shows an increased fall rate among community-dwelling women aged 
≥70 years receiving a single dose of 12500 µg cholecalciferol annually for 3-5 years when 
compared to the placebo group, RR 1.15 with 95% CI 1.02-1.30 [28]. Also, Glendenning 
et al. (2011) observed in their nine month trial that 28.9% of the post-menopausal women, 
assigned to 3750 µg cholecalciferol every three months, experienced at least one fall, whereas 
this was 26.7% in the placebo group. This difference was, however, not significant (OR 1.06 
with 95% CI 0.75-1.49) [44]. RCTs on vitamin D supplementation and falls with sufficient 
power may help to solve this disagreement.
2.5.3 Fractures – evidence from intervention studies
To date, several meta-analysis have been published on vitamin D supplementation and 
fracture risk, using different inclusion criteria [8, 30, 45-49]. In the latest meta-analysis of 
pooled participant-level data of 11 RCTs on oral vitamin D supplementation and fracture 
prevention, Bischoff-Ferrari and colleagues conclude their paper as follows: “High-dose 
vitamin D supplementation (≥20 µg/day) was somewhat favourable in the prevention of 
hip fracture and any non-vertebral fracture in persons ≥65 years”. The authors do mention, 
however, that all trials with vitamin D dosages ≥20 µg/day also supplemented calcium and 
that therefore the effect of an actual vitamin D intake ranging from 19.8-25 µg/day without 
additional calcium could not be assessed [49]. Tang and colleagues (2007) reviewed evidence 
of calcium use and calcium in combination with vitamin D on fracture risk by including 
17 trials, showing a significant risk reduction, RR 0.88 (95% CI 0.83-0.95) [48]. Separate 
analyses of the trials that supplemented calcium only and those supplementing calcium in 
combination with vitamin D shows that there is only a small and non-significant difference 
between the two. The authors postulate that this may be because the vitamin D dosages 
used - 800 IU or lower - were not high enough to be effective in reducing fracture risk. A 
meta-analysis performed by the US Department of Health and Human Services (UDHHS) 
including ten double-blinded and three open design trials (n=58,712) investigated the effect 
of vitamin D supplementation on total fracture risk among postmenopausal women and 
men aged ≥50 years and did not find a significant fracture reduction (pooled OR 0.90 with 
95% CI 0.81-1.02) [46]. The authors suggest that the benefit of vitamin D may depend 
on additional calcium and may be primarily seen in institutionalized individuals, which is 
consistent with the meta-analysis of Boonen and colleagues [45]. Also in the DIPART Study, 
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including seven RCTs in which vitamin D or vitamin D in combination with calcium was 
used to prevent fractures, Hazard Ratios (HR) of 1.01 (95% CI 0.92-1.12) and 0.92 (95% 
CI 0.86-0.99) were found for analyses including any fracture, respectively [47]. Subgroup 
analyses within the analysis by the UDHHS, including four trials reporting 25(OH)D 
concentrations >74 nmol/L at the end of the study, showed a statistically significant decreased 
fracture risk for participants reaching those concentrations [46]. These results are consistent 
with the outcomes of the more recent meta-analysis [30], which included 12 double-blind 
RCTs for non-vertebral fractures (n=42,279) and eight RCTs for hip fractures (n=40,886). 
Significant heterogeneity for received dose of vitamin D and achieved concentration of 
25-hydroxyvitamin D in the treatment group for hip and any non-vertebral fractures was 
found [30]. No fracture reduction was observed for a received dose of 10 µg/day or less or 
achieved 25(OH)D concentrations <74 nmol/L. Conversely, a higher received dose of 12-19 
µg/day supplemental vitamin D reduced non-vertebral fractures by 20% (pooled RR 0.80 
with 95% CI 0.72-0.89; n=33,265 from nine trials) and hip fractures by 18% (pooled RR 
0.82 with 95% CI 0.69-0.97; n=31,872 from five trials). The IOM confirms a significant 
fracture reduction among those that reach ≥75 nmol/l in the treatment group. However, the 
IOM questions this finding as different assays were used to measure 25(OH)D concentrations 
with uncertain accuracy [8, 50, 51]. However, in an earlier meta-analysis of double-blind 
RCTs Bischoff-Ferrari et al. (2005) argue that despite inter-laboratory differences there would 
still be a similar trend between higher 25(OH)D status and fracture reduction [52]. The 
aforementioned differences in interpretation and other methodological differences between 
studies has resulted in the current discussion on optimal 25(OH)D concentrations [49, 53-
57].
2.5.4 Physical performance
Human muscle tissue is also a potential target organ for vitamin D action [58]. Clinical 
findings in vitamin D deficiency-associated myopathy include proximal muscle weakness, 
diffuse muscle pain, and gait impairments such as waddling way of walking [59]. RCTs 
demonstrated that 20 µg/day vitamin D3 resulted in a 4-11% gain in lower extremity 
strength or function [60, 61], a 9%-28% improvement in body sway in adults aged ≥65 
years after 2-12 months of treatment [61, 62] and in an up to 72% reduction in the rate of 
falls [43]. In fact, it has been suggested that the benefit of vitamin D on fracture risk may 
be mediated by the effect on muscle strength and fall prevention [63]. Extending to trials 
among individuals with a lower risk of vitamin D deficiency and including open design 
trials, a meta-analysis by Stockton et al. (2011) identified 17 RCTs that tested any form 
of vitamin D treatment and documented a muscle strength related endpoint. The authors 
suggested that based on their pooled findings, vitamin D may not improve grip strength, but 
a benefit of vitamin D treatment on lower extremity strength could not be excluded among 
individuals with 25(OH)D starting concentrations of >25 nmol/L. In addition, the authors 
report a significant benefit among two studies with participants that started with 25(OH)D 
concentrations <25 nmol/L [64]. Muir and Montero-Odasso (2011) also conducted a review 
of RCTs on the effect of vitamin D supplementation on physical performance and showed an 
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effect on strength and balance, but not gait. One of the issues addressed by the authors is the 
possibility of selection bias [9]. The authors speculated that RCTs that excluded persons with 
specific medical conditions may have resulted in the attenuation of an probable relationship, 
as the persons with these specific conditions may be the ones experiencing the greatest benefit 
of supplementation with vitamin D [9]. Mechanistic studies show several pathways through 
which vitamin D may stimulate muscle mass and muscle strength, including amongst others 
the promotion of muscle cell proliferation and growth, and an increase in the diameter 
and the percentage of type II muscle fibres [58]. Moreover, a genomic pathway has been 
postulated via binding with the vitamin D receptor (VDR) in muscle resulting in de novo 
protein synthesis [65, 66]. However, a recent publication questions the presence of VDR in 
muscle tissue as the receptor could not be located in this study while using a highly specific 
antibody [67].
2.5.5 Insulin Resistance and Type 2 Diabetes
Based on association studies it has been suggested that there is a possible role for vitamin 
D in the regulation of glucose and insulin concentrations [68-71]. Vitamin D receptors 
and 1-α-hydroxylase have been identified in the pancreatic β-cell. Via its ability to regulate 
calcium fluxes, vitamin D may furthermore influence insulin release as well as insulin action. 
Moreover, by affecting cytokine production, vitamin D may play a beneficial role in β-cell 
survival and insulin sensitivity. The evidence up to now shows that although animal studies 
and several epidemiological cohort studies point towards a protective effect of 25(OH)D 
status on the development of type 2 diabetes [72], RCTs have not yet provided convincing 
evidence [12]. Mitri and colleagues (2011) discuss that results of observational studies have to 
be interpreted with caution as they are limited by the possibility of residual confounding and 
reverse causation. Moreover, studies often rely on only one serum 25(OH)D measurement, 
while 25(OH)D concentrations fluctuate during the year [12]. The authors also speculate 
about the inconclusive data from trials. RCTs were often small, not specifically designed 
to assess the effect of vitamin D on glucose outcomes and used relatively low dosages. 
Furthermore, it is difficult to account for exposure to other sources of vitamin D, including 
UV-radiation and oral intake via foods [12]. 
2.5.6 Cognitive functioning and dementia
A growing body of evidence implicates low serum 25(OH)D concentrations in the 
pathogenesis of brain dysfunction including multiple sclerosis [13] and stroke [73]. Low 
25(OH)D concentrations are also associated with prevalent cognitive impairment and 
dementia as reviewed by Balion et al. (2012) [11]. For example, in older adults in the Health 
Survey for England who were severely vitamin D deficient (<25 nmol/L) an almost three 
times increased odds of cognitive impairment was observed when compared to those who 
had adequate vitamin D concentrations (>75 nmol/L) [74]. Similarly, severely deficient US 
older adults in the NHANES were almost four times more likely to be cognitively impaired 
than those with a sufficient vitamin D status (OR 3.9 with 95% CI 1.5-10.4) [75]. However, 
cross-sectional studies are unable to exclude the possibility that such associations are a result 
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of disease progression rather than being causal. Animal and in vitro experiments suggest 
that vitamin D is neuroprotective through several mechanisms, including vasoprotection and 
amyloid phagocytosis and clearance [76, 77]. Two large prospective studies go some way 
to establish the temporal relationship with cognitive decline. The risk of cognitive decline, 
as assessed with the Mini Mental State Examination (MMSE), was 60% higher in older 
Italian adults in the InCHIANTI study who are severely deficient when compared with those 
with sufficient concentrations [78]. After adjustment for age, site and season of blood drawn 
an OR of 1.41 (95% CI 0.61-3.28) for cognitive decline was observed when Slinin and 
colleagues (2010) compared older US men in the Osteoporotic Fractures in Men Study in 
the lowest quartile (<50 nmol/L) with those in the highest quartile (>74 nmol/L), however 
the association was not significant [79]. Future neuroimaging studies and randomized trials 
are needed to provide further information about the underlying mechanisms and the efficacy 
of vitamin D supplements in combating dementia.
2.5.7 Adverse health effects
There is little or no data on toxicity of high doses of vitamin D for more than one year. A safe 
upper intake of 250 µg/day (10,000 IU/day) based only on serum calcium data is described 
in the most recently published benefit - risk assessment by Bischoff- Ferrari et al. (2010) [80]. 
In 2010 the IOM applied a safety factor of 2.5 and defined a safe upper limit of 100 µg/
day [8]. A recent cross-sectional post mortem bone histology study showed no pathologic 
accumulation of osteoid in a mixed German population of men and women with serum 
25(OH)D concentrations >75 nmol/L although in 97.5% of the cases abnormal osteoid 
was only present <50 nmol/L. On the other hand, a reasonable proportion of those with 
25(OH)D concentrations <25 nmol/L appeared to have normal bone mineralization, 
suggesting that it is not possible to directly extrapolate these results to the individual level 
[81]. Care has to be taken with regard to calcium intake, as a too high calcium intake may 
increase cardiovascular disease (CVD) risk [82]. Gallagher and colleagues (2012) observed 
hypercalciuria in 30% of women treated with vitamin D and a calcium intake of 1260 
mg/day [83]. Moreover, an increased prevalence of nephrolithiasis was observed in the 
Women’s Health Initiative, in which participants were assigned to 10 µg/day vitamin D 
in combination with 1000 mg calcium during on average 7 years [84]. At this moment, 
evidence for an adverse effect of high serum 25(OH)D concentrations is inadequate, possible 
adverse interactions with high calcium intakes may require further attention.
2.6 Diet, sunlight and 25(OH)D 
The interaction between diet and sunlight exposure on 25(OH)D concentrations, functional 
markers of calcium metabolism, and bone health has been investigated in Asian and Caucasian 
women living in Surrey, Southern England, participating in the D-FINES Study. Comparing 
D-FINES data with data of women living in Aberdeen (North England), Macdonald and 
colleagues (2011) showed that the average 25(OH)D concentrations were 10 nmol/L lower 
during the winter period compared to women living at lower latitude [85]. Although there 
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was three times as much rainfall in the summer of 2007, when compared to the summer of 
2005 and 2006, spring 25(OH)D concentrations in 2008 were not significantly affected. 
Caucasian women had consistently higher serum 25(OH)D concentrations than Asian 
women. Premenopausal status was associated with a 6 nmol/L higher serum 25(OH)D 
concentration when compared to postmenopausal status. Vitamin D intake levels were on 
average 2-3 µg/day and did not differ between the two ethnic groups. None of the Asian 
women was using vitamin D supplements at the start of the study, and exposure to sunlight 
appeared to be lower when compared to Caucasian women. 
As vitamin D2 and D3, the two calciferols, display different affinities for the vitamin D binding 
protein, food fortification with either vitamin D2 or D3 may differently affect 25(OH)D 
status. Studies in the 1930s did not point towards a distinction, but a recent trial comparing 
large doses of vitamin D2 versus vitamin D3 1250 µg/week for 12 weeks does suggest that 
vitamin D3 supplementation results in a higher increase of 25(OH)D concentrations over 
time [86]. Using smaller doses of D2 and D3 (25 µg/day), no differences in serum 25(OH)D 
were shown after 12 weeks of supplementation [87]. Currently, the D2-D3 study is conducted 
to further explore this dissimilarity between ergocalciferol and cholecalciferol. The study aims 
to compare the efficiency of 15 µg/day of both calciferols, determine whether there is a 
difference in effect of the calciferol when carried by either solid or fluid foods and disentangle 
potential underlying mechanisms. Based on aforementioned results it was suggested that 
dietary vitamin D intakes in the UK may be too low to significantly affect 25(OH)D status. 
As vitamin D only occurs in a small range of foods, food fortification may be one of the 
methods to increase dietary vitamin D intakes. Supplementation may, however, be necessary 
in specific populations like Asian people, which are at an increased risk for developing vitamin 
D deficiency. In future research it may be interesting to address the question whether there is 
a metabolic adaptation of populations accustomed to low 25(OH)D concentrations during 
specific periods of the year.
2.7 How to close the gap - Outlook for Europe
The meeting was concluded with a short overview of the current evidence of vitamin D 
recommendations and its effect on skeletal health and beyond. The main discussion among 
vitamin D researchers was related to the optimal 25(OH)D concentrations; do we aim for 
either concentrations ≥50 nmol/L or concentrations ≥75 nmol/L? The implications are 
that meeting a concentration of 50 nmol/L requires about 15-20 µg/day (600-800 IU), 
whereas meeting a concentration of 75 nmol/L requires 40-50 µg/day (1600-2000 IU) 
[83]. Before reaching a consensus on the optimal DRIs, participants of the meeting stated 
that the postulated DRIs should preferably be based on RCTs and had to be applicable to 
the general population. For those at an increased risk for developing inadequate 25(OH)D 
concentrations a more specific advice had to be formulated. Lastly, recommendations should 
preferably be harmonized across Europe. Subsequently, the experts concluded that up to now 
for most health outcomes, except bone health and risk reduction of falls (EFSA claim), there 
is insufficient evidence with regard to the optimum 25(OH)D concentration or vitamin 
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D intake. When summarizing the evidence several aspects have to be taken into account. 
Firstly, most RCT examining the effect of vitamin D on bone health and fall prevention 
co-administered calcium. The individual effect of vitamin D is therefore difficult to assess. 
Secondly, in vitamin D supplementation trials it is difficult to account for difference in 
UV-radiation, which may interact with the relations studied. Thirdly, most human studies 
on vitamin D and health outcomes beyond bone health were observational, using either 
cross-sectional or prospective data. Therefore, the possibility of reverse causation and residual 
confounding cannot be excluded. Fourthly, evidence from in vitro and molecular studies have 
to be read with caution as they often link 1,25(OH)D concentrations with specific target 
tissues [88], while 1,25(OH)D is not the optimal biomarker for vitamin D and showing a 
low correlation with 25(OH)D status [89]. Finally, pooling and comparing studies is difficult 
due to the lack of standardization of 25(OH)D assays [90]. Most assays used today are able 
to distinguish between high and low 25(OH)D concentrations, however there may be quite 
some variation when looking at the absolute concentrations. 
2.7.1 Infants and children 
Critical analysis of the current scientific evidence shows that, in children, rickets is preventable 
by a dose of 10 µg vitamin D each day, which is in consensus with the current guidelines 
for this target group in the US, UK, Belgium and the Netherlands. Therefore, the consensus 
dose for both infants and children was set at 10 µg/day. Difficulties in implementing these 
recommendations, however, include that more and more vitamin D enriched products are 
sold. 
2.7.2 Adults and elderly
Osteoporotic fracture risk has been shown to decrease with vitamin D intakes of 12-19 µg/
day [30], in combination with an adequate calcium intake. Direct and indirect evidence 
indicates furthermore that 25(OH)D concentrations of ≥50 nmol/L are desired and not 
contraindicated with regard to other health outcomes, including the optimal functioning 
of the parathyroid glands/PTH secretion [91, 92], calcium metabolism [93, 94] and BMD 
[95-97]. Moreover, valid hypotheses based on preclinical data and in vitro studies have 
been raised for a role of vitamin D in the development of extra-skeletal diseases, including 
respiratory infections, tuberculosis, multiple sclerosis, cancer, diabetes and CVD. RCTs, 
however, are needed to verify these results. As supplementation of 15-20 µg/day has been 
shown to increase 25(OH)D concentrations ≥50 nmol/L and since there is, at present, 
insufficient evidence supporting an amplified beneficial role of vitamin D with 25(OH)D 
serum concentrations >50 nmol/L, the meeting considered a vitamin D intake of 20 µg/day 
to be sufficient in a population of healthy adults and elderly, which is in line with the recently 
published DACH recommendations [20]. To date, there is insufficient data on the optimal 
25(OH)D concentrations in order to achieve the maximum peak bone mass in adolescence 
and young adulthood, therefore no specific DRI was formulated for this age group. Issues 
remaining after the discussion were related to the safety level of intakes higher than 50 µg/day 
during a longer period, whether a higher dose of vitamin D eliminates the need for calcium 
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supplements and how to implement and increase the compliance to current guidelines. In 
conclusion, there is evidence suggesting that vitamin D - besides its established role in bone 
health - may contribute to reduce the risk of a variety of chronic diseases to benefit human 
health, but more evidence is warranted. It is generally felt that in adults a daily intake of 20 
µg vitamin D is a safe dose to assure an appropriate vitamin D status. 
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Abstract 
Background 
Sun exposure and vitamin D intake are known to have the ability to raise serum vitamin 
D concentrations. Despite this knowledge, the prevalence of vitamin D deficiency is high 
and particularly older adults are at risk. To improve the current prevention and treatment 
strategies, this study aims to identify determinants of vitamin D status in a population of 
community-dwelling Dutch older adults. 
Methods 
Serum vitamin D (25(OH)D) was measured in 2857 older adults aged ≥65 years. Sun 
exposure was assessed using a structured questionnaire. Dietary vitamin D intake and 
supplement use were assessed with a Food Frequency Questionnaire. Relevant single 
nucleotide polymorphisms (SNPs) were genotyped using the Illumina Omni-express 
array.  
Results 
Serum 25(OH)D concentrations <50 nmol/L were observed in 45% of the population, 
of which only 6% reported vitamin D supplement use. Higher summer sun exposure 
(outside daily two weeks prior to blood sampling: 66±25 nmol/L vs. not outside daily 
two weeks prior to blood sampling: 58±27 nmol/L, F633=5.6, P=0.02) and vitamin D 
intake (summer: β 1.0±0.4 µg/day, P=0.02, winter: β 3.1±0.8 µg/day, P<0.0001) were 
associated with higher 25(OH)D concentrations. Major allele carriers of SNPs related 
to DHCR7, CYP24A1, GC, and CYP2R1 minor allele carriers had the highest 25(OH)D 
concentrations. Age, sex, BMI, education, alcohol consumption, smoking, physical activity 
level, self-rated health status, sun exposure (R2=0.16), vitamin D intake (R2=0.12) and 
vitamin D related genes (R2=0.15) together explained 35% (R2=0.35) of the variation in 
25(OH)D concentrations during the summer period. 
Conclusion 
Of the three main determinants under study, sun exposure was the most important 
determinant of serum 25(OH)D, closely followed by genes and vitamin D intake. Given 
the low frequency of vitamin D supplement use, promoting supplement use may be an 
inexpensive, easy and effective strategy to fight vitamin D deficiency. 
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3.1 Introduction
In the Netherlands about half of the community-dwelling older adults have a vitamin D 
status (25(OH)D) <50 nmol/L [1] and are classified as having an insufficient vitamin D 
status according to recent guidelines of the Institute of Medicine (IOM) [2]. In order to 
tackle this issue of low 25(OH)D concentrations it is important to gain knowledge on its 
main determinants. 
With a limited number of foods that contain vitamin D, one of the sources of vitamin D is the 
diet. However, vitamin D is mainly acquired through sunlight exposure, specifically ultraviolet-B 
radiation (UV-B), which activates the cutaneous synthesis of pre-vitamin D3 in the skin [3]. The 
efficiency of sun exposure and vitamin D intake to increase 25(OH)D concentrations depends 
on a variety of factors, including latitude, season, air pollution, sunscreen use, skin pigmentation, 
age, efficiency of absorption in the gut, liver and kidney functioning, and medication use [4]. To 
illustrate this, at higher latitudes (i.e. >50°N) the intensity of UV-B during the winter months 
is assumed to be too low to activate the vitamin D synthesis in the skin [5]. It is also shown 
that 25(OH)D concentrations decrease with age, due to a decrease in cutaneous vitamin 
D synthesis [6]. Also, genetic make-up has been associated with vitamin D metabolism 
and variations in 25(OH)D concentrations [7]. Thus, 25(OH)D concentrations depend 
on a broad variety of factors ranging from environmental factors to genetics. Despite this 
knowledge, vitamin D deficiency is observed worldwide [8, 9], especially among older adults 
[10]. 
This study is performed to assess the prevalence of vitamin D deficiency, and to examine 
the associations of vitamin D intake, vitamin D supplement use, sun exposure, and genetic 
variance with 25(OH)D concentrations in a population of community-dwelling Dutch older 
men and women aged ≥65 years. Identification of the relative contribution of these factors 
to 25(OH)D status, might help to pinpoint important determinants in the prevention and 
treatment of vitamin D deficiency.
3.2 Methods
3.2.1 Participants
This cross-sectional study was performed using baseline data of the B-PROOF study; a 
randomized double-blind, placebo-controlled trial designed to assess the efficacy of daily oral 
supplementation with vitamin B12 and folic acid on fractures in mildly hyperhomocysteinemic 
(plasma homocysteine 12-50 µmol/L) older adults ≥65 years. Details of this study have 
been reported elsewhere [11]. Data on 25(OH)D concentrations were available of 2857 
participants. Genetic information on vitamin D related genes was obtained from 2530 
participants. Sun exposure was assessed in 1012 participants and vitamin D intake in 596 
participants. The Medical Ethics Committee of Wageningen UR approved the study protocol 
and the Medical Ethics Committees of VUmc and Erasmus MC confirmed local feasibility. 
All participants gave their written informed consent.
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3.2.2 Dietary assessment
Dieticians at the division of Human Nutrition at Wageningen University developed a 190-
item Food Frequency Questionnaire (FFQ) to measure vitamin D intake and vitamin D 
supplement use. The questionnaire was developed based on two validated FFQs [12, 13], and 
updated to include vitamin D intake by means of the Dutch FFQ-TOOL™. Specifically, food 
items contributing to ≥0.1% of the total intake of vitamin D intake were included, which 
was estimated to cover 80% of total vitamin D intake based on the Dutch National Food 
Consumption Survey of 1998 [14]. 
3.2.3 Sun exposure
Habitual sunlight exposure was assessed using a questionnaire that was administered on the 
day of blood sampling. Data were collected on the amount of time spent outdoors and in 
the sun during the summer, use of sun protection and solariums, type of clothing worn 
during the summer, and holidays with a sunny destination in the three months prior to blood 
sampling. 
3.2.4 Biochemical analyses
Blood samples were collected in the morning when the participants were fasted or had 
consumed a restricted breakfast, and collected throughout the year. Samples were stored at 
-80˚C until determination. Serum 25(OH)D was measured by isotope dilution-online solid 
phase extraction liquid chromatography-tandem mass spectrometry (ID-XLC-MS/MS) [15]. 
3.2.5 Genotyping
DNA was isolated from buffy coats. Samples were genotyped for about 700000 SNPs using the 
Illumina Omni-express array, covering >90% of all common variations in the genome. SNPs 
selected for this study included rs12785878 (DHCR7), rs6013897 (CYP24A1), rs10741657 
(CYP2R1) and rs2282679 (GC), which was based on a genome-wide association study on 
relations between genes and serum 25(OH)D concentrations by Wang and colleagues (2010) 
[7].
3.2.6 Covariates
Height was measured at baseline with a stadiometer to the nearest 0.1 cm. Weight was 
measured to the nearest 0.5 kg with a calibrated analogue scale, while wearing light cloths. 
Body Mass Index (BMI) was calculated as weight/height2. Data on educational level (years), 
smoking status (never, current, former), physical activity (kcal/day) [16], and alcohol 
consumption (light, moderate, excessive) [17] were collected by means of questionnaires. 
Self-rated health was obtained from the Short-Form Health Survey (SF-12) [18]. Season 
of blood collection was dichotomized into summer/autumn (June-November) and winter/
spring (December-May).
3.2.7 Statistical Analyses
Participants characteristics are reported as mean with standard deviation (SD), or 
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percentages. To compare baseline characteristics of participants with inadequate serum 
25(OH)D concentrations (<50 nmol/L) with participants with adequate serum 25(OH)D 
concentrations (≥50 nmol/L), chi-squared tests for categorical variables and independent t-tests 
for continuous variables were performed. To assess the association between the total vitamin 
D intake and serum 25(OH)D status multiple linear regression analyses were conducted with 
adjustment for age, sex, BMI, years of education, alcohol consumption, smoking, physical 
activity and self-rated health status, stratified by season. Analyses of Covariance (ANCOVA) 
was used to explore the associations between sunlight exposure and serum 25(OH)D with 
adjustment for age, sex and BMI, and stratified by season. Associations between vitamin 
D related genetic make-up and 25(OH)D concentrations were tested using ANOVA. In 
order to further investigate the importance of summer sunlight exposure, vitamin D intake 
and genes to the variation in serum 25(OH)D concentrations, all three factors for serum 
25(OH)D were individually and simultaneously added to the multiple linear regression 
model, where age, sex, BMI, years of education, alcohol consumption, smoking, physical 
activity and self-rated health status were included as potential covariates. In view of the 
seasonal variation in 25(OH)D status, only data obtained during the summer were included 
in the model. All tests were two-sided (P<0.05). Analyses were performed using the statistical 
package SPSS, version 21.0 (SPSS Inc., Chicago, IL, USA). 
3.3 Results
Descriptive data of the population are shown in Table 1. Of 2857 Dutch men and women 
45% had a vitamin D deficiency defined as a serum 25(OH)D concentration <50 nmol/L. 
As expected, stratification for season showed that the prevalence of vitamin D deficiency was 
higher when blood samples were collected during the winter/spring (63%) than summer/
autumn (37%). Participants with vitamin D deficiency were more likely to be older, and 
woman, to have a higher BMI, and a lower physical activity level, and intake of vitamin D 
and alcohol. Figure 1 confirms the expected age-related differences in serum 25(OH)D. 
Table 1. Descriptive statistics of 2857 Dutch men and women aged ≥65 years.
25(OH)D
<50 nmol/L
25(OH)D
≥50 nmol/L
P-value N
25(OH)D, nmol/L 34±10 74±18 <0.0001 2857
Age, years 75.1±7.1 73.2±5.9 <0.0001 2857
Sex, n (% men) 597 (42) 831 (58) <0.0001 2857
BMI, kg/m2 27.5±4.3 26.8±3.6 <0.0001 2842
Physical activity level, kcal/day 598±440 691±502 <0.0001 2842
Education, years 9.8±3.9 10.3±4.0 0.11 2855
Smoking, n (%)
• Never
• Current
• Former
459 (36)
142 (11)
690 (53)
510 (32)
135 (9)
921 (59)
0.01 2857
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Note: values are expressed as a mean ± SD, median (IQR) or n (%).
3.3.1 Sunlight
Figure 1 shows a clear fluctuation in serum 25(OH)D throughout the year. Additionally, 
ANCOVA indicates that all sunlight measures are significantly associated with serum 
25(OH)D in participants that are included during the summer months, while taking into 
account age, sex and BMI (Table 2) (n=1012). Specifically, ‘daily outside two weeks prior 
to blood sampling’ (F633=5.6, P=0.02), ‘daily outside during summer’ (F633=4.9, P=0.03), 
‘clothing’ (F621=19.5, P<0.0001), ‘sun holiday’ (F631=18.9, P<0.0001), ‘sun lamps’ (F628=13.6, 
P<0.0001) and ‘sunscreen use’ (F631=5.8, P<0.01). Associations for ‘daily outside two weeks 
prior to blood sampling’ (F362=4.1, P=0.04) and ‘sun lamp use’ (F360=11.0, P<0.01) with 
serum 25(OH)D were less strong, but still significant, in participants that were included 
during the winter months. ‘Daily outside during summer’ (F359=1.0, P=0.32), ‘clothing’ 
(F355=3.0, P=0.09), ‘sun holiday’ (F358=4.0, P=0.05) and ‘sunscreen use’ (F359=3.0, P=0.05) 
were not significant anymore during the winter.
Figure 1. Serum 25(OH)D distribution (mean±SE) per month and per age group in Dutch men and women 
aged ≥65 years.
25(OH)D
<50 nmol/L
25(OH)D
≥50 nmol/L
P-value N
Alcohol consumption, n (%)
• Light
• Moderate
• Excessive
925 (72)
318 (25)
46 (3)
998 (64)
505 (32)
63 (4)
<0.0001 2855
Self-experienced health, n (%)
• Excellent
• Very good
• Good
• Mediocre
• Poor
79 (6)
230 (18)
787 (61)
183 (14)
11 (1)
130 (8)
386 (25)
874 (56)
170 (11)
5 (0)
<0.0001 2855
Blood sampling, n (%)
• December until May
• June until November
813 (63)
478 (37)
543 (35)
1023 (65) 
<0.0001 2857
Vitamin D supplement use, n (%) 174 (6) 411 (14) <0.0001 2857
Total vitamin D intake, µg/day 4.2±2.1 5.2±3.2 <0.0001 596
Vitamin D intake from foods, µg/day 4.0±1.9 4.5±2.1 0.002 596
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Table 2. Associations between sun exposure and serum 25(OH)D of 1012 Dutch men and women aged ≥65 
years, stratified for season.
Note: Serum 25(OH)D concentrations (nmol/L) are displayed as means±SD. Models are adjusted for age, sex 
and BMI. 
3.3.2 Vitamin D intake
Mean vitamin D intake was 4.9±2.9 µg/day. Vitamin D intake was significantly associated 
with serum 25(OH)D; stratification for season revealed that the association between vitamin 
D intake and 25(OH)D status was more pronounced during winter (β 3.1±0.8, P<0.0001) 
than during summer (β 1.0±0.4, P=0.02). These linear regression coefficients suggest that a unit 
increase in vitamin D intake is associated with a 3.1 nmol/L increase in serum 25(OH)D during 
the winter, and with a 1.0 nmol/L increase in serum 25(OH)D during the summer. 
3.3.3 Vitamin D related genetic make-up
Figure 2 shows that vitamin D status significantly differed between allele carriers for 
all genes, except for the CYP24A1 gene. As expected there were difference in 25(OH)D 
concentrations between summer/autumn and winter/spring, but differences between the 
alleles were reasonably comparable. The gene GC, which encodes for the protein related to 
vitamin D transport in the circulation, was most strongly associated with serum 25(OH)D 
(P<0.0001), indicating that minor allele carriers have the lowest 25(OH)D concentrations 
(53±20 nmol/L) and major allele carriers the highest 25(OH)D concentrations (68±25 
nmol/L). 
Summer Winter
25(OH)D Fdf , P-value 25(OH)D Fdf , P-value
Daily outside 2 weeks 
before blood sampling
• No
• Yes
58±27
66±25
F633=5.6, P=0.02
41±19
47±21
F362=4.1, P=0.04
Daily outside 
during summer 
• No
• Yes
57±25
66±25
F633=4.9, P=0.03
42±20
46±21 
F359=1.0, P=0.32
Clothing
• Long sleeved
• Short sleeved
51±27
66±25
F621=19.5, P<0.0001
42±22
47±20
F355=3.0, P=0.09
Sun holiday in 3 
months before 
blood sampling
• No
• Yes
62±25
73±23
F631=18.9, P<0.0001
44±21
51±18
F358=4.0, P=0.05
Use of sunlamps
• No
• Yes
64±26
78±20
F628=13.6, P<0.0001
44±20
59±27
F360=11.0, P<0.01
Sunscreen use
• Always
• Sometimes
• Never 
69±24
67±26
60±25
F631=5.8, P<0.01
51±22
45±18
43±22
F359=3.0, P=0.05
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Figure 2. Differences in 25(OH)D concentrations by alleles of vitamin D related genetic make-up analysed 
using ANCOVA, stratified by period of blood sampling (n=2530). Note: June-November: Bonferroni post hoc 
tests indicate significant differences for DHCR7 [heterozygotes vs. major], CYP2R1 [minor vs. major] and 
GC [minor vs. heterozygotes, heterozygotes vs. major, minor vs. major]. December-May: Bonferroni post hoc 
tests indicate significant differences for DHCR7 [minor vs. major], CYP2R1 [heterozygotes vs. major] and GC 
[minor vs. heterozygotes, heterozygotes vs. major, minor vs. major].
Table 3. Regression analysis to assess the relative importance of vitamin D intake, sunlight exposure and 
vitamin D related genetic make-up, using data of 185 Dutch men and women aged ≥65 years that were 
obtained during the summer months.
Note: The model was adjusted for age (sβ -0.21, P=0.003), sex (sβ -0.15, P=0.06), BMI (sβ -0.21, P=0.004), years 
of education (sβ -0.12, P=0.08), smoking (sβ -0.03, P=0.66), alcohol consumption (sβ 0.11, P=0.12), physical 
activity level (sβ 0.05, P=0.45) and self-experienced health (sβ -0.09, P=0.24). sβ = standardized beta.
3.3.4 Sunlight, vitamin D intake, genetic make-up and serum 25(OH)D
Finally, after considering the individual associations of sun exposure, vitamin D intake and 
vitamin D related genetic make-up with 25(OH)D concentrations, a multiple linear regression 
analysis was conducted with the data of participants that were included during summer. 
First of all, the individual R2 was calculated for sunlight (n=613), intake (n=370) and genes 
(n=1318) with serum 25(OH)D, while taking into account age, sex, BMI, education, alcohol 
consumption, smoking, physical activity and self-rated health status. Vitamin D intake 
explained 12% of the variance in 25(OH)D concentrations, sun exposure 16%, and genes 
15%. Together these factors (n=185) were able to explain 35% of the variance in 25(OH)D
β SE sβ P-value
(Constant) 147.7 34.1 - <0.0001
CYP24A1 4.1 3.1 0.09 0.18
GC 7.4 2.6 0.18 0.005
DHCR7 2.5 2.9 0.06 0.39
CYP2R1 -4.2 2.3 -0.12 0.07
Outside past 2 weeks 15.6 6.2 0.24 0.01
Outside past summer -9.2 6.5 -0.14 0.16
Clothing worn 2.4 6.7 0.03 0.72
Sunscreen use -2.2 2.6 -0.06 0.41
Sunlamp use 12.7 5.7 0.14 0.03
Sun holiday 3.7 4.4 0.06 0.40
Vitamin D intake 0.4 0.5 0.06 0.38
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concentrations as reflected by an R2 of 0.35 (adjusted R2: 0.27), again also age, sex, BMI, 
education, alcohol consumption, smoking, physical activity and self-rated health status were 
included in the model (Table 3 and Figure 3). 
Figure 3. Explained variance per component (n=613 for sunlight exposure, n=370 for total vitamin D intake 
and n=1318 for genes) and for the total model using data of the people that were included during the summer 
months (n=185 for the total model), adjusted for age, sex, BMI, years of education, alcohol consumption, 
smoking, physical activity and self-rated health status.
3.4 Discussion
In this population of community-dwelling older adults living at a latitude of ±52°N, 45% of 
the participants had 25(OH)D concentrations <50 nmol/L. Total vitamin D intake was far 
below the recommended levels of 20 µg/day as set by the Dutch Health Council for adults 
≥70 years [19]. Supplement use was reported by 20% of the participants. Total vitamin 
D intake, sunlight exposure and vitamin D related genetic make-up were all significantly 
associated with serum 25(OH)D. When exploring the individual contribution of the three 
factors to serum 25(OH)D status, while taking into account covariates, vitamin D intake 
explained 12% of the variance in 25(OH)D concentrations, sunlight exposure 16% and 
vitamin D related genetic make-up 15%. Including these three factors simultaneously, again 
taking relevant covariates into account, explained 35% of the variance in serum 25(OH)D.
3.4.1 Methodological considerations
In order to appreciate these findings several methodological issues of this study warrant 
further discussion. To the best of our knowledge, this is the first study examining the relative 
contribution of habitual sunlight exposure, vitamin D intake, and genetic make-up to the 
variation in serum 25(OH)D in community-dwelling older adults. Since participants were 
included throughout the year, we had the possibility to study the associations in the winter and 
the summer period. Unfortunately, we could not account for the potential role of medication 
R2=0.35
adjR2=0.27
R2=0.16
adjR2=0.14
R2=0.15
adjR2=0.15
R2=0.12
adjR2=0.10
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use or diseases known to alter the absorption and metabolism of vitamin D. However, as 
persons with elevated creatinine concentrations were excluded from participation in the 
study, we do not assume that renal dysfunction substantially influenced the associations 
studied. Another possible limitation is the use of a non-validated FFQ. The FFQ, however, 
was compiled using a validated FFQ tool. In addition, our vitamin D intake data are in line 
with recent vitamin D intake data of this age group that were obtained from the Dutch Food 
Consumption Survey of 2013 [20], suggesting that the reported vitamin D intake estimates 
can be considered relatively accurate. Finally, we used a very basic questionnaire to assess 
sun exposure, which probably resulted in an underestimation of the explained variation in 
25(OH)D concentrations resulting from UV-B exposure. The use of dosimeters might have 
provided a more accurate estimate of UV-B exposure [21]. 
3.4.2 Vitamin D deficiency
Serum 25(OH)D concentrations of 50 nmol/L or higher are considered sufficient in order to 
prevent disturbances in calcium metabolism [2]. Recent insights also indicate that 25(OH)D 
deficiency may relate to cardiovascular problems, glucose homeostasis, autoimmune disease, 
muscle strength and cognitive function  [4, 9, 22-24]. Thus, the low 25(OH)D concentrations 
in this population of older adults are alarming. 
3.4.3 Sunlight exposure and 25(OH)D concentrations
Despite the fact that the role of sunlight exposure in the maintenance of adequate serum 
25(OH)D concentrations has been shown to decrease with age [6], the surrogate markers 
for sun exposure obtained in this study did significantly associate with 25(OH)D status. 
Interestingly, serum 25(OH)D was higher among the participants that reported to use 
sunscreen. It may be that participants with a higher sun exposure were the same participants 
that felt the necessity to use sunscreen, and that due to their overall higher sun exposure these 
participants still had the highest 25(OH)D concentrations. 
3.4.4 Vitamin D intake and 25(OH)D concentrations
Total vitamin D intake - including both dietary intake and supplement use - in this population 
was 4.9±2.9 µg/day. Vitamin D supplement use was reported by 20% of the population 
of which 6% had a 25(OH)D deficient status. Studies in southern European countries as 
well as Australia have reported vitamin D intakes ranging from 1.2-1.4 µg/day [25-27]. In 
Scandinavian countries, where vitamin D fortified products are more common, substantially 
higher vitamin D intake levels have been observed, ranging from 6-8 µg/day [28, 29]. The 
vitamin D intake in this Dutch population is far from adequate [19], which can be explained 
by the facts that the Dutch diet does not contain many foods that are naturally rich in 
vitamin D, and that fortified products are hardly available. Therefore, Dutch men and women 
≥70 years are recommended to use 20 µg vitamin D daily via supplements [19]. However, 
based on our data and data from the Dutch Food Consumption Survey 2013 [20], it can 
be concluded that the adherence to this recommendation is low. Therefore, more actively 
promoting the vitamin D recommendation may be important to reduce the prevalence of 
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25(OH)D deficiency, particularly during the winter months. The dose-response analyses 
between vitamin D intake and serum 25(OH)D in our study showed that a µg increase 
in vitamin D intake associates with a 1.0 nmol/L higher serum 25(OH)D concentration 
during the summer/autumn, and with a 3.1 nmol/L higher serum 25(OH)D concentration 
during the winter/spring. This finding is in line with previous studies that showed that the 
magnitude of the association between dietary vitamin D intake and 25(OH)D status was 
stronger during winter period, than during summer period [26, 29-31]. 
3.4.5 Vitamin D related genetic make-up and 25(OH)D concentrations
In this population three out-of four investigated genes in the pathway of vitamin D 
metabolism (i.e. DHCR7, CYP2R1, and GC) were significantly associated with serum 
25(OH)D concentrations. These results are in line with the findings of a genome-wide 
association study by Wang and colleagues (2010) [7]. Our data suggests that the major 
allele frequency of the DHCR7 gene is associated with a higher 25(OH)D concentration. 
DHCR7 encodes for the enzyme 7-dehydrocholesterol reductase. This enzyme catalyses 
the conversion of 7-dehydrocholesterol into cholesterol in the skin, and thus prevents that 
7-dehydrocholesterol is metabolized into vitamin D. CYP2R1 minor allele frequency was also 
associated with higher 25(OH)D concentration. CYP2R1 encodes for the hepatic enzyme 
25-hydroxylase that converts vitamin D into 25(OH)D. Higher 25(OH)D concentrations 
were also observed in carriers of the major allele frequency of CYP24A1 and GC. CYP24A1 
encodes for an enzyme that initiates the degradation of 25(OH)D and 1,25(OH)D into 
calcitroic acid. GC is the major transport protein of vitamin D metabolites, such as 25(OH)D, 
to different target organs, tissues and cells [7]. 
3.4.6 Important determinants of serum 25(OH)D 
Previous estimations indicate that sunlight accounts for 70-90% of the 25(OH)D supply of 
the body [4]. In this study, summer sun exposure (16%) was also shown to explain most of 
the variance in serum 25(OH)D, closely followed by genetic make-up (15%) and vitamin 
D intake (12%). However, larger differences between the influence of sun exposure and 
vitamin D intake in relation to serum 25(OH)D were expected. Assessing sun exposure 
is, however, challenging and measurement error is very likely to occur. The three factors, 
together with potential relevant covariates, explained 35% of the variance in serum 
25(OH)D. When extending our findings to other studies that also calculated R2 in order to 
identify determinants of serum 25(OH)D, we conclude that there are substantial differences 
with respect to predictors included in the models. To the best of our knowledge, this is the 
first study taking into account genetic factors. Gilbert and colleagues (2012) did consider 
the integration of genetic information in their model. However, it was concluded that this 
information did not improve the fit of the prediction score of the data, which explained 
28% of the variation in 25(OH)D concentrations when sun exposure, vitamin D intake, 
anthropometrics, clinical factors, demographics, age, season, study centre and batch assay 
were included [32]. Other previous studies that included vitamin D intake, sun exposure, 
demographic and environmental factors were able to explain 21-33% of the variation in 
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25(OH)D status [27, 33, 34]. Studies considering vitamin D intake, demographic and 
environmental factors and season of blood sampling have shown an explained variation in 
25(OH)D concentration ranging from 19-28% [35-37]. 
3.4.7 Conclusion
In summary, the findings of this study acknowledge the previously reported inadequate 
vitamin D intake and the relatively high prevalence of 25(OH)D deficiency in older adults. 
Moreover, it was shown that UV-B exposure, vitamin D intake and vitamin D-related 
genetic make-up substantially contribute to the variability in 25(OH)D concentrations. 
The high prevalence of vitamin D deficiency as well as the low intake of vitamin D 
supplements indicate that more effort should be undertaken to encourage the use of vitamin 
D supplements in order to optimize the 25(OH)D concentrations in Dutch older adults, 
particularly during the winter months. Moreover, given the suggested importance of genes 
involved in vitamin D metabolism, in combination with the on-going debate on the question 
whether the associations found between 25(OH)D concentrations in non-skeletal health 
can be considered causal [38], these results plea for studies examining associations between 
vitamin D related genetic make-up and the health outcomes under debate. 
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Abstract
Purpose 
The classical consequence of vitamin D deficiency is osteomalacia, but recent insights into 
the function of vitamin D suggest that it may play a role in other body systems as well. The 
objective of this study was to examine the association between serum 25-hydroxyvitamin 
D (25(OH)D) and markers of glucose homeostasis (n=593), global cognitive performance 
(n=116), and depression (n=118) in European older adults participating in the SENECA 
study. Moreover, we wanted to explore whether the observed associations of serum 
25(OH)D with depression and global cognitive performance were mediated by fasting 
plasma glucose (FPG) concentrations.
Methods 
Cross-sectional associations between serum 25(OH)D and FPG, fasting plasma insulin 
(FPI) and Homeostasis Assessment-estimated Insulin Resistance (HOMA-IR) were 
estimated using multiple regression analyses. Associations of 25(OH)D status with global 
cognitive performance (MMSE) and depression (GDS-15) were examined using Poisson 
regression. 
Results
An inverse association was observed between serum 25(OH)D and FPG (β -0.001), 
indicating a 1% decrease in FPG per 10 nmol/L increase in serum 25(OH)D. However, 
after full adjustment for demographic factors, lifestyle factors, and calcium intake this 
association was not statistically significant anymore (P=0.07). Although participants with 
intermediate and high serum 25(OH)D concentrations showed a tendency towards 
a lower depression score after adjustment for demographic and lifestyle factors, RR 
and 95% CI: 0.73 (0.51-1.04) and 0.76 (0.52-1.11), respectively, these findings were not 
statistically significant.
Conclusion
An inverse association of serum 25(OH)D with depression, and FPG was observed, but 
these associations were not statistically significant. There was no association between 
serum 25(OH)D and FPI, HOMA-IR, or global cognitive performance. More studies are 
needed to further explore the possible role of vitamin D in the various body systems. 
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4.1 Introduction
Worldwide approximately 347 million people are affected by diabetes mellitus [1], which 
is mainly type 2 diabetes. Recent epidemiological studies suggest that diabetes patients are 
at increased risk of dementia [2] and depression [3]. The question whether the observed 
associations between these three ageing related diseases are the result of shared risk factors or 
specific biological mechanisms, however, remains to be solved. Vitamin D deficiency is one 
of the postulated links [4-8].
Vitamin D inadequacy is commonly observed in the elderly population. Restricted sun 
exposure, low vitamin D intake, and a decreased skin synthesis capacity may be involved in 
the development of vitamin D inadequacy in ageing populations. In the NHANES III study 
Martins and colleagues (2007) observed lower 25(OH)D concentrations in women, persons 
≥60 years, and obese and diabetic participants [9]. In 1984 a study among middle-aged and 
elderly English men and women showed that post-prandial glucose concentrations were higher 
during winter than during summer [10]. Since then, evidence supporting a role for vitamin 
D in glucose homeostasis expanded, including amongst others the identification of vitamin 
D receptors (VDRs) in the human pancreatic β-cell [11], the expression of 1-α-hydroxylase 
enzyme in the β-cell [12], and stimulation of the expression of insulin receptors by vitamin 
D in vitro [13]. The presence of 1-α-hydroxylase in cerebrospinal fluid and the existence 
of VDRs on various brain structures [14], support the hypothesis that vitamin D may be 
involved in brain function. 
However, while animal experiments point towards a protective effect of vitamin D with regard 
to development of several age-related diseases, population based studies have not yet provided 
conclusive evidence for the association with diabetes [4, 15], cognitive performance [16-24], 
and depression [6-8, 25-28]. Therefore, our objective in this European multicentre study 
was to examine serum 25(OH)D and the association with markers of glucose homeostasis, 
cognitive performance, and depression in older European men and women. 
 
4.2 Methods
4.2.1 Participants
The study is conducted using data of older adults participating in the SENECA study; Survey 
in Europe on Nutrition and the Elderly, a Concerted Action [29]. Men and women aged 70-
75 years who were living in preselected towns across Europe were invited for participation in 
the study. Towns were selected based on their representativeness of the population and social-
economic structure for the whole country. Psycho-geriatric patients living in nursing homes, 
persons who were not fluent in the country’s language, or not able to independently answer 
questions were excluded from participation. The total SENECA population comprised 
2586 participants. Markers of glucose homeostasis and serum 25(OH)D concentrations 
were measured in 1989 and available for 1554 and 860 participants, respectively. Of 593 
participants both serum 25(OH)D and markers of glucose homeostasis were measured. Data 
on cognitive performance and depression were obtained in 1993 and available for 443 and 
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482 participants, of whom serum 25(OH)D concentrations were measured in 116 and 118 
participants, respectively. Measurements of serum 25(OH)D, markers of glucose homeostasis, 
cognitive performance, and depression were available of 98 (GDS) and 94 (MMSE) 
participants (Figure 1). Included in the analyses were participants from: Belgium: Hamme; 
Denmark: Roskilde; France: Strassbourg and Valence; Hungary: Monor; The Netherlands: 
Culemborg; Norway: Elverum; Switzerland: Yverdon, Burgdorf, and Bellinzona; Greece: 
Athens and Iraklion; Portugal: Lisbon; Spain: Madrid.
Figure 1. Flow diagram describing the data used in the analyses.
4.2.2 Cognitive performance and depression
Overall cognitive performance was assessed using the Mini Mental State Examination 
(MMSE). The variable for analyses was defined as the maximum MMSE score minus the 
MMSE score of the participant, reflecting the number of erroneous answers. Mitchell, et al. 
recently reviewed the accuracy of the MMSE and showed a 85.1% sensitivity and a 85.5% 
specificity in non-clinical community settings [30]. The 15-item Geriatric Depression Scale 
(GDS) was used as a screenings tool for depression. Validation with the Diagnostic and 
Statistical Manual of Mental Disorders (DSM-IV) revealed that 97.0% of the persons with 
depression (sensitivity) and 54.8% persons without depression (specificity) were correctly 
classified [31]. 
4.2.3 Biochemical analyses
Blood samples were taken between 7:30 and 9:30 AM while the participant was in a fasting 
state. Fasting blood samples (25 mL) were collected, and 10 mL was transferred to another 
tube for serum separation. A portion (0-5 mL) of each serum sample was stored at -80°C for 
SENECA study± 2586 participants (1988/1989)
GDS (n=482) and MMSE 
(n=443) (1993)
Serum 25(OH)D (n=860)     
(1988/1989)
Plasma glucose and insulin 
(n=1554) (1988/1989)
Serum 25(OH)D with 
MMSE (n=116) 
and GDS (n=118)
Serum 25(OH)D with 
plasma insulin and glucose 
(n=593) 
Serum 25(OH)D, plasma glucose, 
insulin and MMSE (n=94)
 
Serum 25(OH)D, plasma glucose, 
insulin and GDS (n=98)
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serum 25(OH)D determination. All blood samples were sent on dry ice to the coordinating 
center in Wageningen, Netherlands, and stored at -80°C. Serum 25(OH)D values were by 
competitive protein-binding assay (coefficients of variation: within-assay 4-7%, between-
assay 7-10%) at the TNO Nutrition and Food Research Institute, Zeist, the Netherlands. 
As 25(OH)D concentrations may fluctuate seasonally, 25(OH)D concentration was only 
determined in blood samples collected between January and March 1989. Plasma glucose 
concentration was measured by the hexokinase method using the Hitachi 911 auto-analyser. 
Plasma insulin concentration was measured by using enzyme immunoassay (Boehringer-
Mannheim, Mannheim, Germany) and insulin resistance was calculated using Homeostatic 
Model Assessment-Insulin Resistance (HOMA-IR) from glucose and insulin concentrations 
[32]. 
4.2.4 Covariates
Information on education level (i.e. illiterate, primary, secondary or higher education), 
smoking status (i.e. non-smokers, former smokers or current smokers), and presence of chronic 
disease (i.e. hypertension, ischaemic heart disease, stroke, malignancy, arthritis, inflammatory 
bowel disease, respiratory problems, chronic liver disease, osteoporosis, Parkinson’s disease, 
other) was collected using questionnaires. The Voorrips questionnaire, which is designed 
to assess physical activity level in older adults, was used to obtain information on habitual 
physical activity [33]. Participants were divided into three groups according to sex specific 
tertiles: low, moderate, or high physical activity level. Trained dieticians assessed dietary 
intake, using the dietary history method. The method consisted of a three-day record and a 
frequency checklist of foods, based on the meal pattern of the country and with the previous 
month as a reference period. Portion sizes were checked by weighing quantities of food and 
household measures. Intakes of nutrients and food groups were calculated in each country 
using local food composition tables. Food consumption data were arranged into food groups 
following the EUROCODE classification system [34]. 
4.2.5 Statistical analyses
Participant characteristics are reported as mean with standard deviation (SD), or percentages. 
Medians with interquartile range are reported for skewed variables. Chi-squared tests 
for categorical variables and one-way analysis of variance for continuous variables were 
performed to compare baseline characteristics over tertiles of serum 25(OH)D. Multiple 
regression analyses were performed to study the associations between serum 25(OH)D and 
fasting plasma glucose (FPG), fasting plasma insulin (FPI) and HOMA-IR, as markers of 
insulin resistance. FPG, FPI and HOMA-IR were not normally distributed and therefore 
logarithmically transformed. βs are presented as percentages (%) with 95% CI per one 
nmol/L increase in serum 25(OH)D. As both mental health variables followed a Poisson 
distribution, Relative Risks (RRs) for serum 25(OH)D with global cognitive performance 
[35], and depression were calculated using multiple Poisson regression, with the number of 
erroneous answers as outcome for global cognitive performance and the number of depressive 
symptoms as the outcome for depression. Participants were categorized according to tertiles 
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of serum 25(OH)D, using the lowest tertile as the reference category. In addition, the P-for- 
trend across tertiles of serum 25(OH)D was calculated. All analyses were adjusted for age, sex 
(model 1), BMI, education, smoking, alcohol consumption, physical activity, study centre 
(model 2), and intake of calcium (model 3). To control for total energy intake, calcium intake 
was adjusted for total energy intake by using the regression residual method. The analyses 
were performed using the statistical package SAS, version 9.1 (SAS Institute Inc., Cary, NC, 
USA).
4.3 Results
General characteristics of the study population are presented in Table 1 and Table 2. The 
average serum 25(OH)D concentration of the total population was 37.8±20.6 and ranged 
from 6-141 nmol/L. Serum 25(OH)D concentrations <50 nmol/L and <75 nmol/L were 
observed in 79% and 94% of the participants, respectively. Participants living in the southern 
part of Europe were more likely to have a suboptimal 25(OH)D concentration than those living 
in northern countries (data not shown). Those with the highest 25(OH)D concentrations 
were more likely to be men (P=0.02), older (P<0.0001) and higher educated (P=0.001). 
Moreover, BMI (P=0.07), FPG (P=0.04), FPI (P=0.06) and HOMA-IR (P=0.05) were lower 
and physical activity levels (P=0.0005) and total cholesterol concentrations (P=0.001) were 
higher among those with the highest serum 25(OH)D concentrations. Thirty-two percent of 
the participants had FPG concentrations >6.0 mmol/L. FPI and FPG concentrations were 
lowest in those in the highest serum 25(OH)D tertile. Mean MMSE and median GDS scores 
of the population were 27.4±2.0 and 2.0 (IQR 3.0), respectively. As the maximum scores for 
the MMSE and GDS are 30 and 15, respectively, these results indicate a low prevalence of 
mild cognitive impairment and depressive symptoms. When compared to the total sample, 
persons in the mental health subsample were somewhat younger, had a lower prevalence of 
chronic disease, and moreover, parameters of glucose homeostasis were slightly lower. 
Table 1. Characteristics of 593 European older adults of the SENECA study by tertile of serum 25(OH)D.
T1: 6-27  nmol/L T2: 28-42 nmol/L T3: 43-141 nmol/L P-value
N 204 196 193
25(OH)D, nmol/L 19.2±5.3 34.3±4.1 61.0±18.3 <0.0001
Men, n (%) 86 (42) 98 (50) 108 (56) 0.02
Age, years 74.9±1.4 74.6±1.5 74.2±1.6 <0.0001
Body Mass Index, kg/m2* 27.4±4.4 26.8±4.1 26.5±3.4 0.07
Fasting plasma glucose, mmol/L 6.2±1.9 6.1±1.6 5.8±1.5 0.04
Fasting plasma insulin, pmol/L 67.9 (46.8) 74.5 (61.3) 62.4 (43.4) 0.06
Homa-IR 1.31 (0.91) 1.45 (1.17) 1.21 (0.88) 0.05
Chronic disease present, n (%)# 166 (81) 158 (81) 144 (75) 0.24
Total cholesterol, mmol/L 6.2±1.2 6.5±1.3 6.7±1.1 0.001
Hypertension, n (%) 49 (24) 42 (21) 30 (16) 0.23
Stroke, n (%) 5 (2) 13 (7) 11 (6) 0.10
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Note: Values are expressed as a mean ± SD, median (IQR) or n (%). P-value was obtained using the X2 test for 
categorical variables and one-way analysis of variance for continuous variables. *12 missing values. #Presence of 
chronic disease was defined as hypertension, ischaemic heart disease, stroke, malignancy, arthritis, inflammatory 
bowel disease, respiratory problems, chronic liver disease, osteoporosis, Parkinson’s disease, others.
Table 2. Characteristics of 135 European men and women of the SENECA study per tertile of serum 
25(OH)D (mental health subsample).
Note: *19 missing values; #17 missing values; γ21 missing values;  π11 missing values; ∆Presence of chronic disease 
was defined as hypertension, ischaemic heart disease, stroke, malignancy, arthritis, inflammatory bowel disease, 
respiratory problems, chronic liver disease, osteoporosis, Parkinson’s disease, others. 
Table 3 presents the associations of serum 25(OH)D with FPG, FPI and HOMA-IR, shown 
in percentages per nmol/L increase in serum 25(OH)D. An inverse association was observed 
between serum 25(OH)D and FPG (-0.1%, 95% CI -0.2-0.0), indicating a 1% decrease in 
FPG per 10 nmol/L increase in serum 25(OH)D. However, after adjustment for demographic 
factors, lifestyle factors and calcium intake, this association was not statistically significant 
anymore (P=0.07). Significant inverse associations were also observed for serum 25(OH)D 
with FPI and HOMA-IR, but these associations attenuated after full adjustment. Stratified 
analysis for calcium intake demonstrated a stronger association for serum 25(OH)D with 
T1: 6-27  nmol/L T2: 28-42 nmol/L T3: 43-141 nmol/L P-value
Smoking status, n (%)
  Non-smoking
  Current smoker
  Former smoker
122 (60)
39 (19)
43 (21)
106 (54)
33 (17)
57 (29)
100 (52)
31 (16)
62 (32)
0.16
Physical activity level, n (%)
  Low
  Average
  High
44 (22)
74 (36)
86 (42)
30 (15)
67 (34)
99 (51)
16 (8)
58 (30)
119 (62)
0.0005
Educational level, n (%)
  Primary education
  Secondary education
  Higher education
  Illiterate
122 (60)
48 (23)
14 (7)
20 (10)
110 (56)
64 (33)
9 (4)
13 (7)
102 (53)
54 (28)
29 (15)
8 (4)
0.001
Calcium intake, mg/day* 960±433 998±424 1021±358 0.33
Alcohol intake, g/day* 0 (10) 2 (13) 1 (9) 0.17
T1: 7-33  nmol/L T2:  34-52 nmol/L T3: 53-125 nmol/L P-value
N 50 43 42
Age, years 73.8±1.8 73.7±1.7 73.2±1.6 0.06
MMSE-score* 27.3±2.1 26.8±2.1 27.9±1.9 0.06
GDS-score# 2.0 (3.0) 2.0 (2.5) 2.0 (2.0) 0.32
Fasting plasma glucose, mmol/Lγ 5.7±0.9 6.1±2.1 5.7±1.3 0.43
Fasting plasma insulin, pmol/Lγ 63.8 (46.3) 64.8 (57.4) 48.6 (44.3) 0.84
Homa-IRγ 1.17 (0.88) 1.22 (1.01) 0.93 (0.89) 0.76
Chronic disease present, n (%)∆ 34 (77) 26 (68) 28 (67) 0.54
Calcium intake, mg/dayπ 899±352 934±325 1064±360 0.07
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FPG among those with a high calcium intake (-0.2%, 95% CI -0.3-0.0), compared to those 
with a low calcium intake (0.0%, 95% CI -0.2-0.1). The interaction term, however, was not 
statistically significant, P=0.38. 
 
Table 3. Associations between serum 25(OH)D and markers of glucose homeostasis of 593 men and women 
participating in the SENECA study, presented as % with 95% CI per nmol/L increase in serum 25(OH)D.
Fasting plasma glucose (mmol/L) Fasting plasma insulin (pmol/L) HOMA-IR
Crude -0.1 -0.2-0∆ -0.4 -0.7-   0π -0.4 -0.7-  0π
Model 1* -0.1 -0.2-0∆ -0.3 -0.6-0.1 -0.3 -0.9-0.1
Model 2# -0.1 -0.2-0 -0.1 -0.4-0.3 -0.1 -0.5-0.3
Model 3γ -0.1 -0.2-0 -0.1 -0.4-0.3 -0.1 -0.5-0.3
Note: *Adjusted for age and sex. #Adjusted for M1 and BMI, education (categorical), alcohol intake (categorical), 
smoking (categorical), physical activity (categorical), and study centre (categorical). γAdjusted for M2 and 
calcium intake (continuous) πP<0.05 ∆P≤0.01
Data on serum 25(OH)D concentrations and depression were available of 118 participants 
(Table 4). Fully adjusted models showed that compared to the reference group, those in the 
middle or upper serum 25(OH)D tertile had on average a 27% (RR 0.73, 95% CI 0.51-
1.04) and 24% (RR 0.76, 95% CI 0.52-1.11) (P for trend: 0.16) lower depression score, 
respectively. Additional adjustment for calcium intake  (RR upper tertile 0.82 and 95% CI 
0.59-1.14), FPG (RR upper tertile 0.88 and 95% CI 0.61-1.25) (n=83), or hypertension 
(RR upper tertile 0.82 and 95% CI 0.59-1.14) did not alter the direction of the results. 
Table 4. Associations between serum 25(OH)D and mental health in 118 men and women participating in 
the SENECA study.
Note: *Adjusted for age and sex. #Adjusted for age, sex, BMI, education (categorical), smoking (categorical), 
physical activity (categorical), alcohol intake (categorical), and study centre (categorical). γAdjusted for age, sex, 
BMI, education (categorical), smoking (categorical), physical activity (categorical), alcohol intake (categorical), 
study centre (categorical), and calcium intake (continuous). π P≤0.05 
Among 116 participants of whom 25(OH)D concentrations were known and the MMSE 
was completed (Table 4), age and sex adjusted models did not show significant associations 
T1: 0-34 nmol/L T2: 34-52 nmol/L T3: 52-125 nmol/L P for trend
GDS (depression)
Crude model (n=118) 1.0 0.78 (0.53-1.14) 0.76 (0.50-1.15) 0.05
Model 1          (n=118)* 1.0 0.80 (0.55-1.16) 0.76 (0.49-1.17) 0.05
Model 2          (n=103)# 1.0 0.73 (0.51-1.04) 0.76 (0.52-1.11) 0.16
Model 3          (n=103)γ 1.0 0.74 (0.53-1.06) 0.82 (0.59-1.14) 0.41
MMSE (global cognitive functioning)
Crude model (n=116) 1.0 1.19 (0.87-1.64) 0.78 (0.54-1.12) 0.04
Model 1          (n=116)* 1.0 1.19 (0.86-1.63) 0.76 (0.54-1.08) 0.04
Model 2          (n=103)# 1.0 1.42 (1.02-1.97)π 0.92 (0.63-1.36) 0.39
Model 3          (n=103)γ 1.0 1.39 (1.00-1.94)π 0.94 (0.63-1.39) 0.51
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for those in the middle or highest serum 25(OH)D group, RR 1.19 (95% CI 0.86-1.63) 
and RR 0.76 (95% CI 0.54-1.08), respectively. Further adjustment unexpectedly resulted 
in a statistically significant higher number of erroneous answers for those with intermediate 
25(OH)D concentrations, RR 1.39 (95% CI 1.00-1.94). No such association was, however, 
observed for those with the highest 25(OH)D concentrations, RR 0.94 (95% CI 0.63-
1.39). Associations did not substantially change when FPG concentrations, hypertension or 
depression were included in the model (RRs upper tertile 0.90 (95% CI 0.56-1.45), 1.03 
(95% CI 0.69-1.55) and 0.89 (95% CI 0.58-1.35), respectively).
4.4 Discussion
In this cross-sectional population-based study in European older adults, participants 
with higher serum 25(OH)D concentrations tended to have less depressive symptoms. 
The associations observed do not support the hypothesis that higher serum 25(OH)D 
concentrations are associated with a better cognitive performance. Moreover, despite a modest 
inverse association between serum 25(OH)D and fasting plasma glucose, the hypothesized 
independent health benefits of serum 25(OH)D on insulin resistance could not be confirmed 
in this study.  
Before interpreting the results, several methodological issues warrant further discussion. 
Firstly, blood samples were collected during the winter season and therefore reflect the lowest 
25(OH)D concentrations throughout the year. Secondly, serum 25(OH)D was measured 
only once and may therefore not reflect long-term status. Furthermore, the debate on 
the most accurate method to determine serum 25(OH)D concentrations is still ongoing 
[36], but the competitive protein-binding (CPB) assay applied in this study might not be 
the most optimal method. A previous study comparing different serum 25(OH)D assays 
showed that CPB-assay was highly correlated with radioimmunoassay (RIA) (r=0.72) and 
high-performance liquid chromatography (HPLC) (r=0.69). Additionally, mean 25(OH)D 
concentrations as measured with CPB-assay appeared to be systematically higher compared 
to HPLC and RIA [37]. Therefore, CPB-assay used in our study may have overestimated 
the true 25(OH)D status. However, as it concerns a systematic overestimation, it will not 
have affected the direction of the observed associations. A strength of this study is that serum 
25(OH)D samples were taken in ten countries all over Europe, collected during the same 
month, and analysed in one single laboratory. Therefore, seasonal variation or inter-laboratory 
variation cannot have affected the results. Another strength of the SENECA database is that 
it includes extensive information on lifestyle and dietary factors including physical activity 
level and calcium intake, reducing the possibility of confounding. Residual confounding, 
however, cannot be ruled out.
Descriptive analyses showed lower serum 25(OH)D concentrations among those with a 
higher BMI, lower physical activity level, and persons at older age. It may be suggested that 
in our population those with a higher physical activity level performed part of their exercises 
outdoors, which may have resulted in higher serum 25(OH)D concentrations. The decrease 
in serum 25(OH)D with age may be explained by the fact that the production of vitamin 
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D in the skin decreases while ageing [38]. Lower 25(OH)D concentrations among persons 
with a higher BMI has also been observed in previous studies and has been suggested to be 
the consequence of the storage of 25(OH)D in fat tissue, and thus not being bioavailable in 
serum [39].  
Among individuals in the SENECA study FPG decreased with 1% when serum 
25(OH)D increased with 10 nmol/L, however, this was not statistically significant after 
adjustment for multiple factors. No association was observed between serum 25(OH)D 
and FPI, or HOMA-IR. Biological evidence that vitamin D may affect markers of glucose 
homeostasis and the development of diabetes, is increasing [4, 40]. Previous published cross-
sectional studies show, however, inconsistent results [41-46]. Among 142 Dutch men, aged 
70-88 years, serum 25(OH)D was inversely associated with the AUC for both glucose and 
insulin, which remained significant after adjustment for BMI, skinfold thickness, alcohol 
consumption, smoking and physical activity [41]. High concentrations of serum 25(OH)D 
were furthermore positively associated with insulin sensitivity, and inversely correlated with 
β-cell function in a population of 126 young adults who underwent a hyperglycemic clamp 
experiment [44]. Moreover, inverse associations with measures of insulin resistance were 
observed among participants of the Framingham Heart Study [43] and NHANES III [46]. 
The LIPGENE study [45] and the Women’s Health Initiative [42] were not able to confirm 
previous evidence for a possible link between serum 25(OH)D and glucose homeostasis. A 
recently published systematic review and meta-analyses with data of five prospective cohort 
studies showed that persons with 25(OH)D concentrations >62.5 nmol/L had a 43% lower 
risk of developing type 2 diabetes when compared to those with concentrations <35 nmol/L 
[15]. Mitri and colleagues (2011) also summarized the results of RCTs in this field and 
concluded that these trials do not yet provide definite evidence for a beneficial role of vitamin 
D supplementation on glycemic outcomes [15]. 
Despite a small sample size, this cross-sectional study showed a modest non-significant 
association between serum 25(OH)D and depression. Up to now, only very few population 
based studies examined the possible link between serum 25(OH)D and depressive symptoms, 
showing contradictory results. For instance, one year follow-up of 7358 middle-aged and 
older Americans diagnosed with a cardiovascular event, without previous depressive episode, 
showed that patients with a serum 25(OH)D concentration >125 nmol/L were less often 
depressed compared to persons with serum 25(OH)D concentrations ≤37.5 nmol/L, HR 
2.70 (95% CI 1.35-5.40) [7]. Physical activity, social economic status or BMI were, however, 
not included as covariates. At six years of follow-up, women participating in the InCHIANTI 
Study with the lowest serum 25(OH)D concentrations reported significantly more depressive 
symptoms, compared to those in the highest tertile. It has to be mentioned that a relatively 
large number (42%) of the women participating in this study reported to have a depressed 
mood [8]. Furthermore, significantly lower serum 25(OH)D concentrations were observed 
among 1282 Dutch middle-aged and older adults with minor and major depressive 
symptoms, compared to those without depressive symptoms [6]. No clear beneficial role 
for vitamin D in depression was observed in population based studies among Chinese older 
adults and Japanese municipal officials aged 21-67 years [25-27]. In one of these studies 
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among Chinese older adults a significant association between 25(OH)D concentration and 
depression was observed at baseline, but not after four years of follow-up. The incidence 
rate of depression at four-years of follow-up was 4% and only 6% of the men had 
25(OH)D concentrations below 50 nmol/L, which may perhaps partially explain the lack of 
the association observed after four years [25]. Inconsistencies between studies may also be the 
result of differences in the ascertainment and prevalence of depression, lack of adjustment for 
covariates and differences in geographical location. As persons with depressive symptoms may 
be less likely to go outside, associations between serum 25(OH)D and depression observed 
in cross-sectional studies may also be the result of reverse causality. By performing RCTs the 
possibility of reverse causation can be eliminated. However, up to now only very few trials 
studied the effect of vitamin D supplementation on mood or depression, showing conflicting 
findings [47-51]. 
While there was evidence of an inverse association between serum 25(OH)D and the number 
of depressive symptoms, no association was observed between serum 25(OH)D and global 
cognitive performance. Results of several small studies reviewed by Annweiler and colleagues 
(2009) [5] and more recent and larger community-based cohort studies show either no or 
a positive association between 25(OH)D and global cognitive performance [16, 18, 21, 
23-25]. In 1766 persons ≥65 years low 25(OH)D concentrations appeared to increase the 
probability of experiencing cognitive impairment, particularly in men [21]. Results of the 
EPIDOS study point towards the same direction in a population of older women (OR 
1.99, 95% CI 1.13-3.52, P=0.02), even after adjustment for iPTH, serum calcium and 
depression [16]. Prospective data of the InCHIANTI Study revealed that non-demented 
25(OH)D deficient (<25 mmol/L) men and women were 64% more likely to experience 
cognitive decline, compared to those in the sufficient group (≥75 mmol/L) [23]. The MrOS 
study [24], NAME study [18], and Os study [25] did not observe an association between 
serum 25(OH)D and global cognitive function. Recently, the first RCT on vitamin D 
supplementation and cognitive functioning was published, which did not show an effect of a 
six-week treatment with 125 µg/day cholecalciferol on working memory, response inhibition 
or cognitive flexibility in young adults [47]. Despite the fact that we could adjust for a large 
number of important confounders, our sample size may not have been large enough to detect 
an association. Moreover, data on global cognitive performance were collected four years 
following the baseline measurements, which may also have affected the associations studied. 
Although serum 25(OH)D concentrations have been shown to decrease with age [52], two-
year follow-up data of 80 frail older adults, with a mean age of 82.1 years, showed only a six 
nmol/L decrease in 25(OH)D concentration [53]. Therefore, we expect that only a subtle 
decrease in 25(OH)D concentration may have occurred during the period until the mental 
health indicators were measured. 
In conclusion, this study showed a tendency towards an inverse association of serum 25(OH)
D with FPG and depression, but not with FPI, HOMA-IR, and global cognitive performance. 
As the overall evidence for a role of vitamin D in glucose homeostasis, cognitive performance, 
and depression is still inconclusive, more prospective epidemiological studies, meta-analyses, 
RCTs, and mechanistic studies are warranted. 
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Abstract
Objectives 
The primary objective of this study was to explore the possible association of serum 
25-hydroxyvitamin D (25(OH)D) and vitamin D intake with markers of glucose 
homeostasis, depression, and cognitive performance. In addition, we examined to what 
extent the associations between vitamin D and cognitive performance were modified or 
mediated by fasting plasma glucose (FPG) concentrations.
Design, Setting and Participants 
Cross-sectional study using data of 127 pre-frail or frail Dutch older adults, aged ≥65 
years. Frailty was defined according to the criteria of Fried and colleagues (2001). A 
participant was classified pre-frail when 1-2 criteria were met; frailty was classified as the 
presence of ≥3 criteria.
Measurements 
Associations of serum 25(OH)D and vitamin D intake with markers of glucose 
homeostasis and domain-specific cognitive performance were examined by multivariable 
regression analyses. The possible association of vitamin D with depression and global 
cognitive performance was explored by Poisson regression. 
Results 
No associations were observed for serum 25(OH)D with FPG, Fasting Plasma Insulin (FPI), 
Homeostasis Model Assessment-estimated Insulin Resistance (HOMA-IR), or depression. 
In contrast, serum 25(OH)D was positively associated with executive functioning (β 
0.007, P=0.01) and tended to be associated with information processing speed (β 0.006, 
P=0.06). FPG did not modify or mediate these associations. Vitamin D intake was not 
associated with cognitive performance, glucose homeostasis, or depression.
Conclusion 
This cross-sectional study suggests an association of serum 25(OH)D with domain-
specific cognitive performance, in particular executive functioning and possibly 
information processing speed, but not with FPG, FPI, HOMA-IR, or depression. Whether 
these associations are causal is yet to be demonstrated.
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5.1 Introduction
Although vitamin D can be obtained via diet and ultraviolet-B exposure to the skin, vitamin 
D deficiency is a common phenomenon all over the globe [1]. Particularly older adults are at 
an increased risk of vitamin D deficiency as outdoor mobility, dietary vitamin D intake, and 
epidermal 7-dehydrocholesterol concentrations often decrease while ageing [2]. Moreover, 
as a consequence of diminished liver and kidney function at older age, the conversion of 
serum/plasma 25-hydroxyvitamin D (25(OH)D) into the biologically active form of vitamin 
D may also be reduced [3]. The increased risk of vitamin D deficiency among older adults, 
along with recent studies indicating that vitamin D may contribute to healthy ageing, has 
led to a rapidly growing scientific interest in this research field [4, 5]. Glucose intolerance, 
cognitive dysfunction and depression are three disorders that may be associated with a poor 
25(OH)D status.
As reviewed by Pittas and colleagues (2007), in vitro and molecular studies have shown the 
existence of vitamin D receptors (VDR) and 1-α-hydroxylase in pancreatic β-cells [6]. In 
addition, several direct and indirect mechanisms for a possible relationship of vitamin D 
with insulin secretion and glucose tolerance have been suggested, namely via the activation of 
insulin receptor expression, the regulation of intra- and extracellular calcium concentrations 
and the down-regulation of cytokine generation [6]. Also a number of human population-
based cohort studies and RCTs examined the possible association between 25(OH)D 
concentrations and glucose homeostasis [6-21]. Mitri and colleagues (2011) reviewed these 
RCTs and prospective cohort studies, and concluded that more research is warranted to 
understand the role of vitamin D in the development and progression of type 2 diabetes [7].
The most evident neurobiological indication for a potential role of vitamin D in brain 
function is the localisation of VDRs on various brain structures and the presence of 
1-OH-ase in cerebrospinal fluid. Moreover, molecular and in vitro studies (as reviewed in 
[22, 23]) have shown that the biologically active form of vitamin D beneficially affects the 
synthesis and degradation of several neurotrophins, specifically the nerve growth factor 
(NGF), neurotrophin-3 (NT-3), neurotrophin-4/5 (NT-4/5), and glial cell line-derived 
neurotrophic factor (GDNF) [24]. Vitamin D administration may also prevent too high 
intraneuronal calcium influxes by down-regulating L-type voltage-sensitive calcium channel 
(L-type VSCCs) expression, and have a beneficial effect on neurotransmission by increasing 
the activity of choline acetyltransferase. Several animal studies confirm the potential effect 
of vitamin D, by showing that mice lacking VDRs demonstrate an increased anxiety level 
[25], inferior nest building [26] and impaired motor performance [27]. The possible role 
of 25(OH)D status in cognitive performance [8, 28-34] and depression [8, 30, 35-42] has 
also been studied in several human population-based studies. Results, however, are still 
inconclusive. In a recent review, Eyles and colleagues (2012) summarized the neurobiological 
evidence and stated that there is data showing that vitamin D may play a role in brain 
function, but that there is still insufficient and inconsistent data from epidemiological studies 
and well-designed RCTs in humans to confirm this potential role of vitamin D [22]. 
Besides a potential unfavourable role of vitamin D deficiency in cognitive decline and 
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depression, glucose intolerance has also been implicated as a risk factor for cognitive decline 
and depression [43]. The potential effect of vitamin D on glucose homeostasis, concurrently 
with the higher rates of depression and cognitive decline among diabetes patients, might 
therefore suggest an indirect role of vitamin D in brain health. Accordingly, associations 
of vitamin D with cognitive decline and depression may be partially mediated by glucose 
intolerance. Alternatively, considering that diabetes patients may be more predisposed to 
experience cognitive decline and depression, a modification effect of glucose intolerance may 
also be observed.
With vitamin D deficiency as a joint risk factor for glucose intolerance and cognitive decline, 
concurrently with studies indicating that diabetes patients may be at an increased risk of 
cognitive decline, this study aimed to further explore the possible interrelatedness between 
vitamin D, glucose homeostasis and brain function. Hence, we investigated the possible 
associations of serum 25(OH)D, vitamin D intake, and sun exposure with markers of glucose 
homeostasis, various domains of cognitive performance, and depression in Dutch prefrail 
and frail older adults. In addition, to get more insight in the underlying mechanism linking 
vitamin D with cognitive performance, we also investigated whether fasting plasma glucose 
concentrations played a mediatory role in this association. Finally, we explored whether 
participants with an impaired glucose tolerance showed more benefit of optimal vitamin D 
concentrations, compared to those with a normal glucose tolerance.
5.2 Methods
5.2.1 Participants
Analyses were performed using baseline data of 127 participants of the ProMuscle study, 
which was originally designed to study the effect of protein supplementation in combination 
with or without progressive exercise training on muscle function and muscle mass [44, 45]. 
Eligibility was defined as ≥65 years, and being prefrail or frail. Frailty was defined according to 
the criteria from Fried and colleagues (2001) as having unintentional weight loss, weakness, 
self-reported exhaustion, slow walking speed, and/or low physical activity level [46]. A 
participant was classified as prefrail when 1-2 of the aforementioned criteria were met, while 
frailty was defined as the presence of ≥3 or more criteria. Participants were excluded if they 
had fasting plasma glucose (FPG) concentrations ≥7.0 mmol/L, cancer, chronic obstructive 
pulmonary disease (COPD), renal failure, or if they had participated in any structured 
exercise training program in the past two years. The Wageningen University Medical Ethical 
Committee approved the study and all participants gave their written informed consent.
5.2.2 Cognitive performance and depression
The 20-item Centre for Epidemiological Studies Depression scale (CES-D) was used as a 
screening tool for depression [47]. Overall cognitive performance was assessed using the Mini 
Mental State Examination (MMSE) [48]. The variable for the analyses was defined as the 
maximum MMSE score minus the MMSE score of the participant, reflecting the number of 
erroneous answers. Domain-specific cognitive performance was measured using an extensive 
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cognitive test battery, performed by well-trained research assistants, and according to a strict 
protocol. The cognitive test battery included the Word Learning Test (WLT) direct recall, 
decayed recall, and recognition to measure episodic memory [49]; Wechsler digit span 
forward and backward test to determine attention and working memory [50]; Trail Making 
Test-A (TMT-A) and Trail Making Test-B (TMT-B) to assess information processing speed 
and concept shifting interference [51]; Stroop Colour-Word Test to determine selective 
attention and susceptibility to behavioural interference [52]; and the Verbal Fluency test 
[53], and Reaction Time Task (RT) [54, 55] to measure executive functioning. Except for the 
RT, all tests were performed in the afternoon. RT was assessed during the morning, in fasted 
state, by the computerized finger precueing task.  
5.2.3 Biochemical analyses
Blood samples were collected at baseline while participants were in a fasting state. EDTA 
containing tubes were centrifuged at 1000g at 4˚C for 10 minutes and serum tubes were 
centrifuged 90 minutes after the blood collection at 1000g at 18˚C for 30 minutes. Aliquots 
of plasma and serum were frozen in liquid nitrogen and stored at -80˚C until further analysis. 
Plasma glucose concentrations were analysed with a COBAS FARA analyser (Uni Kit III; 
Roche, Basel, Switzerland). Insulin was analysed by radioimmunoassay (Insulin RIA Kit; 
LINCO Research Inc, St Charles, MO). Serum 25(OH)D was measured by isotope dilution-
online solid phase extraction liquid chromatography-tandem mass spectrometry (ID-XLC-
MS/MS), which was performed at the Endocrine Laboratory of the VU University Medical 
Centre. Serum 25(OH)D was released from its binding protein(s) and a deuterated internal 
standard (IS: 25(OH)D3-d6) was added. Samples were extracted and analysed by XLC-MS/
MS (a Symbiosis online SPE system (Spark Holland, Emmen, the Netherlands) coupled to 
a Quattro Premier XE tandem mass spectrometer (Waters Corp., Milford, MA)). Method 
characteristics: limit of qualification 4.0 nmol/L; intra-assay coefficient of variation (CV) 
<6% and inter-assay CV <8% for 3 concentrations between 25 and 180 nmol/L.
5.2.4 Dietary intake
Three-day food records were used to obtain dietary intake data. Trained dieticians gave oral 
and written instructions about recording the type of foods and estimation of portion sizes in 
household measures. At a second visit, food records were checked for completeness. Where 
necessary additional information was obtained about unclear items or amounts; household 
measures were used as an example to improve the estimation of portion sizes. Days of 
recording were randomly assigned so that all days of the week, including weekend days, were 
equally represented. Dietary intake data were coded (type of food and amount) and energy 
and nutrient intakes were calculated using a food calculation system (BAS nutrition software, 
2004, Arnhem, the Netherlands), in which the Dutch food composition database of 2006 
was included [56]. 
5.2.5 Sun exposure
Sun exposure was assessed six months following baseline blood sampling using a questionnaire 
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containing eight items about the amount of time spend outdoors and in the sun during the 
summer, use of sun protection and solariums, type of clothing worn during the summer, 
holidays with a sunny destination in the past three months and skin colour. 
5.2.6 Covariates
Height was measured at baseline with a wall-mounted stadiometer to the nearest 0.1 cm. 
Weight was measured in a fasted state to the nearest 0.1 kg with a calibrated digital scale 
(ED-6-T; Berkel, Rotterdam, The Netherlands). Subsequently, Body Mass Index (BMI) 
was calculated as weight/height2. Information on education level (i.e. primary, secondary 
or higher education), smoking status (i.e. non-smoker or current smoker), medical history 
and presence of chronic disease (i.e. kidney disease, liver disease, cardiovascular disease, 
muscle disease, and hip- or knee replacement) was collected using questionnaires. Blood 
pressure was measured in the morning after 10 minutes of rest in supine position with an 
Omron HEM-907 (Lake Forest, IL, USA) device. Habitual physical activity was quantified 
using a triaxial accelerometer (ActiGraph GTX3, 2009, Pensacola, FL) worn on the hip for 
one week. Change of acceleration per second and epochs of 60 seconds were used. After 
seven days, data were uploaded for analysis and analysed using the MAH/UFFE analyser, 
version 1.9.0.3 (MRC Epidemiology Unit, Cambridge, UK). Data files that did not meet 
ten hours of monitoring per day on at least five days as well as files that included periods 
of >100 minutes without activity were excluded from the analysis. Season was entered as 
a dichotomous variable, based on unpublished serum 25(OH)D data obtained from the 
B-PROOF study, a large intervention study conducted at the Division of Human Nutrition 
of Wageningen University [57]. Blood samples collected in June-November were defined as 
summer/autumn; samples collected in December-May were defined as winter/spring.
5.2.7 Potential effect modifiers and intermediates
Serum 25(OH)D may be related to glucose homeostasis and brain function. Moreover, 
diabetes patients have been suggested to be at an increased risk of cognitive decline. Hence, 
we hypothesized that the association between vitamin D and cognitive performance may 
be more beneficial in persons with glucose intolerance/diabetes, compared to those with a 
normal glucose tolerance. Additionally, we hypothesized that the association between vitamin 
D and cognitive performance may be mediated by glucose homeostasis. Therefore, we 
examined the potential modifying as well as the intermediary role of fasting plasma glucose 
in the association between serum 25(OH)D and cognitive performance. 
5.2.8 Statistical Analyses
Characteristics of the study population are reported using the mean with standard deviation 
(SD), or as percentages. Medians with interquartile range were used to report skewed variables. 
Chi-squared tests for categorical variables and one-way analysis of variance for continuous 
variables were performed to compare baseline characteristics over tertiles of serum 25(OH)D. 
Multivariable regression analyses were performed to study associations of serum 25(OH)D 
with fasting plasma glucose, fasting plasma insulin, HOMA-IR and domain-specific cognitive 
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performance. Multivariable regression analyses were also used to explore the associations 
between markers of glucose homeostasis and domain-specific cognitive performance. To 
compare the results of the individual cognitive tests and to limit the number of dependent 
variables, crude test scores were clustered into compound Z-scores for four neuropsychological 
domains: Episodic memory, Attention and working memory, Information processing speed, 
and Executive functioning. In formula form: episodic memory = (WLT total immediate 
recall + WLT decayed recall + WLT recognition)/3; attention and working memory = (Digit 
Span forward + Digit Span backward)/2; information processing speed = (Average Stroop 
card 1 and 2 + -TMT-A + -RT uncued)/3; executive functioning = (Stroop ratio + Verbal 
Fluency + -TMT- ratio + -RT finger-cued + -RT hand-cued + -RT neither-cued)/6. WLT 
decayed recall was calculated as the number of words recalled after approximately 15 minutes 
following the fifth session of the WLT minus the number of words recalled during the fifth 
session of the WLT. Stroop ratio was calculated by the following: Stroop card 3/ ((Stroop 
card 1 + Stroop card 2)/2). Accuracy and speed-accuracy trade-off (SATO) were calculated to 
take into account errors made during the Stroop Test. Accuracy = (maximum right answers – 
amount of errors / maximum right answers). SATO = accuracy / time needed to complete the 
task [58]. TMT-ratio was calculated by TMT-B/TMT-A. As the MMSE-score and the CES-D 
score followed a Poisson distribution, Relative Risks (RRs) for serum 25(OH)D and global 
cognitive performance and depression were calculated using multivariable Poisson regression, 
with the number of erroneous answers as the outcome for global cognitive functioning and the 
number of depressive symptoms as an outcome for depression [59]. This RR corresponds to the 
probability of developing depression or global cognitive dysfunction in participants with either 
intermediate or highest 25(OH)D concentrations in this population compared to participants 
with the lowest 25(OH)D concentrations. Participants were categorized according to tertiles 
of 25(OH)D status, using the lowest tertile as the reference category. All analyses were adjusted 
for age, sex (model 1), BMI, education, smoking, alcohol consumption, physical activity level 
and season of blood sampling (model 2). Spearman and Pearson correlation analyses were 
performed to obtain correlations coefficients between sunlight exposure, vitamin D intake, 
25(OH)D concentrations, domain-specific cognitive performance and measures of glucose 
homeostasis. All analyses were performed using the statistical package SAS, version 9.1 (SAS 
Institute Inc., Cary, NC, USA).
5.3 Results
Participants of the ProMuscle Study were on average 79 years old and serum 25(OH)D 
concentrations were lower with increasing age (P=0.03) (Table 1). The mean serum 
25(OH)D concentration was 54 nmol/L; 17% of the population had serum 25(OH)
D concentrations <30 nmol/L and 53% <50 nmol/L. Only 23% of the participants had 
serum 25(OH)D concentrations ≥75 nmol/L. The mean vitamin D intake was 4.6 µg/
day, with a 25th percentile of 2.5 µg/day and a 75th percentile of 5.8 µg/day. The mean 
FPG concentration was 5.3 and ranged from 4.4-6.5 mmol/L. FPI concentrations ranged 
from 5.1-45.1 µU/ml with a median concentration of 17.5 µU/ml (P=0.01). FPI and 
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HOMA-IR (P=0.04) were lowest in persons with the highest serum 25(OH)D status. 
Calcium intake increased across serum 25(OH)D tertiles (P=0.04). In this frail population 
59% of the persons in the top serum 25(OH)D tertile had one or more chronic diseases, 
which was 55% and 42% in the lowest and intermediate tertile (P=0.25), respectively. 
Table 1. Characteristics of 127 Dutch prefrail and frail older adults per tertile of serum 25(OH)D.
Note: Values are expressed as a mean ± SD, median with Q1-Q3 or n (%); Chi-squared tests for categorical 
variables and one-way analysis of variance for continuous variables were performed to compare baseline 
characteristics over tertiles of serum 25(OH)D; Chronic disease: defined as kidney disease, liver disease, 
cardiovascular disease, muscle disease, hip- or knee replacement; MMSE: Mini Mental State Examination; CES-D: 
Centre for Epidemiological Studies Depression scale; Missing values: physical activity (n=21), executive function 
(n=9), information processing speed (n=8), fasting plasma insulin, fasting plasma glucose and Homa-IR (n=3), and 
blood pressure and creatinine (n=1). 
T1
13-38 nmol/L
T2
38-65 nmol/L
T3
65- 163 nmol/L
P-value
N 40 43 44
Men, n (%) 16 (40) 18 (42) 16 (36) 0.29
Age, years 81.4±7.8 78.7±7.8 77.0±7.3 0.03
Body Mass Index, kg/m2 27.8±4.4 28.0±3.8 26.8±4.8 0.42
Fasting plasma glucose, mmol/L 5.25±0.50 5.28±0.44 5.24±0.48 0.90
Fasting plasma insulin, µU/ml 17.35±6.18 20.96±7.46 16.98±6.67 0.01
Homa-IR 4.1±1.8 5.0±2.1 4.1±1.9 0.04
Chronic disease present, n (%) 22 (55) 18 (42) 26 (59) 0.25
Systolic Blood Pressure, mmHg 152±22 144±22 144±23 0.21
Diastolic Blood Pressure, mmHg 75±9 75±9 74±9 0.76
Serum creatinine, mmol/L 76.6±15.6 74.5±13.1 70.9±15.6 0.21
Smoking status, n (%)
  Non-smoker
  Smoker
35 (88)
5 (12)
43 (100)
0 (0)
40 (91)
4 (9)
0.07
Physical activity, counts/min 91±62 136±75 184±112 0.0001
Educational level, n (%)
  Primary education
  Secondary education
  Higher education
1 (3)
28 (70)
11 (28)
3 (7)
20 (46.5)
20 (46.5)
3 (7)
27 (61)
14 (32)
0.26
Vitamin D intake, µg/day 3.2 (1.7-5.7) 3.9 (2.5-5.0) 4.4 (3.0-7.3) 0.21
Calcium intake, mg/day 921±343 1029±322 1135±476 0.04
Alcohol intake, g/day 4.5 (0-12.2) 6.3 (0.1-19.7) 7.0 (0-20.2) 0.35
MMSE score 27.5±2.3 27.7±2.2 27.8±2.2 0.81
Attention and working memory, z-score -0.16±0.80 0.00±0.86 0.14±0.99 0.31
Executive functioning, z-score -0.15±0.83 -0.07±0.74 0.25±0.62 0.04
Information processing speed, z-score -0.22±0.77 -0.03±0.87 0.24±0.74 0.05
Episodic memory, z-score -0.04±0.76 -0.11±0.58 0.10±0.64 0.36
CES-D score 5.55±5.33 7.42±4.79 7.77±6.77 0.17
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Vitamin D intake was not significantly correlated with serum 25(OH)D, r=0.09 (P=0.30). 
However, significant correlations were found for higher serum 25(OH)D concentrations 
with more sunbathing behaviour during the summer months and less sunscreen use, r=0.18 
(P=0.05) and r=-0.36 (P<0.0001), respectively. Higher 25(OH)D concentrations tended to 
be correlated with the type of clothing worn during the summer/autumn months, r=0.16 
(P=0.09). 
5.3.1 Vitamin D and markers of glucose homeostasis
Table 2 presents the regression coefficients of serum 25(OH)D and vitamin D intakes with 
FPG, FPI and HOMA-IR. After full adjustment no significant associations were observed for 
serum 25(OH)D or vitamin D intake with FPI, FPG, or HOMA-IR. Correlation analyses 
did show modest associations for sunbathing behaviour during the summer months with 
FPG, r=0.17 (P=0.08) and type of clothing worn with FPI and HOMA-IR, r=0.18 (P=0.06) 
and r=0.16 (P=0.08), respectively.
Table 2. Associations of serum 25(OH)D and vitamin D intake with markers of glucose homeostasis of 127 
prefrail and frail older adults participating in the ProMuscle Study.
Fasting plasma glucose 
(mmol/L), β±SE
Fasting plasma insulin 
(µU/mL), β±SE
HOMA-IR,
β±SE 
25(OH)D Vitamin D 
intake*
25(OH)D Vitamin D 
intake*
25(OH)D Vitamin D 
intake*
Crude model -0.002±0.002 
(P=0.30)
0.03±0.01 
(P=0.06)
-0.021±0.02 
(P=0.36)
0.15±0.20 
(P=0.46)
-0.006±0.006 
(P=0.36)
0.05±0.06 
(P=0.38)
Model 1 -0.002±0.002 
(P=0.12)
0.02±0.01 
(P=0.15)
-0.034±0.02 
(P=0.14)
0.06±0.20 
(P=0.77)
-0.010±0.006 
(P=0.14)
0.02±0.06 
(P=0.71)
Model 2 -0.001±0.002 
(P=0.39)
0.01±0.01 
(P=0.37)
-0.016±0.02 
(P=0.51)
0.10±0.21 
(P=0.65)
-0.004±0.007 
(P=0.57)
0.02±0.06 
(P=0.72)
Note: Model 1: Adjusted for age and sex. Model 2: Adjusted for age, sex, BMI, education, alcohol intake, smoking, 
physical activity and season. *Analyses for vitamin D intake are not adjusted for seasonal influences. Crude 
model and model 1: n=126 (FPI) and n=124 (FPG and HOMA-IR). Model 2: n=106 (FPI) and n=104 (FPG and 
HOMA-IR).
5.3.2 Vitamin D and cognitive performance
Compared to participants in the lowest serum 25(OH)D tertile, persons in the intermediate 
and top tertile scored higher on the MMSE. This finding was, however, not significant (Table 
3). Associations between serum 25(OH)D and various cognitive domains are displayed in 
Table 4. Fully adjusted models showed significantly better performance in tasks involving 
executive functioning per 1 nmol/L increase in serum 25(OH)D, β 0.007 (P=0.01). Serum 
25(OH)D tended to be associated with information processing speed, β 0.006 (P=0.06). 
When the models were expanded to capture the impact of depression or calcium, β’s did not 
significantly change (data not shown). Moreover, within the domain executive functioning 
an association was observed for serum 25(OH)D with the reaction time task (neither 
cued: β -2.86, P=0.01; finger cued: β -2.71, P=0.01; hand cued: β -2.86, P=0.01). Serum 
25(OH)D also showed a significant association with the reaction time task uncued (β -2.58, 
P=0.01), a task related to the domain information processing speed. A modest association 
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was observed for serum 25(OH)D with digit span (β 0.02, P=0.07), within the domain 
attention and working memory. Scores on the word learning tests indicated that with every 
11 nmol/L increase in serum 25(OH)D one word more could be memorized (P=0.008) 
(supplementary Table). Vitamin D intake was not associated with any of the domains of 
cognitive functioning (Table 4). There was a significant correlation between type of clothing 
worn during the summer months (i.e. less skin covered) and information processing speed, 
r=0.21 (P=0.03), and a modest correlation with attention and working memory, r=0.17 
(P=0.06). Neither sunscreen use nor sunbathing behaviour was correlated with any of the 
cognitive domains (data not shown).
Table 3. Associations between serum 25(OH)D and mental health of 127 prefrail and frail older adults 
participating in the ProMuscle Study, Relative Risk with 95% CI.
Low serum 
25(OH)D
(<34 nmol/L)
Moderate serum 
25(OH)D
(34-52 nmol/L)
High serum 
25(OH)D
(52-125 nmol/L)
P for trend
CES-D (depression)
Crude model 1.0 1.34 (0.94-1.90) 1.40 (0.95-2.07) 0.0004
Model 1 1.0 1.31 (0.92-1.88) 1.33 (0.87-2.02) 0.005
Model 2 1.0 1.34 (0.89-2.04) 1.47 (0.91-2.40) 0.001
MMSE (global cognitive performance)
Crude model 1.0 0.93 (0.62-1.38) 0.87 (0.58-1.31) 0.79
Model 1 1.0 1.00 (0.68-1.47) 0.98 (0.65-1.47) 0.96
Model 2 1.0 0.83 (0.55-1.24) 0.78 (0.51-1.20) 0.77
Note: Model 1: Adjusted for age and sex; Model 2: Adjusted for age, sex, BMI, education, smoking, physical activity, 
alcohol intake, and season; Crude model and model 1: n=127. Model 2: n=106.
5.3.3 Vitamin D, cognitive performance and the interplay with glucose  homeostasis
The βs for serum 25(OH)D and domain-specific cognitive performance did not significantly 
change when glucose was entered into the fully adjusted model, showing that associations 
between serum 25(OH)D and cognitive performance in this population were not mediated 
by glucose concentrations. The association between serum 25(OH)D and information 
processing speed, however, did become statistically significant after adjustment for glucose, β 
0.006 (P=0.05). Stratifying the data for those with low and high glucose concentrations did 
not suggest a clear modification effect. 
5.3.4 Vitamin D and depressive symptoms
Data on the association between serum 25(OH)D concentrations and depression can be 
found in Table 3. Neither serum 25(OH)D, nor vitamin D intake (data not shown), was 
associated with the number of depressive symptoms observed in this frail population. In 
addition, no significant correlations between sunlight exposure and the number of depressive 
symptoms were observed.
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Table 4. Associations of serum 25(OH)D and vitamin D intake with domain-specific cognitive performance in 
prefrail and frail older adults participating in the ProMuscle Study, β±SE.
Total ‘Low’ FPG 
(<5.20 mmol/L)b
‘High’ FPG 
(≥5.20 mmol/L)b
25(OH)D, nmol/L Vitamin D intake, µg/da 25(OH)D 25(OH)D
Attention and working memory
Crude 0.006±0.003 (P=0.06) -0.007±0.03 (P=0.78) 0.004±0.003 (P=0.19) 0.005±0.005 (P=0.17)
Model 1 0.005±0.003 (P=0.08) -0.013±0.03 (P=0.62) 0.004±0.003 (P=0.26) 0.007±0.006 (P=0.23)
Model 2 0.006±0.004 (P=0.11) -0.02±0.03 (P=0.46) 0.006±0.004 (P=0.17) 0.008±0.008 (P=0.31)
Executive functioning 
Crude 0.007±0.002 (P=0.003) 0.002±0.02 (P=0.94) 0.007±0.003 (P=0.04) 0.010±0.004 (P=0.01)
Model 1 0.006±0.002 (P=0.01) -0.01±0.02 (P=0.65) 0.005±0.003 (P=0.11) 0.009±0.004 (P=0.03)
Model 2 0.007±0.003 (P=0.01) -0.05±0.02 (P=0.06) 0.006±0.004 (P=0.12) 0.007±0.005 (P=0.17)
Information processing speed
Crude 0.007±0.003 (P=0.01) 0.03±0.02 (P=0.24) 0.007±0.004 (P=0.07) 0.01±0.004 (P=0.02)
Model 1 0.006±0.003 (P=0.03) 0.02±0.02 (P=0.47) 0.006±0.004 (P=0.14) 0.008±0.004 (P=0.05)
Model 2 0.006±0.003 (P=0.06) 0.01±0.03 (P=0.59) 0.006±0.004 (P=0.16) 0.004±0.005 (P=0.42)
Episodic memory
Crude 0.003±0.002 (P=0.14) 0.009±0.02 (P=0.65) 0.003±0.003 (P=0.25) 0.004±0.004 (P=0.24)
Model 1 0.002±0.002 (P=0.47) -0.002±0.02 (P=0.93) 0.003±0.003 (P=0.49) 0.002±0.004 (P=0.67)
Model 2 0.002±0.002 (P=0.28) -0.03±0.02 (P=0.17) 0.003±0.003 (P=0.30) 0.001±0.004 (P=0.74)
Note: Model 1: Adjusted for age and sex; Model 2: Adjusted for model 1 and BMI, education level, alcohol, 
smoking, physical activity, and season; aAnalyses for vitamin D intake are not adjusted for seasonal influences; 
bLow and high FPG concentrations were based upon the median split; Crude model and model 1: n=127 (AWM, 
EM), n=118 (EF) and n=119 (IPS). Model 2: n=106 (AWM, EM) and n=99 (EF, IPS).  
5.4 Discussion
In this population of older adults, serum 25(OH)D was positively associated with domain- 
specific cognitive performance; more specifically executive functioning. A near significant 
association was observed for serum 25(OH)D with information processing speed. 
To our knowledge this is the first study exploring the association between vitamin D and 
cognitive performance in a prefrail and frail elderly population. A recent study showed that 
executive function and information processing speed were compromised in frail elders when 
compared to non-frail elders [60]. Therefore, investigating the association between vitamin 
D with cognitive performance in this specific population is an important strength of this 
study. Other strengths include the use of various measures of vitamin D exposure (i.e. serum 
25(OH)D, vitamin D intake and sunlight exposure), the use of LC-MS/MS to quantify the 
25(OH)D concentration, the broad variety of domain-specific cognitive tests used and the 
ability to adjust for a large number of potential confounders. However, also some limitations 
need to be considered, such as the relatively small sample size, cross-sectional design and 
the fact that sun exposure was assessed six months following the baseline measurements. 
Another limitation of this study is the exclusion of participants with FPG concentrations 
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>7.0 mmol/L, which may explain the null finding with regard to serum 25(OH)D and 
markers of glucose homeostasis in this study. 
Whereas associations of serum 25(OH)D with diabetes, cognitive performance, and 
depression are already somewhat more explored, vitamin D intake and its association with 
cognitive performance [61, 62], depression [63], and glucose homeostasis [64-66] has only 
been studied in a limited number of observational studies. In this study we were not able to 
detect any association between vitamin D intake and the aforementioned outcome measures. 
Moreover, correlations between vitamin D intake and serum 25(OH)D appeared to be low. 
One of the explanations for these findings may be the low vitamin D intake levels and the 
narrow range in vitamin D intake in our population, which in turn may be explained by the 
fact that food fortification with vitamin D in the Netherlands is not broadly practiced and 
vitamin D-rich products are often not part of the daily menu. 
In this study, we did not observe an association between serum 25(OH)D and vitamin D 
intake with indicators of glucose homeostasis, specifically FPG, FPI, or HOMA-IR. Already 
in 1984 a study among English men and women showed higher postprandial glucose 
concentrations during the winter period [67]. Baynes and colleagues (1997) observed an 
inverse association between 25(OH)D and the Area Under the Curve (AUC) for both insulin 
and glucose among elderly Dutch men [68]. However, reviews discussing cross-sectional 
studies [6], prospective studies [7] as well as RCTs [7] showed that there is no consensus as to 
what extent vitamin D is involved in glucose homeostasis. 
In this study we observed a statistically significant association between serum 25(OH)D 
and cognitive executive performance, which was assessed using tasks related to response 
inhibition, cognitive flexibility, and mental shifting. Smaller studies as well as larger 
community-based cohort studies investigated the association of 25(OH)D status with global 
cognitive performance [8, 29-31, 33] and domain specific cognitive performance (Table 5) 
[28, 32, 34, 69-71]. 
Table 5. Summary of cross-sectional and prospective studies examining the association between serum 
25(OH)D and domain-specific cognitive performance in populations of older adults.
Study Population Design Domain specific 
cognitive tests
Main findings
NAME Study 
Buell, et al. (2009)
377 black and 
703 non-black 
older adults, 65-
99 years
Cross-sectional Trail Making Test- A 
and B
Digit Symbol Test
Matrix Reasoning
WAIS-III Block 
Design 
WMS-III word list 
learning and logical 
memory  
Digit span
Verbal fluency
Higher 25(OH)D concentrations 
were associated with a better 
performance on:
TMT-B (β = -0.73, P<0.02)
TMT-A (β = -0.49, P<0.03)
Digit Symbol Test (β = 0.19, 
P<0.001)
Matrix reasoning (β = 0.04, P 
<0.02)
Block Design Test (β = 0.07, 
P<0.04) 
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Annweiler and colleagues (2012) reviewed the current literature on serum 25(OH)D and 
domain-specific cognitive performance and speculated that vitamin D may be particularly 
related to executive function, more specifically mental shifting and information updating 
impairments. Moreover, it was postulated that vitamin D deficiency is predominantly 
associated with dysfunction of the frontal-subcortical neuronal circuits [72]. This finding for 
executive function is in line with our findings and also with results of other studies [32, 69, 
70], but not all [71]. In the NAME study participants with higher 25(OH)D concentrations 
completed the TMT-B significantly faster, β -0.73 (P<0.02) [69]. TMT-B results also 
showed a significant higher probability of experiencing cognitive decline among older adults 
with 25(OH)D concentrations <25 nmol/L in the InCHIANTI Study, when compared 
Study Population Design Domain specific 
cognitive tests
Main findings
InCHANTI Study 
Llewellyn, et al. (2010)
858 men and 
women, ≥65 
years
Prospective Trail Making Test- A 
and B
Higher 25(OH)D concentrations 
were associated with a better 
performance on TMT-B. RR 1.32 
with 95% CI 1.03-1.51 for those 
with serum 25(OH)D concentra-
tions <25 nmol/L with RR 1.0 for 
those with concentrations ≥75 
nmol/L (P for trend over quartiles 
0.04). 
MrOS Study 
Slinin, et al. (2010)
1564 men, ≥65 
years
Cross-sectional / 
prospective 
Trail Making Test- B No significant associations.
European Male 
Ageing Study 
Lee et al. (2009)
3133 men, 40-79 
years
Cross-sectional Rey-Osterrieth 
Complex Figure 
test
Camden Topograp-
hical Recognition 
Memory
Digit-Symbol Sub-
stitution Test
Higher 25(OH)D concentrations 
were associated with a better 
performance on the Symbol 
Digit Test, β 0.15 per 10 nmol/L 
(P<0.01).
NHANES III 
McGrath, et al. (2007)
≥60 years: 4809 
men and women
Cross-sectional Memory and 
learning score
Significant difference between 
serum 25(OH)D quintiles: Wald 
test F=3.38, P=0.02. However, 
those with the highest serum 
vitamin D concentrations had the 
lowest scores.
ZENITH Study
Seamans, et al. (2010)
387 men and 
women, 55-87 
years 
Cross-sectional Cambridge Neu-
ropsychological 
Testing Automated 
Battery, including 
assessments of 
spatial working 
memory, pattern 
recognition me-
mory, spatial span, 
reaction time and 
match-to-sample 
tests
Serum 25(OH)D was significantly 
associated with spatial working 
memory: Tertile 1 (ref) vs. Tertile 3 
- between errors β 5.39 (P=0.03), 
strategy β 2.36 (P=0.02) and total 
errors β 5.36 (P=0.04).
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to those with concentrations of ≥75 nmol/L, RR 1.32 (95% CI 1.03-1.51) [70]. Serum 
25(OH)D was also associated with spatial working memory as assessed with the Cambridge 
Neuropsychological Testing Automated Battery among 387 Europeans aged ≥55 years [32]. 
In contrast, no association was found between serum 25(OH)D and TMT-B performance 
in the MrOS study [71]. Information processing speed was also significantly faster among 
those with higher 25(OH)D concentrations in the NAME study, as shown by the results 
from the TMT-A and symbol digit test, β -0.49 (P<0.03) and β 0.19 (P<0.001), respectively 
[69]. Moreover, 25(OH)D status was associated with a higher score on the symbol digit 
test in the European Male Ageing Study, β 0.15 per 10 nmol/L (P<0.01) [34]. Also, serum 
25(OH)D and visuospatial function were positively associated in the NAME study, as shown 
by significant results on matrix reasoning and block design test [69]. In the NHANES III, 
learning and memory, as assessed by one single test, was significantly worse among US older 
adults with the highest 25(OH)D concentrations [73]. 
RCTs examining the effect of vitamin D supplementation on cognitive performance in 
older adults are rare, of small sample size, and had a relatively short intervention period 
[74, 75]. Corless and colleagues (1985) supplemented 64 geriatric patients with 225 µg/day 
vitamin D2 or a placebo. Next, cognitive performance was assessed at 10 (n=64), 24 (n=38) 
and 40 (n=25) weeks. Statistical analyses did not reveal a significant effect of vitamin D2 
supplementation at any of the time points [74]. Stein and colleagues (2011) conducted an 
RCT with 32 participants, which were assigned to either 150 µg vitamin D2 daily or 25 µg 
vitamin D2 daily. After eight weeks of supplementation no statistical differences in cognitive 
performance were observed between those receiving the high dose of vitamin D and those 
receiving the low dose of vitamin D [75].
In the first published MRI-study on vitamin D and cerebrovascular pathology Buell and 
colleagues (2010) found an association between serum 25(OH)D and large vessel infarcts, 
but also with all-cause dementia, white matter hyperintensity volume, and white matter 
hyperintensity severity [76]. Previous studies also indicate an association of diabetes with 
vascular factors and cognitive performance [43]. Therefore, diabetes may be considered 
an intermediate in the association between serum 25(OH)D and cognitive performance. 
Alternatively, diabetes may also be considered a potential effect modifier in the association 
between serum 25(OH)D and cognitive performance, as vitamin D supplementation may 
directly as well as indirectly promote cognitive performance. In the current study we did not 
observe a mediation effect or a modification effect of FPG concentrations in the association 
between serum 25(OH)D and domain-specific cognitive performance. However, it may be 
that a potential modification effect of FPG in our study was masked owing to the small range 
in glucose concentrations. Three other studies also investigated the potential role of diabetes 
in the association between vitamin D and domain-specific cognitive performance [31, 34, 
70], of which only the NHANES III study observed partial mediation by the presence of 
diabetes mellitus [31]. 
Last, neither dietary vitamin D nor serum 25(OH)D was associated with depression, as 
measured by CES-D. Whereas some studies showed results that are in line with our data [40, 
77], others observed a tendency of lower depression rates among those with higher serum 
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25(OH)D concentrations [30, 36-39, 78]. RCTs showed inconsistent results as well [79-83], 
which may, amongst others, be explained by methodological differences and differences in 
responsiveness to vitamin D supplementation. 
Previous studies have suggested a possible relationship between low 25(OH)D concentrations 
and extraskeletal health. This study also suggests an association between serum 25(OH)D and 
cognitive performance. However, we did not observe associations of vitamin D with glucose 
homeostasis or depression, nor did we observe a potential mediatory or modifying role of 
glucose homeostasis in the association between serum 25(OH)D and cognitive performance. 
Yet, more studies are warranted in order to confirm our findings and to define disease specific 
cut-off points for serum 25(OH)D and dietary reference intakes for cognitive function, 
depression, and glucose homeostasis.
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Supplementary material
sTable. Association between serum 25(OH)D and individual cognitive tests in 127 prefrail and frail older 
adults.
β P-value
Information Processing Speed
Stroop average 
Crude model 0.002 0.05
Model 1 0.002 0.10
Model 2 0.002 0.26
Trail Making Test A
Crude model 0.081 0.18
Model 1 0.063 0.30
Model 2 0.113 0.14
Reaction Time Task uncued 
Crude model -2.56 0.004
Model 1 -2.08 0.02
Model 2 -2.58 0.01
Executive function
Stroop ratio 
Crude model 0.000 0.65
Model 1 0.000 0.95
Model 2 0.000 0.94
Verbal Fluency Score
Crude model 0.05 0.02
Model 1 0.06 0.06
Model 2 0.06 0.09
Trail Making Test ratio
Crude model -0.002 0.26
Model 1 -0.002 0.32
Model 2 -0.002 0.32
Reaction Time Task neither cued
Crude model -3.03 0.002
Model 1 -2.51 0.01
Model 2 -2.86 0.01
Reaction Time Task finger cued 
Crude model -2.98 0.003
Model 1 -2.34 0.01
Model 2 -2.71 0.01
Reaction Time Task hand cued
Crude model -2.78 0.004
Model 1 -2.34 0.01
Model 2 -2.86 0.01
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Note: Model 1: Adjusted for age and sex; Model 2: Adjusted for age, sex, BMI, education, alcohol intake, smoking, 
physical activity and season; Numbers for model 2: n=106 digit span and letter fluency, n=102 reaction time task, 
n=101 Stroop, n=103 trail making test, n=106 word learning test.
Trail Making Test B
Crude model -0.059 0.32
Model 1 -0.061 0.30
Model 2 -0.067 0.30
Episodic Memory
Word Learning Test- Total immediate recall
Crude model 0.102 0.003
Model 1 0.069 0.03
Model 2 0.089 0.008
Word Learning Test - Delayed recall
Crude model -0.007 0.20
Model 1 -0.007 0.24
Model 2 -0.005 0.45
Word Learning Test - Delayed recognition
Crude model 0.010 0.20
Model 1 0.005 0.52
Model 2 0.005 0.48
Attention and Working Memory
Digit Span forward
Crude model 0.009 0.10
Model 1 0.009 0.13
Model 2 0.007 0.34
Digit Span backward
Crude model 0.011 0.08
Model 1 0.010 0.12
Model 2 0.014 0.08

Cognitive performance: is there an 
interplay between serum vitamin D 
and glucose homeostasis?
Brouwer-Brolsma EM
Dhonukshe-Rutten RAM 
van Wijngaarden JP 
van der Zwaluw NL 
in ’t Veld PH 
Wins S 
Swart KMA 
Enneman AW 
Ham AC 
van Dijk SC 
van Schoor NM 
van der Velde N 
Uitterlinden AG 
Lips P 
Kessels RPC 
Steegenga WT 
Feskens EJM 
de Groot CPGM
6
6 6
V I TA M I N  D  A N D  C O G N I T I O N : T h e  B - P R O O F  s t u d y
104
Abstract 
Background 
Vitamin D inadequacy is frequently observed all over the globe and has been 
hypothesized to be a modifiable risk factor for cognitive decline. Vitamin D may directly 
influence cognitive decline, but the effect may also be indirect, for instance through 
changes in glucose homeostasis. As glucose homeostasis may also affect cognitive decline 
independent of vitamin D, interactions between vitamin D and glucose homeostasis 
may be observed. Therefore, we studied the cross-sectional interplay of vitamin D with 
glucose homeostasis in the association with domain-specific cognitive performance.
Design 
25-hydroxyvitamin D (25(OH)D), glucose and insulin concentrations were measured. 
Cognitive performance was assessed with an extensive cognitive test battery in 776 
(3 domains) up to 2722 (1 domain) Dutch older adults aged ≥65 years. Prevalence 
Ratio’s (PRs) were calculated to quantify the association between serum 25(OH)D and 
cognition; poor performance was defined as the worst 10% of the distribution of the 
cognitive scores.
Results 
Higher serum 25(OH)D was associated with better attention and working memory, PR 
0.49 (95% CI 0.29-0.83) for the third serum 25(OH)D tertile, indicating a 51% lower 
probability of being a poor performer when compared to participants in the lowest 
tertile. Beneficial trends were shown for serum 25(OH)D with executive function and 
episodic memory. Serum 25(OH)D was not associated with plasma glucose and plasma 
insulin. Plasma insulin modified the association between serum 25(OH)D and executive 
function (P for interaction: 0.001), suggesting that the improvement in executive function 
with high 25(OH)D concentrations is stronger in participants with higher plasma insulin 
than in those with lower plasma insulin concentrations. 
Conclusion 
Higher 25(OH)D concentrations were significantly associated with better attention and 
working memory performance. This study does not show an interplay between serum 
25(OH)D and glucose homeostasis in the association with cognitive performance.  
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6.1 Introduction
Aging is a generally known key risk factor for dementia. However, the exact underlying 
pathophysiological mechanisms still need to be unraveled. Nutritional factors may play a 
role; vitamin D is one of the nutrients under study [1]. 
Several biological studies have provided evidence for a role of vitamin D in cognitive 
performance [2-4]. The discovery of vitamin D receptors (VDRs) and 1-OH-ase, the enzyme 
that catalyses the conversion of the biological inactive form of vitamin D in the biological active 
form, in brain tissue are probably the two most consistent findings supporting a potential 
vitamin D effect. The potential favourable effect of vitamin D on cognitive performance may 
also be partially explained by its effect on glucose homeostasis. Serum vitamin D has in fact 
been associated with glucose homeostasis [5], and an impaired glucose tolerance has been 
associated with an increased risk of cognitive decline [6]. 
So far, results from observational studies exploring the association between vitamin D and 
cognition in humans have been equivocal [1, 7-16]. Four studies adjusted their final analyses 
for a marker of glucose homeostasis [9, 10, 15, 16]; one suggests a modest role for diabetes. 
Unfortunately, more detailed studies examining the influence of glucose homeostasis in the 
association between serum 25(OH)D and cognitive performance are lacking.  
Therefore, we studied the association between serum 25(OH)D and domain-specific 
cognitive performance in Dutch older adults aged ≥65 years, with a specific interest for the 
potential mediating and modifying role of glucose homeostasis.
6.2 Methods
6.2.1 Participants
This cross-sectional study was performed using baseline data of the B-PROOF study; a 
randomized, double blind, placebo-controlled trial designed to assess the effect of daily oral 
supplementation of vitamin B12 and folic acid on fractures in mildly hyperhomocysteinemic 
(plasma Hcy 12-50 µmol/L) older adults ≥65 years; details have been reported previously 
[17]. The Medical Ethics Committee of Wageningen UR approved the study protocol and 
the Medical Ethics Committees of VUmc and Erasmus MC confirmed local feasibility. All 
participants gave written informed consent. For the current analyses, only data of participants 
with serum 25(OH)D measurements have been used (n=2857) (supplementary Figure 1).
6.2.2 Cognitive performance
Cognitive performance was assessed according to a standard protocol, by a well-trained staff. 
The Mini-Mental State Examination (MMSE) was administered to assess overall cognitive 
status [18]. An extensive neuropsychological test battery covered four cognitive domains: 
attention and working memory (n=787), executive functioning (n=776), information 
processing speed (n=797) and episodic memory (n=2722). 
The Rey Auditory Verbal Learning Test (RAVLT) was used to measure immediate and delayed 
recall, as well as recognition for word lists, as indices of episodic memory [19]. RAVLT 
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decayed recall was calculated as the number of words recalled approximately 15 minutes after 
the fifth session of the RAVLT minus the number of words recalled at the fifth session of the 
RAVLT. The Digit Span forward and backward from the Wechsler Adult Intelligence Test 
(WAIS-III) measures attention and working memory, respectively [20]. Trail Making Test 
(TMT) part A measures information processing speed and part B assesses concept-shifting 
interference as part of executive functioning [21]. Stroop Color-Word Test determines 
selective attention and inhibition as part of executive functioning [22]. To control for the 
effect of motor speed on TMT and Stroop performance, we calculated interference measures, 
specifically TMT-ratio (TMT B/TMT A) and Stroop (Stroop3/((Stroop1+Stroop2)/2)). The 
Symbol Digit Modalities Test (SDMT) measures information processing speed [23]. Letter 
Fluency - using three letters - measures response generation as part of executive function [24]. 
The letter fluency score was composed of the sum score of the three letters. To compare the 
results of the individual cognitive tests and to limit the number of dependent variables, raw 
test scores were clustered into compound scores for the four neuropsychological domains. 
Data of baseline measurements were used as norm data to create individual Z-scores (Z-score 
= (score test - mean baseline)/SD baseline) and the following domains in formula form 
were created: Episodic memory = (ZRAVLT total immediate recall + ZRAVLT decayed recall + ZRAVLT recognition)/3, 
Attention and working memory = (ZDigit Span forward + ZDigit Span backward)/2, Information processing 
speed = (-ZStroop mean I and II + -ZTrail making test part A + ZSymbol Digit Modalities Test)/3, Executive functioning 
= (-ZStroop interference + -ZTrail making ratio + ZVerbal Fluency)/3. Cognitive performance was dichotomized: 
a participant belonging to the worst 10% of cognitive performers was defined as being a poor 
performer. The other 90% of the population was defined as ‘normal’ performer [25].
6.2.3 Biochemical analyses 
Blood samples were drawn in the morning when the participants were fasted or had consumed a 
restricted breakfast. Samples were stored at -80˚C until determination. Serum 25(OH)D was 
measured by isotope dilution-online solid phase extraction liquid chromatography-tandem 
mass spectrometry (ID-XLC-MS/MS) [26]. Plasma glucose concentrations were analysed 
using a hexokinase method (Gluco-quant, Roche Diagnostics). Plasma insulin concentrations 
were determined using an immunometric assay (ADVIA Centaur immunoassay system, 
Siemens Medical Solutions Diagnostics).
6.2.4 Covariates
Height was measured at baseline with a stadiometer to the nearest 0.1 cm. Weight was 
measured to the nearest 0.5 kg with a calibrated analogues scale. Body Mass Index (BMI) 
was calculated as weight/height2. Data on education level (i.e. primary, secondary or higher 
education), smoking status (i.e. non-smoker or current smoker), physical activity (kcal/day) 
[27] and alcohol consumption (i.e. light, moderate, excessive) [28] were collected by means 
of questionnaires. The 15-item Geriatric Depression Scale (GDS) was used as a screening 
tool for depression. Scores ≥5 are indicative of a depressive episode [29]. Season was based 
on the month of blood sampling. Season of blood collection was dichotomized into summer 
(June–November) and winter (December–May). 
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6.2.5 Statistical Analyses
Participant characteristics are reported as mean with standard deviation (SD), or 
percentages. Medians with interquartile range (IQR) were used to report skewed variables. 
Cox proportional hazards analysis with robust error variance was conducted to calculate 
Prevalence Ratios (PRs) for domain-specific cognitive performance per serum 25(OH)D 
tertile, using the lowest tertile as the reference group. By assigning a constant risk period 
to all participants in the study, the obtained hazard ratio can be considered as a prevalence 
ratio (PR) [30]. This PR corresponds to the probability of being defined as a poor cognitive 
performer in participants with moderate or high serum 25(OH)D concentrations, compared 
to participants with low serum 25(OH)D concentrations. Analyses were adjusted for age, sex 
(model 1), BMI, education, smoking, alcohol consumption, habitual physical activity, and 
season of blood sampling (model 2).
The dose-response of the association between serum 25(OH)D with plasma glucose and 
plasma insulin was explored by restricted cubic spline regression, and multiple linear 
regression analyses. Plasma glucose and plasma insulin were not normally distributed and 
therefore logarithmically transformed. All analyses were adjusted for age, sex (model 1), BMI, 
education, smoking, alcohol consumption, habitual physical activity, and season of blood 
sampling (model 2). 
Cox proportional hazards analysis was used to evaluate the associations of plasma glucose and 
plasma insulin with domain-specific cognitive performance by estimating prevalence ratios 
as suggested by Barros and Hirataka (2003) [30]; results are presented per 0.1 and 5 unit 
increment in plasma glucose and plasma insulin, respectively. Analyses were adjusted for age, 
sex (model 1), BMI, education, smoking, alcohol consumption, habitual physical activity 
(model 2), and depression.
Mediation of the association between serum 25(OH)D and cognitive performance by glucose 
homeostasis was examined by studying the association 1) between serum 25(OH)D and glucose 
homeostasis, 2) between glucose homeostasis and domain-specific cognitive performance, 
and 3) by adding plasma glucose and plasma insulin, independently, to fully adjusted Cox 
proportional hazards models that were used to explore the associations between serum 
25(OH)D and domain-specific cognitive performance. Moreover, the interaction between 
serum 25(OH)D and glucose homeostasis in its association with cognitive performance 
was tested. In case of significant findings, data were also presented stratified. Analyses were 
performed using the statistical package SAS, version 9.1 (SAS Institute Inc., Cary, NC, USA). 
Spline regression analyses were performed using R version 2.15.
6.3 Results
Table 1 shows the population characteristics. Participants of the subsample who participated 
in more extensive cognitive performance assessment were on average 72.6±5.8 years of age, 
and had a median MMSE score of 29 (IQR: 28-30). Mean serum 25(OH)D concentration 
was 60±26 nmol/L. Thirty-seven percent of the participants had serum 25(OH)D 
concentrations below the recommended concentration of 50 nmol/L [31]. Mean plasma 
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glucose concentration was 5.8±1.4 mmol/L and median plasma insulin concentration was 
66 pmol/L (IQR: 41-127). Participants with the lowest 25(OH)D concentrations were more 
likely to be older (P<0.0001), have a higher BMI (P=0.002), a lower physical activity level 
(P=0.006), more depressive symptoms (P=0.009), and more likely to be included in the study 
during the winter/spring months (<0.0001).
Table 1. Population characteristics, overall and by tertile of serum 25(OH)D.
Note: MMSE=Mini-Mental State Examination. GDS-15=Geriatric Depression Scale-15. T=Tertile. P-value refers 
to differences between tertiles. Missing (n): BMI (16), plasma glucose (11), plasma insulin (10), physical activity 
(16), alcohol intake (2), MMSE (14), GDS-15 (19). 
6.3.1 Vitamin D and cognitive performance
Unadjusted models showed that low serum 25(OH)D was associated with a higher probability 
of a poor performance on all four cognitive domains (Table 2). After full adjustment only the 
association of serum 25(OH)D with attention and working memory remained significant, 
Total 
population
Cognition
subsample
Cognition subsample, 
by tertile of serum 25(OH)D
P-value
T1 
<47 nmol/L
T2
47-70 nmol/L
T3
>70 nmol/L
N 2857 846 280 286 280
25(OH)D, nmol/L 56±25 60±26 33±10 59±7 89±17 <0.0001
Sex, men (%) 1459 (50) 500 (58) 149 (53) 174 (61) 172 (61) 0.09
Age, years 74.1±6.5 72.6±5.8 74.1±6.6 72.1±5.2 71.4±4.7 <0.0001
Body Mass Index, kg/m2 27.1±4.0 27.2±3.9 27.5±4.4 27.6±3.8 26.5±3.3 0.002
Glucose, mmol/L - 5.8±1.4 5.7±1.3 5.9±1.5 5.8±1.6 0.50
Insulin, pmol/L - 66 (41-127) 71 (44-133) 68 (44-136) 61 (38-105) 0.23
Smoking, n (%)
  Non
  Current
  Former 
989 (34)
281 (10)
1649 (56)
267 (31)
87 (10)
503 (59
80 (29)
34 (12)
166 (59)
89 (31)
29 (10)
168 (59)
92 (33)
23 (8)
165 (59)
0.56
Physical activity, 
kcal/day
650
(343-826)
576 
(344-862)
496 
(289-785)
581 
(382-874)
625 
(386-894)
0.006
Education, n (%)
  Primary 
  Secondary 
  Higher 
1547 (53)
615 (21)
757 (26)
368 (43)
190 (22)
299 (35)
122 (44)
63 (23)
95 (34)
127 (44)
65 (23)
94 (33)
113 (40)
59 (21)
108 (39)
0.68
Alcohol intake, n (%)
  Light
  Moderate
  Excessive
1966 (67)
839 (29)
112 (4)
556 (65)
272 (32)
29 (3)
201 (72)
68 (24)
11 (4)
171 (60)
105 (37)
10 (3)
174 (62)
98 (35)
8 (3)
0.02
MMSE score, 
range 0-30
29 (28-30) 29 (28-30) 29 (27-30) 29 (28-30) 29 (28-30) 0.16
GDS-15 score,
range 0-15
1.0 (0-2.0) 1.0 (0-2.0) 1.0 (0-2.0) 1.0 (0-2.0) 0 (0-2.0) 0.009
Blood sampling from 
June - November
1531 (52) 557 (65) 145 (52) 191 (67) 216 (77) <0.0001
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showing that participants in the upper serum 25(OH)D tertile had a 51% lower probability 
of being a poor performer. For associations with executive function and episodic memory a 
non-significant trend remained. Specifically, for executive function, people in the second and 
third tertile had a 53% lower (PR 0.47 (95% CI 0.27-0.80) and borderline non-significant 
39% lower (PR 0.61 (95% CI 0.35-1.06)) probability of a poor performance. A borderline 
significant association was observed for episodic memory, PR 0.75 (95% CI 0.55-1.02) for 
the upper serum 25(OH)D tertile. Additional adjustment for depression did not alter these 
results. 
Table 2. Associations of serum 25(OH)D with domain-specific cognitive performance as shown by Prevalence 
Ratio’s (PRs) with 95% Confidence Interval (CI), continuously and by tertile of 25(OH)D.
Prevalence Ratio’s by tertile of serum 25(OH)D (nmol/L)
WUR 
(total population)
T1: 4-47
(4-42)
T2: 47-70
(42-65)
T3: 70-194
(65-194)
P for trend
AWM, n (cases)* 263 (38) 262 (27) 262 (18)
Crude model 1.0 0.69 (0.44-1.09) 0.46 (0.27-0.78) 0.005
Model 1 1.0 0.70 (0.44-1.11) 0.47 (0.27-0.81) 0.008
Model 2 1.0 0.72 (0.45-1.14) 0.49 (0.29-0.83) 0.008
EF, n (cases)* 254 (40) 260 (17) 262 (19)
Crude model 1.0 0.39 (0.23-0.67) 0.43 (0.26-0.72) 0.004
Model 1 1.0 0.46 (0.27-0.79) 0.53 (0.31-0.91) 0.04
Model 2 1.0 0.47 (0.27-0.80) 0.61 (0.35-1.06) 0.13
IPS, n (cases)* 260 (32) 267 (29) 270 (19)
Crude model 1.0 0.86 (0.54-1.37) 0.56 (0.33-0.95) 0.04
Model 1 1.0 1.35 (0.84-2.15) 0.95 (0.56-1.62) 0.95
Model 2 1.0 1.44 (0.91-2.27) 1.01 (0.59-1.74) 0.86
EM, n (cases)* 896 (108) 918 (96) 908 (70)
Crude model 1.0 0.87 (0.67-1.12) 0.64 (0.48-0.85) 0.002
Model 1 1.0 1.02 (0.78-1.31) 0.76 (0.57-1.02) 0.07
Model 2 1.0 0.99 (0.76-1.29) 0.75 (0.55-1.02) 0.07
Note: *Participants were characterized as poor cognitive performers when cognitive test scores fell below the 
10th percentile. Model 1 is adjusted for age and sex.  Model 2 is adjusted for age, sex, BMI, education, alcohol 
consumption, smoking, physical activity, season of blood sampling, and centre. None of the PRs substantially 
changed after additional adjustment for depression, glucose or insulin. AWM=Attention and Working Memory. 
EF=Executive Function. IPS=Information Processing Speed. EM=Episodic Memory. WUR: Wageningen subsample.
6.3.2 Vitamin D and glucose homeostasis
Tests for non-linearity of the restricted cubic splines showed that the dose-response association 
of serum 25(OH)D status with log-transformed plasma glucose and plasma insulin could be 
considered linear (supplementary Figure 2). Subsequently, multiple linear regression 
analyses showed significant associations for serum 25(OH)D with plasma insulin after 
adjustment for age and sex, β -0.003 (P=0.02). However, in the fully adjusted regression 
analysis this association attenuated and became non-significant, β -0.001 (P=0.31). 
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6.3.3 Glucose homeostasis and domain-specific cognitive performance
In fully adjusted models only a significant association between plasma glucose and attention 
and working memory was observed, PR 1.01 (1.00-1.02) per 0.1 unit increase in plasma 
glucose, which roughly suggests a 10% higher probability of being a poor performer with 
every unit increase in plasma glucose. Plasma glucose and insulin did not significantly 
associate with any of the other cognitive outcome measures (data not shown).
6.3.4 Is there an interplay of serum 25(OH)D and glucose homeostasis?
The above-mentioned findings on (1) serum 25(OH)D and cognitive performance, (2) serum 
25(OH)D with glucose homeostasis, (3) glucose homeostasis and cognitive performance, 
(4) and the association between serum 25(OH)D and cognitive performance adjusted for 
either plasma glucose or plasma insulin, imply that there is no mediation effect by glucose 
homeostasis in the associations between serum 25(OH)D and domain-specific cognitive 
performance (Figure 1). Exploration of a potential modification effect of plasma glucose and 
plasma insulin (5) showed a significant interaction of plasma insulin with serum 25(OH)D for 
the domain executive function (P=0.001), indicating a stronger association between serum 
25(OH)D with executive function when having high plasma insulin concentrations compared 
to having low plasma insulin concentrations (Figure 1 and Figure 2). In line, a modest 
trend towards a modification effect was also shown for plasma glucose on the association 
of serum 25(OH)D with executive function, suggesting that the association between high
(1) Yes
(4) No
Vitamin D Attention &
working memory
Glucose
homeostasis
(3) Yes(2) No
(5) Vitamin D*Glucose: No, but trend
Vitamin D*Insulin: No
(1) No, but trend
(4) No
Vitamin D Executive functionGlucose
homeostasis
(3) No(2) No
(5) Vitamin D*Glucose: No, but trend
Vitamin D*Insulin: Yes
(1) No
Vitamin D Information 
processing speed
Glucose
homeostasis
A
B
C
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Figure 1. Overview of the associations studied. Associations of (1) serum 25(OH)D with cognitive performance, 
(2) serum 25(OH)D with glucose homeostasis, (3) glucose homeostasis and cognitive function, (4) serum 
25(OH)D and cognitive function that were adjusted for either plasma glucose or plasma insulin, (5) interactions 
between vitamin D*plasma glucose and vitamin D*plasma insulin in association to cognitive performance.
Figure 2. Associations of serum 25(OH)D with the domain executive function, stratified for (A) glucose and 
(B) insulin. Note: Associations are shown by Prevalence Ratio’s (y-axis). Participants were characterized as poor 
cognitive performers when cognitive test scores fell below the 10th percentile.
25(OH)D concentrations and executive function is stronger in participants with high plasma 
glucose concentrations compared to those with low plasma glucose concentrations (P for 
interaction: 0.11). Finally, a modest trend was observed for a modification effect of plasma 
glucose in the association of serum 25(OH)D with attention and working memory (P for 
interaction: 0.12). 
(4) No
(5) Vitamin D*Glucose: Possibly
Vitamin D*Insulin: Yes
(1) No
(4) No
Vitamin D Information 
processing speed
Glucose
homeostasis
(3) No(2) No
(5) Vitamin D*Glucose: No
Vitamin D*Insulin: No
(1) No, but trend
(4) No
Vitamin D Episodic memoryGlucose
homeostasis
(3) No(2) No
(5) Vitamin D*Glucose: No
Vitamin D*Insulin: No
C
D
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6.4 Discussion
In this study, serum 25(OH)D was associated with attention and working memory. Borderline 
significant trends for associations of serum 25(OH)D with executive function and episodic 
memory were observed. There was not convincing evidence for an interplay between vitamin 
D and glucose homeostasis in these associations.
Already several studies investigated the association between 25(OH)D status and global 
cognitive performance [1, 7], but only some focussed on specific cognitive domains [8-15]. In 
line with our results on serum 25(OH)D and attention and working memory, participants of 
the NAME study (n=1069) [8] and the ZENITH study (n=387) [12] also performed better 
on tasks related to working memory with increasing 25(OH)D concentrations. In the ISAAC 
study (n=159) [11], a trend towards an association with the domain working memory was 
observed. We furthermore observed a trend towards an association between serum 25(OH)D 
and executive function. Four other studies also provided evidence for a potential role of serum 
25(OH)D in executive function [8, 10, 13, 15]. Data of the MrOS (n=1559) [14] and the 
ISAAC study [11] did not support an association between vitamin D and executive function. 
The association between serum 25(OH)D and episodic memory has been studied before, 
but none of these studies observed a trend association as shown in our study [8, 9, 11, 12, 
32]. McGrath and colleagues showed in the NHANES III (n=4809) that, in contrast to their 
hypothesis, older adults with higher serum 25(OH)D concentrations had worse memory and 
learning scores after adjustment for age, sex, ethnicity and physical activity [32]. We did not 
observe an association between serum 25(OH)D and information processing speed, which is 
in line with results of the ZENITH study [12]. In contrast, the European Male Ageing study 
[9] and the NAME study [8] have shown significant associations of serum 25(OH)D with 
information processing speed tasks. Trials examining the effect of vitamin D on cognitive 
performance are scarce and most of them were suboptimal, having a small sample size, being 
relatively short term, or lacking a control group [33-36]. 
Mechanistic studies suggest a role for vitamin D in the production of neurotrophins and 
neurotransmitters, inflammation, oxidative stress, and excitotoxicity, which may influence 
neurogenesis, neurotransmission, synaptic plasticity as well as neuronal survival [4]. Based 
on previous neuropsychological findings in observational studies, Annweiler and colleagues 
(2012) proposed that low vitamin D concentrations may be particularly associated with 
executive dysfunction, and as such with dysfunction of frontal-subcortical neuronal circuits 
[37]. In our study a significant association was shown between serum 25(OH)D and 
attention and working memory; trends were observed for executive function and episodic 
memory. Explanations for these findings may lie in the fact that conceptually, the domains 
executive function and working memory overlap, as reflected in strong correlations between 
tasks of working memory and executive function (r=0.97) [38], and that executive function 
and working memory by themselves may determine episodic memory task performance [38]. 
Due to this conceptual overlap between the specific brain functions [38] it is challenging to 
identify what specific brain regions are affected in case of vitamin D deficiency. 
To further explore these underlying mechanisms linking vitamin D to cognitive performance 
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we explored the potential modification and mediation effect of markers related to glucose 
homeostasis in the association between serum 25(OH)D and cognitive performance. It was 
shown that plasma glucose or plasma insulin did not mediate the pathway between serum 
25(OH)D and cognitive performance. Our analyses did reveal a significant interaction of 
serum 25(OH)D with plasma insulin on the domain executive function. To the best of our 
knowledge, this is the first study examining the role of glucose homeostasis in this detail. 
Four other studies adjusted for diabetes or surrogate markers of diabetes in the association 
between serum 25(OH)D and cognitive performance [9, 10, 15, 16]; only the NHANES III 
data suggested that diabetes may be involved [16].
Our participants were mainly community-dwelling Caucasian men and women with a 
slightly elevated homocysteine concentration (≥12 µmol/L). Even though a substantial 
proportion of the Dutch older adults have such an elevated concentration [39], our findings 
may not be generalizable to other populations. Another limitation of this study is the cross-
sectional design. We observed that vitamin D concentrations were higher in persons with 
a better attention and working memory. Consequently, we suggest that the lower vitamin 
D concentrations may result in a poorer attention and working memory. However, it is 
also plausible that participants with a poor attention and working memory were less likely 
to go outside and that low 25(OH)D concentrations are the result of the poor cognitive 
performance observed. Another limitation is that participants were allowed to consume 
a restricted breakfast. Therefore, the plasma glucose and plasma insulin concentrations 
measured cannot be considered completely fasting. Consequently, associations in this study 
with plasma glucose and plasma insulin as the outcome may have been biased towards the null. 
Associations with plasma glucose and plasma insulin as the exposure may be underestimated. 
Strengths of this study are the extensive cognitive test battery used, its large sample size, the 
possibility to adjust for a large number of potential confounders, and the possibility to further 
explore the potential role of glucose homeostasis in the association between 25(OH)D and 
cognitive performance.
In all, we conclude that this study points towards a link between serum 25(OH)D and 
cognitive performance, specifically attention and working memory. This study did not 
provide convincing evidence for an interplay between vitamin D and glucose homeostasis 
in association with cognitive performance. The fact that we mainly observed non-significant 
trends for the associations between serum 25(OH)D and cognitive performance may be 
because our participants were too young and healthy to show a clear clinical manifestation 
of cognitive problems. While in our population brain regions may already function less 
efficiently, it is likely that this decreased efficiency is compensated for via the activation of 
alternative brain networks [40]. In future studies it might therefore be interesting to further 
explore this potential ‘compensatory’ mechanism by including brain activity measurements, 
for instance by using near-infrared spectroscopy, functional Magnetic Resonance Imaging, 
or EEG.
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Supplementary material 
sFigure 1. Flow diagram describing the data used for the statistical analyses.
sFigure 2. Associations of serum 25(OH)D with glucose and insulin concentrations. Note: Associations were 
adjusted for age, sex, BMI, education, alcohol consumption, smoking, physical activity and season of blood 
sampling. Knots were at 30, 58 and 91 nmol/L.
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Abstract 
Background 
The existence of vitamin D receptors in the brain point to a possible role of vitamin D 
in brain function. We examined the association of vitamin D status and vitamin D related 
genetic make-up with depressive symptoms among 2839 Dutch older adults aged ≥65 
years.
Methods 
Serum 25-hydroxyvitamin D (25(OH)D) was measured and seven ‘vitamin D SNPs’ were 
selected. Depressive symptoms were measured with the 15-point Geriatric Depression 
Scale. Results were expressed as the Relative Risk (RR) of the score of depressive 
symptoms by quartiles of 25(OH)D concentration or the number of affected alleles, 
using the lowest quartile or minor allele group as the reference. 
Results 
A clear cross-sectional and prospective association between serum 25(OH)D and the 
depressive symptom score was observed. Fully adjusted models indicated a 22% (RR 
0.78, 95% CI 0.68-0.89), 21% (RR 0.79, 95% CI 0.68-0.90) and 18% (RR 0.82, 95% CI 0.71-
0.95) lower score of depressive symptoms in people in the 2nd, 3rd and 4th 25(OH)D 
quartile, when compared to people in the 1st quartile (P for trend <0.0001). After two-
years of 15 µg/day vitamin D supplementation, similar associations were observed. Serum 
25(OH)D concentrations did not significantly interact with the selected SNPs.
Limitations 
Serum 25(OH)D concentrations at two-years of follow-up were not measured. 
Conclusion 
Low serum 25(OH)D was associated with a higher score of depressive symptoms. No 
interactions between 25(OH)D concentrations and vitamin D related genetic make-up 
were observed. In view of the probability of reverse causation we propose that the 
association should be further examined in prospective studies as well as in randomized 
controlled trials.
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7.1 Introduction
Globally almost 350 million people are affected by depression [1]. Depression is regularly 
accompanied by a reduced quality of life, a variety of co-morbidities, and a higher mortality 
rate [2]. The high prevalence of depression [1], its possible consequences [2], plus the 
unwanted side-effects [3] that often accompany the use of anti-depressive medication 
emphasize the need for preventive measures.
One of the factors that has been suggested to beneficially influence mood and depression is 
sun exposure [4]. Sun exposure, more specifically exposure to ultraviolet-B radiation, may 
amongst others positively reduce depressive symptoms by activating the vitamin D synthesis 
in the skin. Mechanistic studies on brain function support this hypothetical pathway [5, 
6]. Furthermore, as low vitamin D concentrations have been associated with diabetes [7], 
and diabetes with depression [8], vitamin D may also indirectly affect the prevalence of 
depressive symptoms by influencing glucose homeostasis. In addition, it has been postulated 
that vitamin D inadequacy may make the brain more susceptible to neurobiological triggers, 
like diabetes. Thus, both interaction and modification effects by diabetes may be observed 
when examining the association between vitamin D and depression.
One of the groups at risk for a vitamin D inadequacy are older adults, which may be 
explained by their reduced skin capacity to synthesize vitamin D, reduced outdoor activities 
and decreased dietary intake. To our knowledge, seven observational studies investigated 
the potential association between 25(OH)D concentrations and depression in populations 
aged ≥60 years [9-15]. Six studies observed significant associations [11-15], indicating that 
persons with higher 25(OH)D concentrations had a lower probability of having higher scores 
of depressive symptoms when compared to those with lower 25(OH)D concentrations. Even 
though most of these studies plea for vitamin D, it needs to be emphasized that there is 
considerable heterogeneity between studies due to differences in study design, populations, 
sample sizes, the covariates adjusted for and the method to quantify depression. Moreover, 
specific pathways clarifying the association between serum 25(OH)D and depressive 
symptoms in these populations have not been investigated. Thus, more evidence is warranted.
In the current study we investigated the cross-sectional association between serum 25(OH)D 
and the score of depressive symptoms in a large sample of older adults. To further elucidate 
the effect of temporality, we also explored the association between baseline 25(OH)D 
concentrations and the score of depressive symptoms after two years of 15 µg/day vitamin 
D3 supplementation. In addition, interactions between 25(OH)D concentrations and 
seven vitamin D related SNPs were examined, specifically DHCR7, CYP2R1, CYP24A1, 
GC, TaqI/BsmI, ApaI and Cdx2. Finally, to further investigate the potential underlying 
mechanisms, also the potential modification and mediation effects of self-reported diabetes 
were studied. 
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7.2 Methods
7.2.1 Participants
This study was performed using data of the B-PROOF study; a randomized, double-blind, 
placebo-controlled trial designed to assess the efficacy of two-year daily oral supplementation 
of vitamin B12 and folic acid on fractures in mildly hyperhomocysteinemic (plasma 
homocysteine 12-50 µmol/l) older adults ≥65 years; details have been reported previously 
[16]. Given the known beneficial effect of vitamin D on bone health, 15 µg/day vitamin 
D3 was added to both placebo and treatment tablets. The Medical Ethics Committee of 
Wageningen UR approved the study protocol and the Medical Ethics Committees of VUmc 
and Erasmus MC confirmed local feasibility. All participants gave written informed consent. 
At baseline 25(OH)D status and depression score data was available of 2839 participants; 
after two-years of follow-up data for 2544 participants was available. See Figure 1 for a 
detailed overview of the participant flow. 
Figure 1. Flowchart of B-PROOF study data used for the cross-sectional and prospective analyses on 25(OH)D 
concentrations and depression scores. Note: GDS indicates Geriatric Depression Score-15 questionnaire.
7.2.2 Biochemical analyses and genotyping
Blood samples were drawn in the morning when the participants were fasted or had consumed 
a restricted breakfast. Samples were stored at -80˚C until determination. Serum 25(OH)D 
was measured by isotope dilution-online solid phase extraction liquid chromatography-tandem 
mass spectrometry (ID-XLC-MS/MS) [17]. DNA was isolated from buffy coats. Samples 
were genotyped for about 700000 SNPs using the Illumina Omni-express array, covering 
B-PROOF population (n=2919)
25(OH)D baseline (n=744)
GDS baseline (n=774)
GDS follow-up (n=680)
25(OH)D baseline (n=846)
GDS baseline (n=845)
GDS follow-up (n=772)
25(OH)D baseline (n=1267)
GDS baseline (n=1280)
GDS follow-up (n=1149)
Received 400 µg folic acid and 
500 µg vitamin B12 (n=1270)
Received placebo tablet
(n=1274)
25(OH)D & GDS baseline (n=2839)
25(OH)D & GDS follow-up (n=2544)
VU medical centre (n=778) WUR (n=856) Erasmuc MC (n=1285)
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>90% of all common variation in the genome. SNPs selected for this study included SNPs 
affecting vitamin D synthesis (rs12785878 [DHCR7] and rs10741657 [CYP2R1]), SNPs 
affecting vitamin D metabolism (rs6013897 [CYP24A1] and rs2282679 [GC]) and vitamin 
D receptor (VDR) SNPs (rs731236 [TaqI], rs1544410 [BsmI], rs7975232 [ApaI] and 
rs11568820 [Cdx2]).
7.2.3 Mental Health
The 15-item Geriatric Depression Scale (GDS) is a widely used self-report questionnaire, 
which is designed to measure to number of depressive symptoms in a population of older 
adults [18]. Scores can range from 0-15 points, where higher scores are indicative of more 
depressive symptoms. Scores ranging from 5-7 are suggestive of mild depression; scores 
ranging from 8-9 are indicative of moderate depression [18].  
7.2.4 Covariates
Height was measured at baseline with a stadiometer to the nearest 0.1 cm. Weight was 
measured to the nearest 0.5 kg with a calibrated analogue scale. Body Mass Index (BMI) 
was calculated as weight/height2. Data on education level (i.e. primary, secondary or higher 
education), smoking status (i.e. no, current, former), physical activity (kcal/day) [19], 
and alcohol consumption (i.e. light, moderate, excessive) [20] were collected by means of 
questionnaires. Diabetes diagnosis was ascertained by asking participants whether they had 
diabetes (questionnaire). Season was based on the month of blood sampling and dichotomized 
in summer/autumn (June-November) and winter/spring (December-May).
7.2.5 Statistical Analyses 
Participants characteristics are reported as mean with standard deviation (SD), or as 
percentages. Medians with interquartile range were used to report skewed variables. Restricted 
cubic splines were used to estimate the dose-response for serum 25(OH)D with the score of 
depressive symptoms. The association between serum 25(OH)D and the score of depressive 
symptoms was further explored using multiple Poisson regression, resulting in Relative Risks 
(RRs) for 25(OH)D status with the score of depressive symptoms. This RR corresponds 
to the probability of reporting a higher score of depressive symptoms when allocated to 
the second, third or fourth quartile of this population compared to participants allocated 
to the first quartile (i.e. those with the lowest 25(OH)D concentrations). Analyses were 
adjusted for age, sex (model 1), BMI, education, smoking, alcohol intake, physical activity, 
season of blood sampling, center (model 2), and diabetes (model 3). Follow-up analyses were 
additionally adjusted for treatment. 
Poisson regression was also used to test whether self-reported diabetes and vitamin D SNPs 
were associated with the score of depressive symptoms. Associations between self-reported 
diabetes and the score of depressive symptoms were adjusted for age, sex, BMI, education, 
smoking, physical activity, alcohol intake, and center. 
Cox proportional hazards regression was applied to examine the associations between serum 
25(OH)D and self-reported diabetes. By assigning a constant risk period to all participants 
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in the study, the obtained hazard ratio can be considered as a prevalence ratio (PR) [21]. 
This PR corresponds to the probability of having diabetes when allocated to the second, 
third or fourth serum 25(OH)D quartile, compared to participants allocated to the first 
serum 25(OH)D quartile (i.e. lowest serum 25(OH)D concentrations). These analyses were 
adjusted for age, sex (model 1), BMI, education, smoking, physical activity, alcohol intake, 
season of blood sampling, and center (model 2). 
Finally, Poisson regression was conducted to examine potential interactions between serum 
25(OH)D and self-reported diabetes, and serum 25(OH)D and vitamin D related SNPs, 
in the association with the depressive symptom score. All analyses were performed using 
the statistical package SAS, version 9.1 (SAS Institute Inc., Cary, NC, USA), except for the 
restricted cubic spline regression analysis, which was performed in the program R.
7.3 Results
Population characteristics are presented in Table 1. Participants were on average 74.1±6.5 
years old and had a mean serum 25(OH)D concentrations of 56±25 nmol/L. 45% of the 
participants had a 25(OH)D concentration <50 nmol/L, 7% (baseline) / 8% (follow-up) 
reported ≥5 depressive symptoms, and 10% indicated to have diabetes. Over quartiles of 
serum 25(OH)D, significant differences were observed for age, sex, BMI, smoking habits, 
alcohol consumption, physical activity level, season of blood sampling, the score of depressive 
symptoms, self-reported diabetes, DHCR7 and CYP2R1.
Table 1. Characteristics of Dutch older adults participating in the B-PROOF study per quartile of serum 
25(OH)D in nmol/L. 
Q1
<36.7
Q2
36.7-53.4
Q3
53.4-71.7
Q4
>71.7
P-value
N* 711 718 712 716
25(OH)D, nmol/L 26±7 45±5 62±5 89±15 <0.0001
Sex, number of men (%) 306 (43) 365 (51) 383 (54) 374 (52) 0.0002
Age, years 76.1±7.4 73.7±6.3 73.7±6.1 72.7±5.7 <0.0001
Body Mass Index, kg/m2 27.7±4.6 27.3±3.9 27.3±3.7 26.3±3.5 <0.0001
Smoking status, n (%)
  Non-smoker
  Smoker
  Former smoker
266 (37)
83 (12)
362 (51)
240 (33)
72 (10)
406 (57)
232 (33)
66 (9)
414 (58)
231 (32)
56 (8)
429 (60)
0.02
Physical activity, kcal/day 544±385 681±504 679±539 693±451 <0.0001
Educational level, n (%)
  Primary education
  Secondary education
  Higher education
393 (55)
142 (20)
176 (25)
309 (54)
151 (21)
177 (25)
386 (54)
155 (22)
171 (24)
347 (48)
152 (21)
217 (30)
0.07
Alcohol intake,  n (%)
  Light
  Moderate
  Excessive
512 (72)
168 (24)
29 (4)
509 (71)
188 (26)
21 (3)
446 (63)
239 (34)
27 (3)
456 (64)
228 (32)
32 (4)
0.001
GDS score at baseline 
(% GDS score ≥5)
1 (3)
(11)
1 (2) 
(5)
1 (2)
(6)
1 (2)
(6)
<0.0001
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Note: Values are expressed as mean±SD, median (IQR) or n (%). Chi-squared tests for categorical variables, and 
one-way analysis of variance for continuous variables were performed to compare baseline characteristics over 
quartiles of 25(OH)D. *Drop-out after 2-years of follow-up: Q1 (n=94), Q2 (n=75), Q3 (n=74) and Q4 (n=52).
Restricted cubic spline regression showed a modest dose-response association between serum 
25(OH)D and the score of depressive symptoms, leveling off around 60-65 nmol/L (Figure 
2). The test for non-linearity indicated that the association does not follow a linear tendency 
(P for non-linearity: 0.04). Fully adjusted Poisson regression (model 2) subsequently showed 
a 22% (RR 0.78, 95% CI 0.68-0.89), 21% (RR 0.79, 95% CI 0.68-0.90) and 18% (RR 
0.82, 95% CI 0.71-0.95) lower score of depressive symptoms in people in the second, third 
and fourth quartile of serum 25(OH)D, respectively, when compared to people in the first 
quartile (Table 2). Prospective analyses using baseline serum 25(OH)D and depression data 
Q1
<36.7
Q2
36.7-53.4
Q3
53.4-71.7
Q4
>71.7
P-value
GDS score 2-years follow-up 
(% GDS score ≥5)
1 (3)
(11)
1 (2)
(5)
1 (2)
(9)
1 (2)
(7)
<0.0001
Self-reported diabetes, n (%) 79 (14) 55 (10) 54 (10) 43 (8) 0.01
Blood sampling in summer, 
n (%)
224 (32) 324 (45) 429 (60) 524 (73) <0.0001
Vitamin B12 and folic acid 
treatment, n (%)
372 (52) 359 (50) 329 (46) 373 (52) 0.07
TaqI/BsmI (n=2555)
• 0 affected alleles, n (%)
• 1 affected alleles, n (%)
• 2 affected alleles, n (%)
108 (18)
285 (48)
206 (34)
113 (18)
315 (49)
211 (33)
110 (17)
316 (49)
173 (34)
127 (20)
318 (49)
198 (31)
0.75
ApaI (n=2555)
• 0 affected alleles, n (%)
• 1 affected alleles, n (%)
• 2 affected alleles, n (%)
137 (23)
299 (50)
163 (24)
141 (22)
328 (51)
170 (27)
155 (24)
302 (46)
192 (30)
134 (21)
316 (49)
193 (30)
0.55
Cdx2 (n=2555)
• 0 affected alleles, n (%)
• 1 affected alleles, n (%)
• 2 affected alleles, n (%)
21 (4)
180 (30)
398 (66)
23 (4)
201 (31)
415 (65)
25 (4)
193 (30)
431 (66)
25 (4)
200 (31)
418 (65)
0.99
DHCR7 (n=2555)
• 0 affected alleles, n (%)
• 1 affected alleles, n (%)
• 2 affected alleles, n (%)
50 (8)
261 (44)
288 (48)
59 (9)
252 (40)
328 (51)
49 (7)
232 (36)
368 (57)
37 (6)
233 (36)
373 (58)
0.004
CYP2R1 (n=2555)
• 0 affected alleles, n (%)
• 1 affected alleles, n (%)
• 2 affected alleles, n (%)
112 (19)
251 (42)
236 (39)
97 (15)
307 (48)
235 (37)
98 (15)
337 (52)
214 (33)
116 (18)
318 (49)
209 (33)
0.01
CYP24A1 (n=2555)
• 0 affected alleles, n (%)
• 1 affected alleles, n (%)
• 2 affected alleles, n (%)
35 (6)
218 (36)
346 (58)
25 (4)
198 (31)
416 (65)
25 (4)
226 (35)
398 (61)
25 (4)
199 (31)
419 (65)
0.06
GC (n=2555)
• 0 affected alleles, n (%)
• 1 affected alleles, n (%)
• 2 affected alleles, n (%)
75 (13)
234 (39)
290 (48)
62 (10)
278 (43)
299 (47)
55 (8)
252 (39)
342 (53)
20 (3)
215 (33)
408 (64)
<0.0001
V I TA M I N  D  A N D  D E P R E S S I O N : T h e  B - P R O O F  s t u d y
126
7 7
obtained after two years of vitamin 
D supplementation with 15 µg of per 
day showed 26%, 18% and 21% less 
depressive symptoms in people in the 
second, third and fourth quartile of 
serum 25(OH)D, when compared to 
people in the first quartile (model 2). 
Additional adjustment for treatment 
group did not substantially alter the 
results. Associations between vitamin 
D-related genetic make-up and the 
score of depressive symptoms were 
non-significant (supplementary 
Table 1). Moreover, no significant 
interactions between serum 25(OH)D 
and any of the vitamin D-related SNPs 
were observed in association to the 
score of depressive symptoms. 
Table 2. Associations between serum 25(OH)D at baseline with the number of depressive symptom score at 
baseline and after 2-years of vitamin D supplementation with 15 µg/day, Relative Risks (95% CI).
Note: Model 1 is adjusted for age and sex. Model 2 is adjusted for age, sex, BMI, education, smoking, physical 
activity, alcohol intake, season of blood sampling, and center. Model 3 is adjusted for age, sex, BMI, education, 
smoking, physical activity, alcohol intake, season of blood sampling, center, and self-reported diabetes.
As vitamin D inadequacy has been suggested to be a potential modifiable risk factor for 
diabetes [7], and diabetes patients have been shown to be at an increased risk of depression 
[8], also the potential mediation and modification effect of diabetes was examined. First of all, 
the association between serum 25(OH)D and self-reported diabetes was explored, showing 
strong associations over quartiles of serum 25(OH)D. Namely, crude models showed an up 
to 42% lower probability of having diabetes in the upper quartile, PR 0.58 (95% CI 0.41-
Q1 Q2 Q3 Q4 P for trend
25(OH)D Status (nmol/L) <36.7 36.7-53.4 53.4-71.7 71.7>
Baseline, n 704 714 709 712
Crude model (n=2839) 1.0 0.69 (0.60-0.79) 0.69 (0.61-0.79) 0.68 (0.60-0.78) P<0.0001
Model 1 (n=2899) 1.0 0.76 (0.66-0.87) 0.77 (0.67-0.88) 0.78 (0.68-0.90) P<0.0001
Model 2 (n=2880) 1.0 0.78 (0.68-0.89) 0.79 (0.68-0.90) 0.82 (0.71-0.95) P<0.0001
Model 3 (n=2183) 1.0 0.71 (0.61-0.83) 0.73 (0.62-0.86) 0.83 (0.70-0.98) P=0.0001
2-year follow-up, n 610 639 635 660
Crude model (n=2544) 1.0 0.66 (0.58-0.76) 0.74 (0.64-0.85) 0.68 (0.59-0.78) P<0.0001
Model 1 (n=2544) 1.0 0.72 (0.64-0.84) 0.82 (0.71-0.95) 0.78 (0.67-0.90) P<0.0001
Model 2 (n=2531) 1.0 0.74 (0.64-0.84) 0.82 (0.71-0.95) 0.79 (0.68-0.92) P<0.0001
Model 3 (n=1996) 1.0 0.69 (0.59-0.79) 0.78 (0.66-0.93) 0.76 (0.64-0.89) P<0.0001
Figure 2. Cross-sectional association between serum 
25(OH)D and the number of depressive symptoms.
127
7 7
0.82). In the full-adjusted model the associations attenuated, which was mainly attributable 
to the inclusion of BMI, the PR was 0.77 (0.52-1.14) in the upper quartile (Table 3). Full-
adjusted model that did not include BMI, which was investigated because BMI might be 
an intermediate in the association between serum 25(OH)D and diabetes, indicated a 43% 
lower probability of having diabetes in the upper 25(OH)D quartile. Second, we studied the 
possible association between self-reported diabetes and the score of depressive symptoms, 
showing that participants with diabetes (n=231) reported a 17% higher score of depressive 
symptoms than participants without diabetes (n=2024) after full adjustment, RR 1.17 (95% 
CI 1.00-1.38) (Table 4). Mediation was further examined by extending the model of serum 
25(OH)D and the score of depressive symptoms with self-reported diabetes, showing that 
the observed associations were even slightly strengthened. Finally, including the interaction 
term serum 25(OH)D*diabetes did not point towards a modification effect in the association 
with the score of depressive symptoms (P for interaction=0.82). 
Table 3. Associations between serum 25(OH)D and self-reported diabetes, PRs (95% CI). 
25(OH)D Status 
(nmol/L)
n Q1
4.1-36.7
Q2
36.7-53.4
Q3
53.4-71.7
Q4
71.7-193.6
P for 
trend
Diabetes, n (cases) 569 (79) 560 (55) 543 (54) 536 (43)
Crude model 2208 1.0 0.71 (0.51-0.98) 0.72 (0.52-0.99) 0.58 (0.41-0.82) 0.003
Model 1 2208 1.0 0.68 (0.49-0.95) 0.69 (0.50-0.96) 0.56 (0.39-0.80) 0.002
Model 2 2191 1.0 0.80 (0.57-1.11) 0.81 (0.57-1.16) 0.77 (0.52-1.14) 0.20
Note: Model 1 is adjusted for age and sex. Model 2 is adjusted for age, sex, BMI, education, smoking, physical 
activity, alcohol intake, season of blood sampling, and centre. 
Table 4. Associations of self-reported diabetes with the number of depressive symptom score at baseline, 
analysed with Poisson regression resulting in Relative Risks (95% CI).
Note: Model 1 is adjusted for age and sex. Model 2 is adjusted for age, sex, BMI, education, smoking, physical 
activity, alcohol intake, season of blood sampling, and centre.
7.4 Discussion
This study showed a clear cross-sectional association between serum 25(OH)D and the score 
of depressive symptoms as reported by the Geriatric Depression Scale-15. This association 
remained after two years of vitamin D supplementation. No significant associations between 
vitamin D-related genetic make-up and the score of depressive symptoms were observed, 
nor did we observe significant interactions between vitamin D SNPs and 25(OH)D 
concentrations. There was also no evidence for a potential mediation or modification effect 
by the presence of self-reported diabetes. 
Self-report diabetes 
No (n=2024) Yes (n=231)
Crude model 1.0 1.22 (1.04-1.43)
Model 1 1.0 1.25 (1.07-1.46)
Model 2 1.0 1.17 (1.00-1.38)
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7.4.1 A broader perspective
Several other observational studies also examined the association between serum 25(OH)D 
and depression in populations ≥60 years [9-15]. A study in 1282 Dutch men and women 
aged 65-95 years from the Longitudinal Aging Study Amsterdam observed that persons 
in the highest 25(OH)D quartile had a lower probability of depression as measured with 
the Center for Epidemiological Studies Depression Scale (CES-D) (β −1.33 P=0.03) when 
compared to the lowest quartile [12]. The Os Study, including 883 Chinese men ≥65 years, 
also showed a beneficial association between 25(OH)D status and depression with an OR 
for depression of 0.46 (95% CI: 0.22-0.98, P for trend=0.004) in the highest quartile after 
adjustment for age, BMI, education, physical activity, number of activities of daily living, diet 
quality index, smoking, alcohol consumption, season, number of chronic diseases, cognitive 
performance, and serum (ln)PTH concentration [11]. Another large study that observed a 
beneficial association between 25(OH)D status and depression was the Health Survey for 
England, which used data of 2070 men and women aged ≥65 years [15]. To the best of our 
knowledge, none of the aforementioned studies accounted for gene profiles. We did, but 
we did not observe any association between vitamin D SNPs and the score of depressive 
symptoms, or interactions between 25(OH)D concentrations and vitamin D SNPs. Kuningas 
and colleagues (2009) also explored associations between several vitamin D-related SNPs and 
observed an association between ApaI and depressive symptoms in 563 Dutch Caucasian older 
adults [22]. However, as we did not observe any association between the vitamin D SNPs, we 
do consider the possibility that it is not a higher 25(OH)D concentration that is responsible 
for a lower score of depressive symptoms, but that the observed association is for instance 
explained by reverse causation or another factor that we could not control for in our analyses. 
Randomized Controlled Trials (RCTs) can provide more conclusive evidence on the direction 
of the association. However, to date, RCT results are inconclusive. It has been argued that 
shortcomings may be the reason for the indecisive evidence, as several studies did not measure 
25(OH)D concentrations, included participants with high 25(OH)D concentrations or used 
a relatively low dose of vitamin D [23]. 
7.4.2 Underlying mechanisms
A low vitamin D concentration may predispose to depression through several biological 
pathways. Vitamin D has amongst others been linked to an increase in serotonin production 
[24] and a decrease in glucocorticoid-induced hippocampal cell death [25]. Vitamin D has 
also been hypothesized to play a role in the synthesis of neurotrophins, the production of 
acetylcholine and glutathione, and the down-regulation of L-type voltage-sensitive calcium 
channel expression [6]. Vitamin D may also indirectly fight depressive symptoms via its 
proposed anti-inflammatory effect [26]. To further explore the underlying mechanisms, we 
investigated the possible role of diabetes. Due to a variety of disease-related stress factors, 
diabetes patients are considered to be at increased risk for developing depression [8]. With 
that, low serum 25(OH)D concentrations may also predispose to glucose intolerance [7]. 
Thus, mediation as well as modification effects could be expected to be present. Nevertheless, 
fully adjusted models did not support an association between serum 25(OH)D and self-
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reported diabetes. In addition, adding self-reported diabetes to the model on serum 25(OH)D 
and depression did not attenuate the association observed. Interaction analyses furthermore 
indicated that there was no difference in the score of depressive symptoms when having 
diabetes or not. All in all, we therefore conclude that our data do not support a mediation or 
modification effect of diabetes in the vitamin D-depression pathway. 
7.4.3 Limitations
A well-known limitation of observational studies is that it is not possible to say something 
about causality, specifically, is the so-called exposure an actual risk factor, or is it merely 
a consequence of the disease? Fortunately, we had the possibility to further explore this 
association in a prospective fashion, showing that two years of vitamin D supplementation 
with 15 µg/day did not change the association as observed at baseline. Interpreting these 
findings, however, is quite challenging, especially because 25(OH)D concentrations were not 
measured after two years of follow-up. It may be suggested that vitamin D supplementation 
did not beneficially affect depressive symptoms, and that the association is explained by 
an unknown other factor that is strongly correlated with 25(OH)D status. On the other 
hand, it may also be that participants in the lowest quartile did reach higher 25(OH)D 
concentrations, but that these concentrations were still not high enough to decrease the 
probability of having a higher score of depressive symptoms relative to the other groups. 
Another limitation of this study is that data were obtained from the B-PROOF study, 
an intervention trial examining the impact of vitamin B12 and folic acid on a variety of 
outcomes, which may have interfered with our prospective analyses. However, adjusting the 
associations between 25(OH)D concentrations and depressive symptoms after two-years of 
supplementation for treatment group did not substantially alter the associations. This study 
is also limited by the fact diabetes diagnosis is based on self-report. Strengths of this study 
were the large study population, the possibility to study the association after two years of 
vitamin D supplementation, the opportunity to adjust for important confounders, as well as 
the possibility to investigate the role of diabetes and SNPs that have been linked to vitamin 
D synthesis, metabolism and vitamin D receptor expression. 
7.4.4 Conclusion
Our data support previously reported cross-sectional associations between higher 25(OH)D 
concentrations and a decreased probability of reporting depressive symptoms. Our subsequent 
finding that two years of vitamin D supplementation does not translate into a shift towards 
less depressive symptoms, however, raises concern about the causality of the association. No 
mediation or modification effect by diabetes was observed. To define the direction of the link 
between serum 25(OH)D and depression, there is a continuous need for prospective studies 
as well as well-designed RCTs.  
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Supplementary material
sTable. Associations between vitamin D related genetic make-up at baseline with the number of depressive 
symptom score at baseline and after 2-years of vitamin D supplementation with 15 µg/day, shown as Relative 
Risks (95% CI).
Continuous Minor allele 
carriers
Heterozygotes Major allele 
carriers
Baseline 
(n=2555)
DHCR7 0.00±0.04 (P=0.99) 1.0 0.96 (0.78-1.17) 0.98 (0.80-1.19)
CYP2R1 -0.02±0.04 (P=0.52) 1.0 1.01 (0.87-1.18) 0.96 (0.82-1.13)
CYP24A1 0.03±0.05 (P=0.58) 1.0 0.93 (0.71-1.22) 0.98 (0.75-1.28)
GC -0.07±0.04 (P=0.11) 1.0 0.93 (0.77-1.14) 0.87 (0.72-1.06)
TaqI / BsmI 0.01±0.04 (P=0.75) 1.0 1.03 (0.88-1.21) 1.03 (0.87-1.22)
ApaI -0.01±0.04 (P=0.79) 1.0 1.03 (0.91-1.17) 0.98 (0.85-1.14)
Cdx2 0.01±0.05 (P=0.79) 1.0 1.01 (0.79-1.32) 1.02 (0.79-1.32)
2-year follow-up 
(n=2307)
DHCR7 0.04±0.05 (P=0.35) 1.0 1.02 (0.81-1.28) 1.07 (0.86-1.35)
CYP2R1 -0.02±0.04 (P=0.68) 1.0 1.03 (0.88-1.20) 0.98 (0.83-1.15)
CYP24A1 -0.04±0.05 (P=0.46) 1.0 0.96 (0.71-1.29) 0.92 (0.69-1.24)
GC -0.04±0.04 (P=0.36) 1.0 0.83 (0.69-1.01) 0.85 (0.71-1.03)
TaqI / BsmI 0.03±0.04 (P=0.51) 1.0 1.02 (0.87-1.20) 1.06 (0.89-1.25)
ApaI -0.04±0.04 (P=0.27) 1.0 0.97 (0.85-1.12) 0.92 (0.78-1.08)
Cdx2 -0.02±0.05 (P=0.75) 1.0 0.87 (0.65-1.15) 0.88 (0.67-1.17)
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Abstract
Aim 
The aim of this study was to investigate the cross-sectional association between vitamin 
D status and brain volume, and to examine whether surrogate markers of glucose 
homeostasis modify this association.
Methods 
Vitamin D status (25(OH)D), glucose and insulin were measured. Measures of total 
brain volume, grey matter volume, and white matter volume were obtained by MRI in 
218 community-dwelling older adults aged ≥65 years. Associations of 25(OH)D status, 
glucose, and insulin concentrations with brain volume were evaluated using linear 
regression analyses.
Results 
After full adjustment, higher 25(OH)D concentrations and lower glucose concentrations 
were associated with more grey matter volume, β 0.20±0.08 (P=0.02) and β -3.26±1.59 
(P=0.04), respectively. No association of 25(OH)D status or insulin concentration with 
total brain volume or white matter volume was observed. There was no evidence for a 
mediation or modification effect of plasma glucose in the association between 25(OH)D 
status and brain volume. 
Conclusion 
Higher 25(OH)D status and lower glucose concentrations are associated with more grey 
matter volume, but not with white matter volume or total brain volume.
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8.1 Introduction
Despite great efforts an effective anti-Alzheimer drug has not yet been developed [1]. Therefore, 
identification of factors that may prevent or slow-down the development of Alzheimer's 
Disease (AD) is important. Vitamin D is proposed as being one of those potential preventive 
factors [2]. Support for this hypothesis originated from pre-clinical studies showing that 
vitamin D beneficially influences several cerebrovascular risk factors, synaptic plasticity, 
synthesis of neurotransmitters and neurotrophins, and slows down synaptic and neuronal 
loss [2]. 
Vitamin D may also be indirectly associated with brain functioning, with glucose homeostasis 
acting as a mediator. Specifically, on a mechanistic level, vitamin D has been shown to promote 
pancreatic β-cell function as well as insulin action [3]. Several observational studies support 
these potential effects by showing beneficial associations between 25(OH)D concentrations 
and fasting glucose, insulin, glucose clearance as well as type 2 diabetes [3, 4]. There is also 
considerable evidence that maintenance of glucose concentrations within a healthy range is 
beneficial to preserve cognitive function [5, 6]. Furthermore, it has been hypothesized that 
vitamin D inadequacy may be particularly harmful in the presence of a second neurobiological 
trigger [7-9]. As glucose intolerance may be such a neurobiological trigger, we therefore also 
hypothesized that markers of glucose homeostasis may act as modifiers in the association 
between vitamin D and brain volume. 
Several human studies provided evidence for a potential role of vitamin D in the maintenance 
of cognitive function. Meta-analyses indicate that participants with concentrations ≥50 
nmol/L have better global cognitive performance [10], episodic memory, information 
processing speed, mental shifting abilities and information updating ability than those with 
25(OH)D concentrations <50 nmol/L [11]. Intervention studies on vitamin D and cognitive 
function in older adults are sparse, and those that have been conducted had a small sample 
size, were of short duration, not blinded and sometimes even without placebo group [12-18]. 
The only randomized controlled trial (RCT) examining the effect of vitamin D, independent 
of calcium, was conducted in young adults and did not point towards a beneficial role in 
cognitive performance [17]. 
Cognitive performance has been associated with the rate of brain atrophy as measured with 
MRI [19, 20]. Via studying grey and white matter loss, MRI may also be a valuable tool to 
get more insight in the association between 25(OH)D concentration and brain function. 
The use of MRI is a relatively new area in vitamin D research and up to now only a few 
studies explored the associations between vitamin D and measures of brain volume [21]. As 
there is a large heterogeneity in study populations and outcome measures in these particular 
studies, and because results are inconclusive [21], more evidence is needed. We therefore 
investigated associations of serum 25(OH)D with total brain volume, grey matter volume, 
and white matter volume in Dutch older adults. The second aim of this study was to explore 
the potential synergism of 25(OH)D concentrations with surrogate markers of glucose 
homeostasis in the association with brain volume. 
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8.2 Methods
8.2.1 Participants
This observational study was performed using data of the B-PROOF study; a randomized 
double blind placebo-controlled trial that was designed to assess the efficacy of 
daily oral supplementation of vitamin B12 and folic acid on bone fractures in mildly 
hyperhomocysteinemic (12-50 µmol/L) older adults aged ≥65 years. Details have been 
reported elsewhere [22]. The Medical Ethics Committee of Wageningen UR approved the 
study protocol and all participants gave their written informed consent. For the current data-
analyses only data of participants with MRI data have been used (n=218) (Figure 1).
 
8.2.2 Biochemical analyses
Blood samples were drawn in the morning when participants were fasted or had 
consumed a restricted breakfast. Samples were stored at -80˚C until determination. Serum 
25(OH)D in baseline samples was measured by isotope dilution-online solid phase extraction 
liquid chromatography-tandem mass spectrometry (ID-XLC-MS/MS) [23]. Glucose 
concentrations were analysed using a hexokinase method (Gluco-quant, Roche Diagnostics). 
Insulin concentrations were determined using an immunometric assay (ADVIA Centaur 
immunoassay system, Siemens Medical Solutions Diagnostics).
B-PROOF population (n=2919)
Invited for MRI (n=413)
Received 400 µg folic acid 
and 500 µg vitamin B12 
supplementation (n=106)
Received placebo tablet 
(n=112)*
VU medical centre (n=778) WUR (n=856) Erasmuc MC (n=1285)
MRI scan made (n=218)
Erasmuc MC (n=1285)
Figure 1. Flowchart of participants that were enrolled in the MRI measurements of the B-PROOF study. 
Note: *One participant was excluded from the analyses because of unknown 25(OH)D status.
8.2.3 MRI
Cranial volumetric MRI scans were made two years after the baseline measurements, at 
Hospital Gelderse Vallei (Ede, the Netherlands) on a 3-Tesla Siemens Magnetom Verio 
139
8 8
(Siemens, Erlangen, Germany), with a 32-channel head coil. We analysed the T1-weighted 
scan (MPRAGE, repetition time=2300ms, echo time=3.0ms, inversion time=900ms, 9º 
flip angle, field of view=256x256mm, 192 sagittal slices, voxel size= 1mmx1mmx1.3mm 
OF 1x1x1mm), acceleration factor (GRAPPA)=2. The voxel-based morphometric (VBM8) 
toolbox within SPM8 (Wellcome Department of Imaging Neuroscience, London, UK, http://
www.fil.ion.ucl.ac.uk/spm/software/spm8/) and FSL-VBM v6.0 (FMRIB Software Library, 
Oxford, UK, http://fsl.fmrib.ox.ac.uk/fsl/fslwiki/FSLVBM) were used for segmentation 
[24]. T1-weighted images were reoriented to match the standard template images in FSL-
VBM. VBM8 spatially normalizes participants’ brain images to a standard space and then 
to automated segments of grey matter, white matter, and cerebrospinal fluid, using a unified 
tissue segmentation approach [25]. Grey and white matter volumes were summed to calculate 
total brain volume. Grey matter, white matter and cerebrospinal fluid measures were summed 
to compute intracranial volume. 
8.2.4 Covariates
Height was measured at baseline with a stadiometer to the nearest 0.1 cm. Weight was 
measured to the nearest 0.5 kg with a calibrated analogue scale. Body Mass Index (BMI) 
was calculated as weight/height2. Data on education level (i.e. primary, secondary or higher 
education), smoking status (i.e. non-smoker or current smoker), physical activity (kcal/day) 
[26], and alcohol consumption (i.e. light, moderate, excessive) [27] were collected by means 
of questionnaires. The 15-item Geriatric Depression Scale (GDS) was used as a screening tool 
for the number of depressive symptoms [28]. The Mini-Mental State Examination (MMSE) 
was used to assess global cognitive status [29]. Season of blood collection was divided into 
summer/autumn (June–November) and winter/spring (December–May).
8.2.5 Statistical Analyses
Participant characteristics are reported as mean with standard deviation (SD), or percentages. 
Medians with interquartile range (IQR) were used to report skewed variables. Characteristics 
are shown for the total population, stratified according to the cut-of values for vitamin D 
deficiency that are currently used by the Institute of Medicine (IOM) [30], and stratified for 
low and high plasma glucose concentrations. Multiple regression analyses were performed 
to explore the associations between serum 25(OH)D and brain volume. All analyses were 
adjusted for intracranial volume (crude model), crude model + age, sex (model 1); model 1 
+ BMI, education, smoking, alcohol consumption, habitual physical activity (model 2); and 
model 2 + the number of depressive symptoms (model 3). 
Multiple regression analysis was also conducted to examine associations between plasma 
glucose, plasma insulin and brain volume. Again, all analyses were adjusted for intracranial 
volume (crude model), crude model + age, sex (model 1); model 1 + BMI, education, 
smoking, alcohol consumption, habitual physical activity (model 2); model 2 + the number 
of depressive symptoms (model 3).
Effect modification by plasma glucose was examined by stratifying the data for low and 
high glucose concentrations (median split), and by testing for interaction. Mediation was 
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examined by adding plasma glucose, independently, to fully adjusted regression models for 
25(OH)D concentrations and brain volumes. Alpha was set at 0.05 and two-tailed analyses 
were performed. Analyses were performed using the statistical package SAS, version 9.1 (SAS 
Institute Inc., Cary, NC, USA). 
8.3 Results
Participant characteristics are presented in Table 1. Participants were on average 72±6 years 
old, had a 25(OH)D concentration of 61±23 nmol/L, BMI of 27.6±4.2 kg/m2, and used 
669±422 kilocalories for habitual physical activities. Fifty-seven percent of this population 
was men, 35% had a degree in higher education, 76% was included in the study during the 
summer/autumn. The median score on the MMSE was 29, suggesting that this population is 
cognitively healthy. No remarkable differences in population characteristics were observed for 
participants with 25(OH)D concentrations <50 nmol/L and those with concentrations ≥50 
nmol/L. Participants with glucose concentrations ≥5.6 mmol/L, however, were more likely to 
be men, smoker, to have a higher BMI, lower educational level, and to be included during the 
winter/spring months, than participants with glucose concentrations <5.6 mmol/L.
8.3.1 Serum vitamin D and brain volumetric measures
Linear regression analyses showed that 25(OH)D status was significantly associated with 
grey matter volume (β 0.25, SE 0.09, P=0.005) and total brain volume (β 0.26, SE 0.11, 
P=0.02) after adjustment for intracranial volume, but not with white matter volume (Table 
2). The association between 25(OH)D status and grey matter remained after adjustment for 
intracranial volume, age, sex, BMI, education, alcohol, smoking, physical activity, season 
and depressive symptoms (β 0.20, SE 0.08, P=0.02), indicating that one unit increase in 
25(OH)D concentration is associated with 0.20 mL (0.01%) more grey matter volume. The 
association between 25(OH)D status and total brain volume was not significant anymore 
after full adjustment.
Table 1. Participant characteristics of 217 Dutch older adults. 
Total 
population
Serum 
25(OH)D 
<50 nmol/L
(n=71)
Serum 
25(OH)D 
≥50 nmol/L
(n=146)
Plasma 
glucose 
<5.63 mmol/L
(n=110)
Plasma 
glucose 
≥5.63 mmol/L
(n=107)
Serum 25(OH)D, nmol/L 61±23 36±10 73±18* 63±26 59±20
Age, years 72±6 72±6 71±6 71±6 72±5
Sex, n (%)
  Men
  Women
124 (57)
94 (43)
39 (54)
33 (46)
85 (59)
59 (41)
55 (50)
56 (50)
69 (64)*
38 (36)
Body Mass Index, kg/m2 27.6±4.2 27.4±4.4 27.7±4.0 26.7±3.7 28.5±4.4*
Educational level, n (%)
  Primary
  Secondary
  Higher
90 (41)
52 (24)
76 (35)
28 (39)
21 (29)
23 (32)
60 (42)
31 (21)
53 (37)
45 (41)
20 (18)
46 (41)
45 (42)*
32 (30)
30 (28)
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Note: Comparing participants with vitamin D concentrations ≤50 nmol/L with participants with vitamin D 
concentrations ≥50 nmol/L using the Chi-square test in case of categorical variables or the Student’s t-test in 
case continuous variables. Variables are displayed as means ± standard deviations or medians (quartile range). 
*Serum 25(OH)D ≥50 nmol/L group is significantly different from serum 25(OH)D <50 nmol/L group (P<0.05), 
or Glucose level <5.63 mmol/L group is significantly different from Glucose level ≥5.63 mmol/L (P<0.05). ICV: 
Intracranial volume.
 
Table 2. Linear regression analyses for serum 25(OH)D with absolute brain volume (mL), β (SE).
Note: Model 1: adjusted for intracranial volume, age and sex. Model 2: adjusted for intracranial volume, age, 
sex, BMI, education, alcohol intake, smoking, physical activity, and season. Model 3: adjusted for intracranial 
volume, age, sex, BMI, education, alcohol intake, smoking, physical activity, season and the number of depressive 
symptoms.
Total 
population
Serum 
25(OH)D 
<50 nmol/L
(n=71)
Serum 
25(OH)D 
≥50 nmol/L
(n=146)
Plasma 
glucose 
<5.63 mmol/L
(n=110)
Plasma 
glucose 
≥5.63 mmol/L
(n=107)
Alcohol intake, n (%)
  Light
  Moderate
  Excessive
147 (67)
61 (28)
10 (5)
54 (75)
16 (22)
2 (3)
93 (64)
45 (31)
8 (5)
81 (73)
25 (23)
5 (4)
66 (62)
36 (33)
5 (5)
Smoking history, n (%)
  Non-smoker
  Smoker
  Former smoker
64 (29)
15 (7)
139 (64)
19 (26)
6 (8)
47 (65)
45 (31)
9 (6)
92 (63)
41 (37)
3 (3)
67 (60)
23 (22)*
12 (11)
72 (67)
Physical activity level, kcal/day 669±422 610±418 698±422 671±428 667±417
Glucose level, mmol/L 5.9±1.3 5.8±1.2 5.9±1.3 5.1±0.5 6.7±1.3*
Number of depressive 
symptoms
1 (1) 1 (1) 1 (1) 0 (1) 1 (2)
Season, n (%)
  December-May
  June-November
52 (24)
166 (76)
24 (33)
48 (67)
28 (19)*
118 (81)
17 (15)
94 (85)
35 (33)*
72 (67)
MMSE score 29 (2) 29 (2) 29 (2) 29 (2) 29 (2)
Grey matter volume, mL 
(% of ICV)
574±56 
(42.2)
567±57 
(41.5)
578±55 
(42.2)
572±58
(42.3)
576±58
(41.6)
White matter volume, mL 
(% of ICV)
493±61 
(35.9)
492±62
(36.0)
493±61
(35.9)
489±59
(36.0)
497±64
(35.8)
Total brain volume, mL 
(% of ICV)
1067±108 
(78.1)
1060±109
(77.5)
1071±108 
(78.1)
1062±104
(78.3)
1073±112
(77.4)
Receiving vitamin B12 and folic 
acid supplement prior to MRI 
measurement, n (%)
106 (49) 38 (53) 68 (47) 54 (49) 52 (49)
Total brain volume Grey matter volume White matter volume
Crude model 0.26 (0.11), P=0.02 0.25 (0.09), P=0.005 0.01 (0.08), P=0.93
Model 1 0.12 (0.08), P=0.13 0.18 (0.08), P=0.02 -0.06 (0.08), P=0.43
Model 2 0.13 (0.08), P=0.11 0.19 (0.08), P=0.02 -0.06 (0.08), P=0.47
Model 3 0.14 (0.08), P=0.09 0.20 (0.08), P=0.02 -0.06 (0.08), P=0.46
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8.3.2 Glucose homeostasis and brain volumetric measures
Higher glucose concentrations were associated with less grey matter volume (Table 3), but 
not with total brain volume or white matter volume. In the fully adjusted model, one unit 
increase in glucose was associated with -3.26 mL (P=0.04) less grey matter volume. After 
further adjustment for serum 25(OH)D, this association became even stronger, β -5.53 mL, 
SE 1.57, P=0.03. No association between glucose and total brain volume, or white matter 
volume was observed.
Table 3. Linear regression analyses for plasma glucose and insulin with absolute brain volume (mL), β (SE).
Note: Model 1: adjusted for intracranial volume, age and sex. Model 2: adjusted for intracranial volume, age, sex, 
BMI, education, alcohol, smoking, and physical activity. Model 3: adjusted for intracranial volume, age, sex, BMI, 
education, alcohol intake, smoking, physical activity, and the number of depressive symptoms.
Table 4. Linear regression analyses for serum 25(OH)D in nmol/L with absolute brain volumetric measures 
(mL), stratified for low and high glucose concentrations in mmol/L,  β (SE). 
Note: Adjusted model: adjusted for intracranial volume, age, sex, BMI, education, alcohol intake, smoking, physical 
activity and season. Interaction is tested for the adjusted model.
8.3.3 Interplay between serum vitamin D and glucose homeostasis
Incorporating glucose in the full-adjusted models for 25(OH)D status and grey matter did 
not support the hypothesis of mediation, β 0.20 mL, SE 0.08, P=0.02. Nor did stratification 
for low and high glucose concentrations (Table 4) or interaction analyses point towards an 
interplay between serum 25(OH)D with plasma glucose in the association with grey matter 
volume, white matter volume, or total brain volume, P- for interaction 0.86, 0.32 and 0.45, 
respectively. 
Total brain volume Grey matter volume White matter volume
Plasma 
glucose
Plasma 
insulin
Plasma 
glucose
Plasma 
insulin
Plasma 
glucose
Plasma 
insulin
Crude model -3.80 (2.0), 
P=0.06
0.01 (0.02), 
P=0.37
-4.60 (1.7), 
P=0.006
0.02 (0.01), 
P=0.13
0.80 (1.5), 
P=0.59
-0.01 (0.01), 
P=0.62
Model 1 -2.70 (1.54), 
P=0.08
-0.00 (0.01), 
P=0.76
-3.96 (1.50), 
P=0.009
0.01 (0.01), 
P=0.21
1.26 (1.42), 
P=0.38
-0.01 (0.01), 
P=0.32
Model 2 -2.54 (1.62), 
P=0.12
-0.00 (0.01), 
P=0.83
-3.45 (1.60), 
P=0.03
0.02 (0.01), 
P=0.20
0.91 (1.51), 
P=0.55
-0.01 (0.01), 
P=0.26
Model 3 -2.38 (1.63), 
P=0.15
-0.00 (0.01), 
P=0.85
-3.26 (1.59), 
P=0.04
0.02 (0.01), 
P=0.19
0.88 (1.52), 
P=0.56
-0.01 (0.01), 
P=0.23
Total brain volume Grey matter volume White matter volume
Glucose
<5.63
(n=110)
Glucose
≥5.63
(n=107)
Glucose
<5.63
(n=110)
Glucose
≥5.63
(n=107)
Glucose
<5.63
(n=110)
Glucose
≥5.63
(n=107)
Crude model 0.38 (0.12), 
P=0.002
-0.01 (0.19), 
P=0.96
0.27 (0.10), 
P=0.01
0.19 (0.16), 
P=0.22
0.11 (0.10), 
P=0.24
-0.21 (0.14), 
P=0.15
Adjusted model 0.20 (0.10), 
P=0.04
0.17 (0.16), 
P=0.31
0.23 (0.10), 
P=0.02
0.29 (0.16), 
P=0.07
-0.03 (0.10), 
P=0.76
-0.12 (0.15), 
P=0.39
P for interaction P=0.45 P=0.86 P=0.32
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8.4 Discussion
This study shows that higher 25(OH)D concentrations and lower plasma glucose 
concentrations are associated with more grey matter volume in a population of cognitively 
healthy Dutch older adults. Markers of glucose homeostasis did not mediate or modify the 
association between 25(OH)D and brain volume. 
8.4.1 Serum vitamin D and brain volumetric measures
Previous studies have shown that in the normal aging brain, grey matter loss predominates 
over white matter loss [31]. In this study, one unit increase in serum 25(OH)D was associated 
with 0.20 mL (0.01%) more grey matter volume, but not with white matter volume, or total 
brain volume. Our results are in line with previous pre-clinical research that indicates that 
the active form of vitamin D, calcitriol, may support neuronal survival, neurogenesis and 
synaptogenesis [2], and with previous observational studies that show associations between 
higher 25(OH)D concentrations and better cognitive performance [8, 10, 32-39]. The 
earliest studies on brain volume were conducted in rats and showed that a prenatal vitamin 
D deficiency resulted in larger total brain volumes, larger lateral ventricles [40, 41], reduced 
cortical thickness and increased cell proliferation [40]. As recently reviewed, studies evaluating 
the association between serum 25(OH)D and brain volumetric measures in humans are 
sparse [21], but suggest that lower vitamin D concentrations are associated with larger 
ventricle volumes [42], more vascular pathologies [43] and a higher rate of cortical thinning 
[44]. In addition, higher plasma 25(OH)D concentrations have been associated with larger 
volumetric measures of white matter, amygdala, thalamus and anterior cingulate gyrus in 28 
patients referred to a memory clinic [45]. Conversely, several other studies did not observe 
associations between 25(OH)D concentrations and total brain volume [43, 46], grey matter 
volume [46], or volume measures of the hippocampus [43], amygdala [43], parahippocampal 
gyrus [43], and temporal horn [42]. Overall, the number of studies examining associations 
between 25(OH)D status and brain volume are sparse and generally had relatively small 
sample sizes, differed largely in type of population studied, and the particular brain volumes 
examined. Hence, as yet, no firm conclusions can be drawn based on these data.
8.4.2 Glucose homeostasis and brain volumetric measures
Previous research has shown that an impaired glucose tolerance may lead to advanced protein 
glycation, oxidative stress, increased secretion of amyloid, decreased breakdown of amyloid, 
microvascular brain complications, brain infarcts an brain atrophy [6, 47]. In line, there 
is substantial evidence that glucose intolerance is associated with cognitive decline. Our 
findings add that higher glucose concentrations associate with less grey matter, which has also 
been observed by others [48-50], and hence confirm that increased glucose concentrations 
may play a role in the pathogenesis of cognitive decline and dementia.
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8.4.3 Interplay between serum vitamin D and glucose homeostasis
In this population, higher 25(OH)D concentrations and lower glucose concentrations 
were associated with more grey matter volume, but glucose concentrations did not seem 
to modify or mediate the association between 25(OH)D status and grey matter volume. 
The hypothesis that glucose homeostasis could (partially) explain or modify the association 
between serum 25(OH)D and brain volume has not yet been extensively studied. To the best 
of our knowledge, four studies examined whether the association between 25(OH)D status 
and cognitive function was influenced when a marker of glucose homeostasis was added 
[8, 33, 34, 51], which showed either no change [8, 33, 34] or a partial attenuation of the 
association between serum 25(OH)D concentrations and cognitive performance [51]. 
8.4.4 Methodological aspects
Several methodological issues of the present study warrant further discussion. Firstly, 
our results are limited due to the observational study design. Secondly, participants were 
selected to have a mildly elevated homocysteine concentration. As approximately 50% of the 
Dutch older adult population has a mildly elevated homocysteine concentration [52], this 
selection criterion limits the generalizability of these results to the whole Dutch population 
of older adults. Thirdly, glucose and insulin concentrations presented in this study cannot 
be considered fasting as participants were allowed to consume a light breakfast prior to 
blood sampling. Therefore, participants may have been misclassified as having ‘high’ glucose 
concentrations, due to the consumption of a light breakfast, even though they did not have an 
impaired glucose tolerance. Finally, MMSE data indicate that this study included cognitively 
healthy older adults, which may have reduced our ability to detect associations between serum 
25(OH)D or plasma insulin and white matter volume and total brain volume. Strengths of 
this study include the possibility to control for several potential covariates and the possibility 
to explore the role of glucose homeostasis.
8.4.5 Conclusion
This study showed that higher 25(OH)D concentrations and lower plasma glucose 
concentrations are associated with more grey matter volume. No associations between 
25(OH)D concentrations and total brain volume or white matter volume were observed. 
Our data do not indicate that the association between serum 25(OH)D and grey matter 
volume is mediated or modified by glucose concentrations. Future prospective studies and 
well-designed randomized controlled trials are warranted to examine whether vitamin D 
treatment could play a significant role in slowing down the progress of brain atrophy.
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Abstract
Background 
Epidemiological studies have shown associations between vitamin D, cognitive 
performance, depression, and glucose homeostasis in older adults. Causal evidence, 
however, is still lacking.
Objective 
The objective of this study was to investigate the importance of vitamin D in the 
prevention of emotional disturbances and cognitive decline in aging C57BL/6 mice, with 
pre-diabetes type II as potential effect modifier.
Methods 
Mice were exposed to one of four diets from 10-24 months of age: low fat vitamin 
D adequate (LFD), low fat vitamin D deficient (LF), moderate fat vitamin D adequate 
(MFD), and moderate fat vitamin D deficient (MF). The MFD/MF diet was applied to 
induce a condition resembling pre-diabetes type II. Behaviour was assessed twice in the 
same group of mice at 6-8 and at 22-23 months of age using the Open Field Test (OFT), 
Elevated Plus Maze (EPM), Object Recognition Test (ORT) and the Morris Water Maze 
(MWM). 
Results 
We successfully induced a vitamin D deficiency in the LF/MF mice. Moreover, fasting 
glucose and fasting insulin concentrations were significantly higher in MFD/MF mice than 
in LFD/LF mice. A significant aging effect was observed for most behavioural parameters. 
A MF(D) diet was shown to delay or prevent the age-related increase in emotional 
reactivity in the EPM. No effect of vitamin D or vitamin D*fat on behavioural outcomes 
was observed.
Conclusion 
Aging significantly affected emotional reactivity and cognitive performance. Although 
other studies have shown effects of vitamin D on emotional reactivity and cognitive 
performance in mice, these findings could not be confirmed in aged C57BL/6 mice in 
this study. 
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9.1 Introduction
Aging is a universally accepted key risk factor for cognitive decline. Recent studies also suggest 
that specific nutritional factors may be linked with brain function, and as such with cognitive 
decline [1] and depression [2]. Since pharmacological treatment of cognitive decline and 
dementia is currently far from effective, knowledge on the effect of modifiable dietary factors 
may bring us a step closer towards preventive solutions. Vitamin D inadequacy is one of the 
suggested modifiable factors for brain dysfunction [3]. Currently, large numbers of mostly 
older adults have a vitamin D inadequacy [4]. Therefore, preventing and/or treating vitamin 
D inadequacy may be a relevant, easy and cost-effective strategy to improve long-term brain 
functioning. Although several observational studies in humans support the notion of a 
beneficial link between vitamin D and cognitive performance [5-10] and depression [11-13], 
other studies do not (for cognition: [14, 15], for depression: [10, 16, 17]). Moreover, evidence 
for a causal relationship from human intervention trials is still limited (for cognition: [18-
22], for depression: [23-27]). 
Studies using rodents as subjects offer more opportunities than human studies to investigate 
causal relationships between vitamin D and brain functions. However, in most studies 
conducted up to now, mice were already vitamin D deficient prenatally or had an inactivated 
vitamin D receptor gene [3]. These models do not mimic the most common clinical 
condition as observed in humans. In humans vitamin D inadequacy usually slowly develops 
over time, mainly because the ability of the human skin to synthesize vitamin D under the 
influence of ultraviolet-B exposure decreases while aging. Thus, alike age-related depression 
and cognitive decline, vitamin D inadequacy in humans often manifests at older age. To our 
knowledge there has not yet been a study that examined the impact of long-term dietary 
vitamin D deficiency on brain functions in aging C57BL/6 mice; a model that more closely 
resembles the clinical condition of vitamin D inadequacy in older adults, and in which the 
physiological consequences and co-existing pathologies can be studied better. 
Various pathways for a role of vitamin D in brain function have been suggested. It has been 
shown that vitamin D stimulates the production of several neurotrophins and acetylcholine, 
reduces oxidative stress, increases phagocytosis and clearance of amyloid β peptide by 
macrophages [3, 28], and interacts with glucocorticoid receptors in hippocampal cell-lines 
[29]. The exact physiological mechanisms underlying possible effects of vitamin D on brain 
function, however, are far from clear. Indirect mechanisms have also to be taken into account. 
There is evidence that vitamin D contributes to the maintenance of glucose homeostasis [30]. 
In accordance, diabetes patients tend to be more prone to develop cognitive deficits than 
non-diabetes patients [31]. Therefore, it has been suggested that vitamin D might indirectly 
affect brain function via this metabolic pathway. Glucose intolerance in mouse models is 
frequently studied by exposing mice to a high fat load. A 60% fat load has for instance been 
shown to result in rapid weight gain and increased fasting glucose and insulin concentrations, 
and insulin insensitivity as measured in glucose tolerance tests [32]. This extremely high fat 
load, however, also adversely affects life expectancy of mice and does not reflect the fat load 
of humans consuming fatty meals. Therefore, the physiological consequences of long-term 
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dietary fat exposure probably can be better studied in a mouse model with a moderate fat 
load. 
The aim of our study was to investigate the effect of long-term adult vitamin D deficiency 
on emotional reactivity and cognitive decline in aging C57BL/6 mice. The potential role of 
glucose homeostasis in the hypothesized relation between vitamin D and brain function was 
examined by studying the effect in mice exposed to a low fat (LF) diet (nine En% from fat) or 
a moderate fat (MF) diet (20 En% from fat). Emotional reactivity was assessed in the Open 
Field Test (OFT) and the Elevated Plus Maze (EPM). Cognitive performance and cognitive 
decline were measured in the Object Recognition Test (ORT) and the Morris Water Maze 
(MWM). 
9.2 Materials and methods
9.2.1 Ethical approval
The experiment was conducted according to the institutional and national guidelines for the 
care and use of animals. The Local Committee for Care and Use of Laboratory Animals at 
Wageningen University approved the experiment (code number: drs-2010123). All effort was 
taken to minimize the number of animals used and their suffering. By contacting researchers 
working in the same field of study, effort was taken to optimally use the tissues of the animals 
subjected to this experiment.
9.2.2 Animals
Seventy-six male C57BL/6j RJ mice were purchased from Janvier Laboratories (Le Genest 
Saint Isle, France). At arrival at the animal facility the mice were five months of age and did 
not show signs of illness or behavioural abnormalities. Until eight months of age all mice 
received a standard chow diet, containing nine En% from fat (low fat diet). From eight 
months of age onwards, following the completion of the baseline behavioural tests, 46 mice 
were randomly allocated to a 20 En% fat diet (moderate fat diet) to provoke a diet-induced 
impaired glucose homeostasis. The remaining 30 mice continued on the low fat diet. At the 
age of ten months, mice in the low fat group and the moderate fat group were rank ordered 
according to body weight and fasting glucose concentrations, and subsequently randomly 
assigned to either a vitamin D adequate diet or a vitamin D deficient diet: 1) Low fat group 
receiving a AIN-93W diet, nine En% fat (LFD) (n=15); 2) Low fat group receiving a vitamin 
D deficient AIN-93W diet, nine En% fat (LF) (n=15); 3) Moderate fat group receiving a 20 
En% fat diet (MFD) (n=23); 4) Moderate fat group receiving a vitamin D deficient 20 En% 
moderate fat diet (MF) (n=23). Mice were weighed once every two weeks. As sensorimotor 
assessment has been shown to be an effective tool to predict health-related drop-out [33], 
general health was assessed every three months using the Horizontal Wire Test, Balance Rod 
Test and Open Field test. At the end of the study, at an age of 24 months, the mice were 
sacrificed and macroscopically examined for pathologies. A laboratory veterinarian monitored 
the study. The timeline of the study is depicted in Figure 1.
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Figure 1. Study design. Note: Mice arrived at the laboratory at an age of five months and were fed a standard 
low fat diet. From eigth months of age onwards 46 mice were randomly allocated to a moderate fat diet to 
provoke a diet-induced impaired glucose homeostasis. At the age of ten months, mice in the low fat group and 
the moderate fat group were randomly assigned to either a vitamin D adequate diet or a vitamin D deficient 
diet. LFD: low fat diet with vitamin D. LF: low fat diet without vitamin D. MFD: moderate fat diet with vitamin 
D. MF: moderate fat diet without vitamin D. 
9.2.3 Housing and test conditions
In order to monitor the dietary intake and to prevent large differences in body weight 
within groups, animals were housed individually. Makrolon® type II cages were cleaned 
every two weeks and contained standard woodchip bedding material. Tissues served as cage 
enrichment. Room temperature and humidity were regulated at approximately 21°C and 
50%, respectively. Mice were held on a reversed 12-hour light/dark cycle. Lights were off 
from 6:00 AM till 6:00 PM. During the mice’s active period red lights were turned on and 
music was played as a background noise to conceal human activities in the lab. During the 
inactive phase, from 6.00 PM – 6.00 AM, there were no activities in the lab and the music 
was turned off. 
9.2.4 Diet
Food and tap water were available at libitum. Food was weighed and refreshed every two 
weeks. Low fat groups were fed a Wageningen variant (AIN-93W) of the AIN-93M diet until 
they were ten months old. The AIN-93M diet is generally accepted as the ‘golden standard’ 
for adult maintenance [34]. AIN-93W is almost similar to AIN-93M diet, with the exception 
that the soybean oil in AIN-93M diet has been partially replaced by palm oil, in order to 
create a diet that is more equivalent to a Western style diet. MF(D) animals were fed an AIN-
93W diet until they were eight months old; from eight to ten months of age, all MF animal 
were switched to an AIN-93W with 20 En% from fat. At the age of ten months, half of the 
mice in the low-fat group (LFD) and moderate fat group (MFD) were switched to a vitamin 
D deficient regimen (LF and MF) containing 0 IU vitamin D3 per gram (Figure 1). The exact 
diet composition of the different diets can be found in the supplementary material (eTable 1).
9.2.5 Biochemical parameters
Glucose homeostasis was assessed via measuring fasting blood glucose concentrations, fasting 
plasma insulin concentrations, and an oral glucose tolerance test (OGTT). Fasting glucose 
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and insulin concentrations prior to the OGTT were determined in samples obtained after 
a 5-6 hour fast. Blood samples were collected by cutting 1-2 mm of tissue from the tail tip 
and then gently massaging the tail. Glucose concentrations were obtained from whole blood 
samples and measured using Accu-Chek hand-held whole-blood glucose devices (Roche 
Diagnostics, Almere, The Netherlands). Plasma insulin was determined using a mouse 
insulin ELISA kit (ALPCO Diagnostics, Salem NH, United States). Following the fasting 
glucose measurement mice received 5 µl of 20% glucose solution per gram body weight via 
a feeding needle in order to determine the glucose response in the OGTT. Blood samples 
were taken at 15, 30, 45, 60, 90 and 150 minutes following the glucose load. Fasting glucose 
and fasting insulin concentrations at the day of sacrifice were determined in arterial blood 
collected by heart puncture using a syringe with EDTA, after 11±1 hours of fasting. During 
the procedure mice were anesthetized with a mixture of isoflurane (1.5%), nitrous oxide 
(70%), and oxygen (30%). Serum 25(OH)D was measured by isotope dilution-online solid 
phase extraction liquid chromatography-tandem mass spectrometry (ID-XLC-MS/MS), 
which was performed at the Endocrine Laboratory of the VU University Medical Center 
(Amsterdam, the Netherlands). Serum was incubated with a deuterated internal standard (IS: 
25(OH)D3- d6), where after  25(OH)D was released from its binding protein(s). Samples 
were extracted and analysed by XLC-MS/MS, a Symbiosis online Solid Phase Extraction 
system (Spark Holland, Emmen, the Netherlands) coupled to a Quattro Premier XE tandem 
mass spectrometer (Waters Corp, Milford, MA). Serum 25(OH)D measurements require 
relatively large sample volumes, specifically 150 µl per sample. Therefore, the 25(OH)D 
concentrations in blood from 17-month-old mice had to be estimated in pooled samples, 
which consisted of equal volumes (25µl) of six randomly selected mice per group. At the 
moment of the sacrifice, larger blood samples could be obtained from each mouse, and as 
such the 25(OH)D concentrations could be determined for each individual mouse. 
9.2.6 Behavioural testing
Setting
To reduce stress due to handling animals were regularly handled after arrival in the lab. One 
month after arrival, at that time mice were six months of age, behavioural parameters were 
measured pre-treatment. The final behavioural measurements started when the mice were 
22-month-old. Behavioural tests were performed according to the expected burden of the 
specific tests, starting with the least stressful tasks: OFT, EPM, ORT and finishing with the 
MWM. The day before the start of the tests, mice were transported to the test room, which 
was about five meters away from their ‘home’ room. Mice were allowed to habituate to their 
new environment for approximately 14 hours before behavioural testing started. The ‘home’ 
and ‘test’ room were similar with respect to the conditions, specifically lighting, temperature 
and humidity. During the testing phase, mice were housed in the test room. Testing mice 
occurred in randomized order, started one hour after the beginning of the dark period and 
was performed under red light conditions. The test equipment was cleaned with a damp 
tissue and dried with a towel after each mouse. 
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Open Field Test
The circular OFT, which is widely used to assess both sensorimotor functioning and 
emotional reactivity [35], was made of grey polyvinyl chloride (PVC) with a 78 cm diameter. 
The surface of the OFT was subdivided in three zones (periphery, middle and center) with 
a width of 13 cm each. Mice were always started from the same point along the wall of the 
open field with their head pointing in the direction of the wall. Behaviour during a five 
minute trial was recorded by a video camera. Total distance moved and the number of times 
entering the center were quantified using the software system Ethovision 3.1. (Noldus IT, 
Wageningen, the Netherlands).
Elevated Plus Maze
The EPM is another validated tool to measure the degree of emotionality [35]. The EPM was 
made of grey PVC and consisted of two open and two closed arms; length 28 cm, width 5 
cm, height closed arms 15 cm. In the center of the four arms there was a squared platform 
of 5x5 cm. The animal was placed in the center of the EPM facing an open arm, having the 
experimenter in the back. Subsequently behaviour was recorded during five minutes and 
analysed using Ethovision 3.1. The number of open arm entries, the time spent in the open 
arms, the percentage of open and closed arm entries and the total number of arm entries were 
key measures in this task. 
Object Recognition Test
Recognition memory was assessed by the ORT [36]. The arena of the ORT consisted of 
a circular field - diameter 48 cm - made of transparent PVC. Objects were placed in a 
symmetrical position about 12 cm from the wall, at a distance of 24 cm from each other. 
Mice were placed in the arena at a standardized point along the wall of the arena always 
facing the wall in front of the experimenter. The first part of the procedure consisted of 
two adaptation days, in which the mice were allowed to explore the empty apparatus twice 
a day for 5 minutes per session. The second part of the ORT included the test day. On the 
test day, the animal underwent two sessions, separated by a retention interval of one hour. 
In the first session the animal was exposed to two identical objects during five minutes. In 
the second session the animal was again placed in the arena for five minutes with a familiar 
object from the first session and a novel object. The time spent exploring the two objects 
during the first and second session were manually registered using a non-commercial software 
program “Object Recognition Task” version 2. Two sets of objects were used, specifically 
small white stones and yellow Lego bricks. Objects met the following requirements: they 
had a comparable height and volume, were too heavy to be replaced by a mouse, were easy 
to clean, and there was no possibility for a mouse to hide under or climb on the objects. 
Habituation, exploration and discrimination were the main parameters measured in this task 
[36]. Habituation was defined as the difference in exploration time between the two sessions 
on the same day, namely exploration time in trial one minus exploration time in trial two. 
Exploration was defined as the time spent exploring both the familiar and new object, namely 
exploration of object one plus exploration of object two. Discrimination was defined as the 
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discrimination between the new and familiar object, that is time spent in exploring the novel 
object minus the time spent in exploring the familiar object. Based upon these measures we 
finally calculated the discrimination index in which we adjusted for total exploration time, 
namely discrimination divided by the total exploration time at both objects.
Morris Water Maze
The MWM test was conducted to measure spatial learning [37]. The MWM was a circular 
pool made of grey PVC with a diameter of 110 cm. The escape platform consisted of grey 
PVC, had a diameter of nine cm and was invisibly hidden at approximately one cm beyond 
the water surface at the north quadrant of the pool. Extra maze cues were placed at two 
of the nearby walls of the testing room. To avoid the negative effects of a decrease in body 
temperature, the water was kept at a constant temperature of 24-26°C. Water was colored 
with non-toxic white paint in order to obtain a clear contrast between the water and the mice 
and to mask the platform position. Mice performed four trials during five daily acquisition 
sessions. In every trial the mouse started from a different starting position, which was pre-
determined by randomization. As soon as an animal succeeded to reach the escape platform 
within the cut-off time of 60 seconds, it was allowed to stay on it for 15 seconds. Thereafter, 
it was removed from the pool and put back in its cage were it was allowed to rest for 15 
seconds, after which the animal was again released into the pool. This procedure was repeated 
four times on each test day. When an animal did not find the escape platform within the cut-
off time, it was placed on the escape platform by hand and stayed on it for 15 seconds. To 
avoid possible olfactory tracks the water was stirred after a mouse completed the test session. 
Moreover, in order to prevent a decrease in body temperature during testing, the cage of the 
animals was placed on a rodent warming pad with a temperature of approximately 37°C 
for ten minutes. In addition, all mice received a new, dry tissue. MWM performance was 
recorded and analysed using Ethovision 3.1.
Morris Water Maze - Probe trial
After completing the fifth testing day in the MWM, a probe trial was conducted in which 
we assessed reference memory [37]. Mice were released into the pool, without the escape 
platform, starting in the south quadrant. During 60 seconds we measured the time spent in 
each quadrant using Ethovision 3.1. Subsequently, we calculated the percentage of time spent 
in the quadrant that initially contained the escape platform. 
9.2.7 Statistical analyses
Analysis of Variance (ANOVA) was used to test whether vitamin D adequate and vitamin 
D deficient mice differed with respect to their serum 25(OH)D concentrations. Similarly, 
ANOVA was performed to test for differences in blood glucose concentrations or plasma 
insulin concentrations between LF(D) and MF(D) mice. Aging effects were tested using a 
paired sample t-test, comparing the results of all mice tested pre-treatment with the results of 
all mice after treatment. Kaplan–Meier survival analysis and Mantel Cox log-rank test were 
used for survival comparisons between the four treatment groups. ANOVA was used to study 
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potential main effects of vitamin D and the type of fat diet and its interaction on the absolute 
change in behaviour in the OFT, EPM, ORT and the MWM. Linear Mixed Models were 
used to assess whether there was a learning curve over test days in the MWM. A P-value of 
<0.05 was used to determine statistical significance. All statistical analyses were performed 
using SPSS Statistics v19 (SPSS Inc. Chicago, IL). 
9.3 Results
9.3.1 Survival and dropout
With survival rates of 87%, 80% and 83% in the LFD, LF and MFD groups respectively, no 
obvious survival differences were observed between these groups. With a survival rate of 59%, 
MF mice did notably though not significantly differ from the LFD (X2=3.0, P=0.08), LF 
(X2=1.2, P=0.27) and MFD (X2=2.6, P=0.11) mice (Figure 2). When reviewing the data of 
the mice that dropped-out during the study and the mice that showed pathologies at necropsy, 
the most frequently observed abnormalities were liver pathologies, followed by abnormal 
coagulating glands and kidney abnormalities (eFigure 1 and eFigure 2). Since the pathologies 
were expected - and in many cases also observed - to interfere with the performance in the 
behavioural tests, the results presented below are based upon the analyses conducted with the 
data of the mice without any sign of underlying illness (n=33), specifically LFD (n=10), LF 
(n=9), MFD (n=8) and MF (n=6). 
Figure 2. Survival per month. Note: Survival 
rates were 87%, 80%, 83% and 59% in the 
LFD, LF, MFD and MF groups, respectively. 
MF mice showed a substantial lower 
survival rate than the LFD, LF and MFD 
mice. Though, survival in MF mice did not 
significantly differ from the LFD (X2=3.0, 
P=0.08), LF (X2=1.2, P=0.27) or MFD mice 
(X2=2.6, P=0.11). LFD: low fat diet with 
vitamin D. LF: low fat diet without vitamin 
D. MFD: moderate fat diet with vitamin D. 
MF: moderate fat diet without vitamin D.
9.3.2 Body weight development 
Mean body weight of the mice in all treatment arms increased until the time of sacrifice at 24 
months of age. As intended, the mice on the MFD/MF diet gained more weight than mice 
receiving a LFD/LF diet. MF mice were on average less heavy when compared to MFD mice 
(Figure 3A).
9.3.3 Serum 25(OH)D concentrations and glucose homeostasis
Serum 25(OH)D analyses at the age of 17 months (data not shown) and at 24 months 
(Figure 3B) showed a clear vitamin D deficiency in mice receiving vitamin D deficient 
diets (F32=388.1, P<0.0001). Moreover, a significant interaction between vitamin D and a 
moderate fat diet in relation to serum 25(OH)D was observed, indicating that mice on a 
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moderate fat diet had higher serum 25(OH)D concentrations than mice on a low fat diet 
(F32=14.1, P=0.001).  In addition, serum 25(OH)D of mice receiving the vitamin D adequate 
diet reached in most cases concentrations ≥50 nmol/L. At sacrifice, mice fed a moderate fat 
diet exhibited higher fasting glucose concentrations (11.4±0.7 mmol/L vs. 9.3±0.7 mmol/L, 
F32=4.1, P=0.05) and higher fasting plasma insulin concentrations (1.9±0.2 ng/mL vs. 
1.5±0.1 ng/mL, F31=4.4, P<0.05) than their low fat counterparts (Figure 3C and Figure 
3D). OGTTs conducted three months before sacrifice did not show a difference in glucose 
response between the four groups (Figure 3E and Figure 3F). 
Figure 3. Body weight development and biochemical characteristics at 21-24 months of age. Note: (A) Body 
weight development of the mice during the study, as shown by the mean with SEM. (B) Serum 25(OH)D 
concentrations at 24 months old. (C) Fasting plasma glucose concentrations at 24 months old. (D) Fasting 
plasma insulin concentrations at 24 months old. (E) Oral Glucose Tolerance Test (OGTT) results at 21 months 
old; blood samples were taken at 15, 30, 45, 60, 90 and 150 minutes following the glucose load of 5 µl of 20% 
glucose solution per gram body weight. (F) Area Under the Curve for OGTT data.
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9.3.4 Aging in relation to behaviour
When comparing the overall mean performance at young age with the overall mean 
performance at old age, it is concluded that aging significantly affected behavioural parameters 
related to exploration and emotional reactivity. At old age, mice travelled significantly less 
far during a five minute trial in the OFT (t32=4.5, P<0.0001), and spent significantly more 
time in the center of the OFT (t32=-2.7, P=0.01) (Figure 4A, Figure 4B and Table 1). In the 
EPM, aging significantly decreased the time spent in the open arms (t32=3.7, P=0.001), the 
percentage of open arm entries (t32=6.0, P<0.0001) and the number of open arm entries 
(t32=6.4, P<0.0001) (Figure 5A, Figure 5B and Table 1). In addition, recognition memory, as 
assessed in the ORT, significantly decreased when comparing mice’s performance at young 
age with the performance at old age (t32=3.5, P=0.001; Figure 6 and Table 1). With respect 
to the MWM, when comparing the Area Under the Curve (AUC) for the escape latency and 
distance moved to platform at young age with the AUC at old age, a significant effect was 
observed for the distance moved to the platform (t32=-2.1, P=0.05), but not for the escape 
latency (t32=-0.31, P=0.76) (Figure 7A, Figure 7B, Figure 7C, Figure 7D and Table 1). At old 
age, mice spent significantly more time in the target quadrant during the probe trial when 
compared to their performance at young age (t32=-6.1, P<0.0001) (Figure 8 and Table 1). 
9.3.5 Vitamin D and impaired glucose homeostasis in relation to behaviour
Exploration and emotional reactivity
In the OFT, there was no significant effect of vitamin D, the type of fat diet or the interaction 
between the two on the total distance moved or the time spent in the center (Figure 4A, Figure 
4B and Table 1). There was also no significant effect of vitamin D or an interacting effect of 
vitamin D with fat on EPM performance. Fat did significantly affect emotional reactivity as 
assessed with the EPM, showing a larger decrease in the percentage of open arm entries in 
LF(D) than MF(D) mice (absolute change ± SEM in MF(D) vs. LF(D) mice: -8±5 vs. -23±2, 
F1,29=9.72, P=0.004) (Figure 5A, Figure 5B and Table 1). Accordingly, the total number of 
arm entries decreased less in the MF(D) than LF(D) mice (absolute change ± SEM in MF(D) 
vs. LF(D) mice: -5±2 vs. -11±2, F1,29=5.31, P=0.03), which was mainly attributable to the 
MFD group that showed a decrease of -2±2 vs. -8±3 in MF mice. Moreover, the decrease in 
the percentage of open arm entries tended to be lower in vitamin D deficient mice than in 
mice receiving a vitamin D adequate diet (absolute change ± SEM in LF/MF vs. LFD/MFD 
mice: -25±11 vs. -41±24, F1,29=3.21, P=0.08).
Recognition memory, spatial learning and reference memory 
We did not observe significant effects of vitamin D, fat or the interaction between vitamin D 
and fat on the adjusted discrimination index in the ORT, but there was a tendency towards 
an vitamin D by fat interaction (F1,29=3.83, P=0.06) (Figure 6 and Table 1). Our treatments 
did also not significantly affect spatial learning (Figure 7A-D and Table 1) or reference 
memory, assessed in the probe trial (Figure 8 and Table 1) as assessed in the MWM. Though, 
the figures of the MWM do suggest a weak tendency for a beneficial effect of vitamin D. 
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Specifically, the absolute increase in time needed to locate the platform tended to be larger 
in vitamin D deficient mice than in vitamin D adequate mice (absolute change±SEM 
in vitamin D adequate vs. vitamin D deficient: -7±7 vs. 10±7, F1,29=2.96, P=0.10). 
Table 1. Behavioural test results at the age of 6-8 and 22-23 months. 
Pre-
treatment
22-23 
months
22-23 
months
Time# Vitamin 
D*Fat*
Vitamin 
D*
Fat*
O
pe
n 
Fi
el
d 
Te
st
Total distance travelled, cm t=4.5,  
P<0.0001
F=0.08, 
P=0.78
F=0.03, 
P=0.88
F=0.33, 
P=0.57
LFD 3737±110 3052±129 3026±216
LF 2926±170
MFD 3018±210
MF 3328±525
Center time, sec t=-2.7
P=0.01
F=0.12
P=0.74
F=0.02
P=0.89
F=0.20
P=0.66
LFD 9±1 13±1 14±1.6
LF 14±2.1
MFD 12±3.3
MF 11±2.6
E
le
va
te
d 
 P
lu
s 
M
az
e
Open arm time, sec t=3.7
P=0.001
F=1.67
P=0.21
F=0.88
P=0.36
F=3.48
P=0.07
LFD 61±6 34±4 25±8
LF 38±5
MFD 32±8
MF 45±13
Open arm entries, % t=6.0
P<0.0001
F=0.20
P=0.66
F=3.21
P=0.08
F=9.72
P=0.004
LFD 35±2 19±2 13±2
LF 21±2
MFD 19±4
MF 26±6
Open arm entries, freq t=6.4
P<0.0001
F=0.13
P=0.72
F=0.17
P=0.68
F=15.8
P<0.0001
LFD 12±0.8 5±0.6 3.3±0.6
LF 5.1±0.6
MFD 5.3±1.3
MF 7.5±2.3
Total arm entries, freq t=5.7
P<0.0001
F=0.05
P=0.83
F=1.82
P=0.19
F=5.31
P=0.03
LFD 34±1.3 26±0.9 26±2
LF 25±1
MFD 26±2
MF 26±3
161
9 9
Note: Values displayed are absolute mean with standard error (SEM). #Degrees of freedom: 32. *Degrees of 
freedom: 29. 
Figure 4. Open Field Test (OFT) performance during a 5-minute trial at 6 (PT) and 22 months old (LFD, LF, 
MFD, MF). Specifically, the total distance travelled and the time spend in the center of the OFT, displayed by the 
mean with SEM. Note: PT: pre-treatment. LFD: low fat diet with vitamin D. LF: low fat diet without vitamin D. 
MFD: moderate fat diet with vitamin D. MF: moderate fat diet without vitamin D.
Pre-
treatment
22-23 
months
22-23 
months
Time# Vitamin 
D*Fat*
Vitamin 
D*
Fat*
O
bj
ec
t 
R
ec
og
ni
ti
on
 
Te
st
Adjusted discrimination index t=3.5
P=0.001
F=3.83
P=0.06
F=0.21
P=0.65
F=0.17
P=0.68
LFD 0.35±0.03 0.21±0.04 0.31±0.08
LF 0.11±0.06
MFD 0.19±0.10
MF 0.21±0.07
M
or
ri
s W
at
er
 M
az
e
Area under the Curve for escape 
latency
t=-0.31, 
P=0.76
F=0.69, 
P=0.41
F=2.96, 
P=0.10
F=0.08, 
P=0.79
LFD 87±4 88±3 83±6
LF 85±8
MFD 95±6
MF 94±8
Area under the Curve for distance 
travelled
t=-2.1, 
P=0.05
F=0.62, 
P=0.44
F=3.55, 
P=0.07
F=0.06, 
P=0.80
LFD 1264±57 1448±64 1362±106
LF 1418±158
MFD 1484±96
MF 1585±166
% in target quadrant during probe trial t=-6.1, 
P<0.0001
F=0.56, 
P=0.46
F=2.01, 
P=0.17
F=0.53, 
P=0.47
LFD 41±2 56±2 60±5
LF 57±5
MFD 55±2
MF 49±5
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Figure 5. Performance in the Elevated Plus Maze (EPM) during a five minute trial at 6 (PT) and 22 (LFD, LF, 
MFD, MF) months old. Specifically, the total time spend in the open arm and the percentage of open arm entries, 
displayed by the mean with SEM. Note: PT: pre-treatment. LF: low fat diet without vitamin D. MFD: moderate fat 
diet with vitamin D. MF: moderate fat diet without vitamin D.
Figure 6. Object Recognition Test (ORT) 
performance at 6 (PT) and 22 (LFD, LF, MFD, 
MF) months old, displayed by the mean with 
SEM of the adjusted discrimination index. Note: 
Discrimination was defined as the discrimination 
between the new and familiar object, specifically 
time spent in exploring the new object minus 
the time spent in exploring the old object. 
Subsequently, this discrimination index was 
adjusted for total exploration time, namely 
discrimination divided by the total exploration 
time. PT: pre-treatment. LF: low fat diet without 
vitamin D. MFD: moderate fat diet with vitamin 
D. MF: moderate fat diet without vitamin D.
Accordingly, a similar pattern was observed when studying the distance travelled before 
locating the platform (absolute change ± SEM in vitamin D adequate vs. vitamin D deficient: 
31±119 vs. 345±123, F1,29=3.55, P=0.07) and reference memory in the probe trial of the 
MWM  (absolute change ± SEM in vitamin D adequate vs. vitamin D deficient: 18±4 vs. 
12±3, F1,29=2.01, P=0.17).
9.4 Discussion
9.4.1 Main findings
Cognitive performance and emotional reactivity of mice at the age of 22-23 months 
- as assessed with the ORT, MWM, OFT and the EPM - significantly differed from the 
performance of the same mice at the age of 6-8 months. Furthermore, a significant effect 
of the type of fat diet was observed on emotional reactivity in the EPM, suggesting that a 
moderate fat diet may prevent or delay the age-related increase in emotional reactivity. This 
study did not provide evidence for an effect of adult vitamin D deficiency on the behavioural 
indices in 22-23 months old C57BL/6 mice.
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9.4.2 Our study in a broader perspective
Laboratory studies have suggested a number of pathways via which vitamin D may 
beneficially affect brain function [3, 28]. When looking into the current literature on studies 
in rodents, it can be concluded that even though the results are mixed [38-42] the majority 
points towards a favorable effect of vitamin D on behaviour [39-42]. When comparing these 
studies, however, it is clear that there are large differences between the applied study designs. 
Three out of five rodent studies were conducted in rats [38, 39, 41] and two in mice [40, 
42]. Whereas four studies intervened by means of a modified dietary regimen [38, 40-42], 
one study intervened with a subcutaneous injection of 42 IU 1,α25(OH)D3 per kg [39]. 
There was also a large variety in the behavioural tests applied. Also physiologically there were 
major differences between the models studied. The age of the behavioural assessment varied 
from 3-20 months, and the duration of the intervention varied from 2-20 weeks. Moreover, 
in two of the studies that observed a vitamin D effect, a very particular neuropathology was 
induced, specifically amyloid plaques deposition [41, 42]. Thus, the mechanisms underlying 
the behavioural deficiencies or changes may differ substantially between the used models, and 
therefore the potential molecular “targets” for vitamin D are model-dependent. As already 
mentioned previously, in this study the aim was to examine the effect of long-term vitamin 
D deficiency on emotional reactivity and cognitive performance in ‘normal’ aging C57BL/6 
mice. In view of the often relatively slowly decreasing vitamin D status with aging in humans, 
we believe that our model more closely resembles the clinical condition of vitamin D
Figure 7. Morris Water Maze (MWM) performance at 7 (PT) and 23 (LFD, LF, MFD, MF) months old. 
Performance was assessed by means of four trails during five daily acquisition sessions; the mean with SEM of 
each daily session is displayed in the figure. Note: (A) Area under the Curve (AUC) for escape latency. (B) AUC 
for distance travelled to platform. (C) Learning curve for escape latency at 23 months old. (D) Learning curve 
for distance travelled to platform at 23 months old. PT: pre-treatment. LF: low fat diet without vitamin D. MFD: 
moderate fat diet with vitamin D. MF: moderate fat diet without vitamin D. 
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Figure 8. Probe trial performance at 7 (PT) 
and 23 (LFD, LF, MFD, MF) months old. Note: Bar 
graph shows the percentage of time spent in the 
target quadrant during a 1-minute trial at the 
end of the fifth test day. PT: pre-treatment. LF: 
low fat diet without vitamin D. MFD: moderate 
fat diet with vitamin D. MF: moderate fat diet 
without vitamin D.
inadequacy and natural aging in older adults than the models that have been described 
previously. However, in future studies the design could be optimized further, for instance 
by reducing the vitamin D content of the food gradually. Such a gradual decrease may even 
more closely mimic the development of vitamin D inadequacy as observed in human aging. 
Groves and colleagues examined the effect of a 10-week vitamin D-deficient diet in 20-week-
old C57BL/6 mice [40], which we consider physiologically most comparable to our design.
The findings in these 20-week-old C57BL/6 mice were in line with the current results, 
specifically no effect of vitamin D was found with regard to behaviour in the EPM, a familiar 
OFT, the hole-board test, the light/dark test, the forced swim test, or the social interaction 
test. Vitamin D deficient C57BL/6 mice did show signs of hyperlocomotion in an unfamiliar 
OFT when compared to their vitamin D adequate counterparts. More robust vitamin D 
effects were observed in the BALB/c strain, showing that deficient mice spent more time on 
the open arms of the EPM and responded faster to heat, sound and shock [40]. However, as 
20-week-old mice cannot yet be considered aged and the period of an absolute vitamin D 
deficiency in these mice was relatively short, Groves and colleagues did not specifically target 
the aging mechanisms related to brain function like we did. This study, however, does suggest 
that BALB/c mice may be more susceptible to vitamin D deficiency than C57BL/6 mice, 
which might advocate the use of BALB/c mice instead of C57BL/6 in future behavioural 
studies on the effect of vitamin D deficiency. When extending our comparison with the 
literature by looking at the behavioural tests used, we saw that three of the five previous 
studies assessed spatial learning using the MWM [39, 41, 42]. All suggested an effect of 
vitamin D on spatial learning. We also assessed spatial learning in the MWM. Our data only 
suggest a weak tendency for a vitamin D effect in the MWM. 
9.4.3 Methodological considerations
Aging
Our longitudinal study showed that age was an important determinant of behaviour. Two of 
these findings warrant clarification. First of all, the finding that old mice spent more time in 
the center of the OFT. This may be explained by the fact that, in view of health monitoring 
throughout the trial, mice had already been exposed to the OFT for five times before the 
final measurements. Thus, whereas the open field at six month of age was a novel open field, 
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at old age the open field had become familiar to the mice, resulting in habituation and hence 
less signs of emotional reactivity. Secondly, although of borderline significance, our results 
showed that the distance travelled towards the platform in the MWM was longer in old mice 
than in young mice, and that probe trial performance improved with age. Stronger age effects 
might have been expected. As shown by previous longitudinal studies, carry-over effects may 
occur when administering the MWM at multiple time points [43, 44]. This may explain the 
modest age effect observed in the MWM in this study. Guidi and colleagues also showed that 
once the reference memory task is learned, animals remain capable to successfully complete 
the task, irrespective of age [43]. As the MWM with varying platform locations did appear 
to be sensitive to detect subtle cognitive changes [43], using this modified version may refine 
future studies. 
Vitamin D deficiency
This study did not provide evidence for a significant effect of adult vitamin D deficiency 
on measures of emotional behaviour (EPM and OFT) or cognitive performance (ORT and 
MWM) in aged mice. Neither did we observe an effect of the type of fat diet in combination 
with vitamin D on emotional reactivity, learning and memory. In order to substantiate 
our conclusion that vitamin D does not seem to play a major role in learning, memory 
and emotional behaviour in aging C57BL/6 mice at the age of 22-23 months, it should be 
evident that the vitamin D status differed sufficiently between the treatment groups. Serum 
25(OH)D measurements in pooled samples collected at seven months after the initiation of 
the vitamin D deficient diet indicated that the concentrations in the deficient group were 
below the detection limit of the assay. Serum 25(OH)D concentrations in the adequate 
groups were around 55 nmol/L, which is considered to be an adequate concentration in 
humans [45]. Measurements in individual blood samples collected at sacrifice showed that 
serum 25(OH)D concentrations were still very low or non-detectable in the deficient mice. 
Thus, these results provide evidence that mice had an absolute vitamin D deficiency for at 
least six months preceding the final behavioural tests, which to our knowledge has never been 
done before. Based upon these data we argue that the difference in vitamin D intake between 
the adequate and deficient group was large enough to show a potential effect of vitamin D on 
brain function and behaviour. Since we did observe weak tendencies for a vitamin D effect 
in the MWM, it might also be postulated that we did not observe an effect of the treatments 
on cognitive decline because brain functions were still too well preserved at 22-23 months of 
age - mice as old as 18-24 months are considered to be comparable to humans at the age of 
56-69 years [46] - resulting in behavioural differences between treatment groups that were 
too small to detect. 
Impaired glucose homeostasis
Another aim of this study was to examine the role of an impaired glucose homeostasis in the 
potential relationship between vitamin D and behaviour. Byrne and colleagues postulated 
that the effect of a vitamin D deficiency might be stronger in the presence of a second 
neurobiological stressor as Parkinson’s disease or brain ischemia [47]. However, we have to 
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conclude that in our study the effect of vitamin D deficiency on behavioural outcomes was 
not stronger in mice with an impaired glucose homeostasis compared to mice with a normal 
glucose tolerance. Our data did suggest that mice with an impaired glucose homeostasis did 
not have an age-related increase in emotional reactivity, whereas mice with a normal glucose 
homeostasis did. We do not have an explanation for this unexpected finding. To induce an 
impaired glucose homeostasis, a subsample of mice in this study were exposed to a moderate 
fat load - a diet where 20% of energy was provided by fat - to mimic the relatively slow 
development of glucose intolerance as often observed at older age in humans. Thus, to reflect 
a more relevant physiological state, the fat load fed in this study was deliberately lower than 
the high fat loads used in previous short-term studies that provoked diet-induced diabetes 
[32]. The moderate fat load appeared to be potent enough to induce a higher weight gain 
and modest differences in fasting glucose and insulin concentrations, which indicates a state 
of impaired glucose homeostasis in MF(D) mice. As there was no significant difference in 
glucose response in the OGTT, it cannot be concluded that the moderate fat diet resulted 
in an impaired glucose clearance. This profile of metabolic changes combined with elevated 
body weight in MF(D) mice mimics a human state which can be described as pre-diabetic. 
However, we feel that the achieved pre-diabetic state was not as strong as we aimed at. To 
increase the impact of a moderate fat diet, future studies might consider the use of a diet 
with a higher fat content, specifically a diet containing 25 En% from fat. However, the rapid 
increase in body weight following the switch to the moderate fat diet as observed in our study, 
does imply that caution is warranted. Besides the fact that a too extensive weight gain may 
result in early dropouts, it may also become a limiting factor in the behavioural assessment.  
Other factors that may have interfered with the relations studied 
As the cognitive and emotional tests involve a clear physical component, it might be argued 
that the results of the behavioural tests are influenced by sensorimotor impairments and 
as such influenced the internal validity of this study. Another factor that may have been 
involved in the relationships studied is hypocalcaemia. Specifically, vitamin D deficiency may 
lead to hypocalcaemia, which has been linked with neuromuscular as well as neuropsychiatric 
symptoms [48]. Unfortunately, serum calcium concentrations have not been measured in 
this study. However, tests of sensorimotor performance and muscle strength - specifically 
the Horizontal Wire Test, the Balance Rod, the Open Field Test as well as ex vivo muscle 
measurements [49] - did not point towards differences between the treatment groups (data 
not shown). Nor did we observe large differences in anxiety related behaviour between 
vitamin D deficient and vitamin D adequate mice. 
Novelty 
During the past decade interest in vitamin D has grown enormously [50]. As vitamin D 
receptors are located on many tissues throughout the body including the brain, vitamin D is 
hypothesized to target a variety of bodily tissues. Likewise, a large number of epidemiological 
observational studies have shown associations linking vitamin D not only to brain health 
but also to cardiovascular disease, fat metabolism, muscle function, and glucose homeostasis 
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[50, 51]. A major issue in many of these human studies, however, is the possibility of reverse 
causation and residual confounding. In randomized clinical trials (RCTs) these factors are 
less likely to disturb the potential relationships studied, and from these studies the effects of 
vitamin D seem to be less clear-cut than they appear from observational studies. A very recent 
review summarized the data of RCTs that studied the effect of vitamin D supplementation on 
a variety of non-skeletal health outcomes in humans, showing no clear vitamin D effect [50]. 
Based on their findings the authors speculate that the discrepancy between observational and 
intervention studies in humans may indicate that low 25(OH)D status is rather a marker of 
ill health than a risk factor of disease. In view of these previous RCTs, our mouse study can 
be regarded as a proof of principle experiment, albeit with a negative result. Thus, despite 
the fact that there are aspects of our study that can be debated, it should be realized that 
this study is unique in its kind. It is the first study that investigated the effect of a one-
year vitamin D deficient diet, and an absolute verified vitamin D deficiency for at least six 
months, on various behavioural parameters related to emotional reactivity and memory in 
natural aging mice. 
9.4.4 Conclusion
This study showed a clear aging effect on various measures of emotional behaviour and 
cognition in male C57BL/6 mice at 22-23 months of age. No large differences in behavioural 
phenotype, as assessed with the OFT, EPM, ORT and MWM, between vitamin D adequate 
mice and vitamin D deficient mice were observed. 
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Supplementary material
sFigure 1. Overview of observed pathological abnormalities during the study (dropout) and at the sacrifice. 
Note: In total 64 pathological abnormalities were observed. In total 43 mice were affected by one or more 
pathological abnormalities and therefore excluded from the analyses.
sFigure 2. Pathological abnormalities during the study (drop-out) and at the sacrifice, stratified according to 
treatment group. 
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sTable 1. Diet composition of the 4 diets. 
Note: Nutrients are displayed in grams, unless specified otherwise.
Ingredients* LFD LF MFD MF
Protein (gram%) 12 12 12 12
Carbohydrate (gram%) 72 72 64 64
Fat (gram%) 4 4 12 12
Casein, lactic 140 140 140 140
L-Cystine 1.8 1.8 1.8 1.8
Corn Starch 447.9 447.9 367.9 367.9
Maltodextrin 100 100 100 100
Dextrose 72.8 72.8 72.8 72.8
Sucrose 100 100 100 100
Cellulose 50 50 50 50
Soybean oil 22 22 40 40
Palm oil 18 18 80 80
Mineral mixture 35 - 35 -
Mineral mixture without vitamin D - 35 - 35
Vitamin mixture  10 - 10 -
Vitamin mixture without vitamin D - 10 - 10

General discussion
Parts of this chapter have been accepted for publication in 
Current Opinion in Clinical Nutrition and Metabolic Care 
as: Vitamin D and cognition in older adults: an update of 
recent findings. Brouwer-Brolsma EM, de Groot CPGM. 
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To contribute to the current state of knowledge, the aim of this PhD thesis was to study 
the role of vitamin D, and its potential interplay with glucose homeostasis, in association 
with cognitive performance and depressive symptoms. Whereas some of our studies suggest 
a potential role for vitamin D in the prevention of cognitive impairment and depressive 
symptoms, others do not. Moreover, our data do not provide evidence for an interplay 
between vitamin D and glucose homeostasis in the association with cognitive performance 
and depressive symptoms. In the following paragraphs it will be addressed how these findings 
fit with the existing literature, whether there is coherence between the different levels of 
evidence, whether the evidence-base on vitamin D and brain health is convincing enough 
to be incorporated once revising the vitamin D recommendations, and what can be done to 
further expand our understanding in this research field. The argumentation in this chapter will 
start off with a paragraph recapping the current vitamin D recommendations, the underlying 
scientific base for these recommendations and some figures related to the adherence to these 
recommendations by older adults.  
10.1 Telling figures on vitamin D deficiency
10.1.1 Current recommendations
In chapter 2 we summarized the outcomes of a vitamin D expert meeting (Ede, 2011) 
that aimed to make a step towards the harmonization of the dietary reference intakes for 
vitamin D across Europe [1]. Following the exchange of recent scientific insights on vitamin 
D relating to a variety of disciplines, it was concluded that the evidence supporting a role for 
vitamin D in bone health is convincing. In addition, it was acknowledged that a substantial 
body of observational evidence suggests that vitamin D may be beneficial for other body 
systems (e.g. muscle, glucose homeostasis, brain, respiratory system). However, trial evidence 
confirming the vitamin D effects on these outcomes was considered insufficient to take into 
account in the revision of the vitamin D recommendations. Furthermore, it was concluded 
that a 25(OH)D concentration of 50 nmol/L can be considered sufficient with respect to 
bone health, and that current evidence is insufficient to conclude that there is an amplified 
beneficial effect of 25(OH)D concentrations that exceed 50 nmol/L. Considering the results 
of dose-response studies on vitamin D, a vitamin D intake of 20 µg/day was assumed to 
assure a 25(OH)D concentration within the optimal range. The outcomes of this expert 
meeting were in line with those proposed by the Institute of Medicine (IOM) [2], but are 
considered conservative by other vitamin D experts [3]. Since 2011 the scientific evidence 
on vitamin D and its possible relation to health effects beyond bone health substantially 
increased. Whether this evidence has implications for the current policy will be discussed in 
paragraph 10.5.
10.1.2 Are the current recommendations met by older adults?
In chapter 3 we explored how well a community-dwelling sample of Dutch older adults met 
the recommendations as set by the vitamin D experts. It was observed that 45% of a population 
of Dutch community-dwelling older adults, aged ≥65 years, had a vitamin D concentration 
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<50 nmol/L. Mean daily vitamin D intake, including dietary sources and supplemental 
vitamin D intake, was 4.9±2.9 µg/day. Only 20% of this population reported the use of 
vitamin D supplements, of which 70% had an adequate vitamin D status. Telling figures, one 
would say, and they do not stand-alone. The Longitudinal Aging Study Amsterdam reported 
a similar prevalence of 25(OH)D inadequacy, namely 46% [4]. With 79% and 53%, even 
higher percentages of vitamin D deficiency were observed in a population of European older 
adults (chapter 4) and pre-frail/frail Dutch older adults (chapter 5). Moreover, our findings 
on vitamin D intake are in line with results of the Dutch Food Consumption Survey that 
was conducted in community-dwelling older adults from 2010-2012. This survey showed 
a median total vitamin D intake of 4.6 µg/day in men and 4.1 µg/day in women; 18% of 
the men and 26% of the women reported the use of vitamin D containing supplements [5]. 
The current level of vitamin D intake, however, may be underestimated [6]. Namely, foods 
may not only contain vitamin D2 and vitamin D3 but also 25(OH)D, a compound that food 
consumption tables do not yet account for. A recent study suggests that taking into account 
25(OH)D in animal-based foods may result in vitamin D intake estimates that are about 
1.7-2.9 µg/day higher than the current estimates [6]. Nevertheless, vitamin D intakes and 
serum vitamin D concentrations are low in a large part of the population and thus action is 
warranted. 
10.2 Evaluating the scientific evidence on vitamin D and brain health in older adults
As concluded by several recommendations setting bodies [2, 3, 7-10] there is convincing 
evidence that vitamin D is important for optimal bone health. However, more evidence is 
needed before conclusions can be drawn on the potential role of vitamin D in other body 
systems, including brain function.
10.2.1 Vitamin D mediated brain processes
Up to now, several biological studies provided evidence that links vitamin D with brain 
function, and new evidence continues to be added. As summarized in chapter 1 many pre-
clinical studies have reported immunohistochemical, biochemical or molecular biological 
findings supporting a role of vitamin D in brain function. Recent evidence adds to this 
that vitamin D may reduce age-related tau hyperphosphorylation [11], nitrosative protein 
damage [12], formation of Aβ oligomers [13], and increase amyloid clearance [13]. The active 
vitamin D metabolite, calcitriol, has also been shown to rebalance inflammation and promote 
Aβ phagocytosis in peripheral blood mononuclear cells (PBMCs) of Alzheimer’s Disease 
(AD) patients [14]. Higher 25(OH)D concentrations have furthermore been associated with 
increased levels of Aβ1-42 in cerebrospinal fluid (CSF) in a cognitively compromised group, 
including patients with Mild Cognitive Impairment (MCI) and AD [15]. In line, vitamin D 
binding protein has been linked with the inhibition of the aggregation and oligomerization 
of Aβ1-42, and attenuation of Aβ-induced neuronal death [16]. In addition to these direct 
pathways, there are also speculations on indirect pathways. Vitamin D has for instance 
been associated with several cardiovascular risk factors [17, 18] that have been postulated to 
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adversely affect brain function [19, 20]. Thus, it may well be that vitamin D affects the brain 
via direct and indirect pathways, including non-vascular and vascular pathways. 
10.2.2 Neuropsychological evidence
Global cognitive performance
Data presented in chapter 4 (SENECA Study) [21] and chapter 5 (ProMuscle Study) 
[22] of this thesis did not show an association between higher 25(OH)D concentrations 
and better global cognitive performance as assessed with the Mini Mental State Examination 
(MMSE). Our data are in contrast with a recent meta-analysis, which shows that participants 
with 25(OH)D concentrations ≥50 nmol/L score on average 1.2 MMSE points higher than 
participants with 25(OH)D concentrations <50 nmol/L [23]. A very reasonable explanation 
for the discrepancy between our findings and the findings of the meta-analysis is a lack of 
power in our studies. Whereas the analyses conducted in chapter 4 and 5 included only 
116 and 127 participants, the meta-analysis was conducted with data of 2749 participants 
[23]. Moreover, although widely used and accepted, the MMSE was originally developed 
to quantify relatively severe cognitive deficits like dementia. As the MMSE scores in the 
SENECA study and the ProMuscle study were relatively high, a low prevalence of dementia 
is assumed. Therefore, the MMSE may not have been sensitive enough to detect cognitive 
differences. Given the relative small sample size and the supposed low prevalence of cognitive 
impairment, it is not expected that an updated meta-analysis including the two studies 
presented in chapter 4 and 5 would demonstrate substantially different results. Domain-
specific cognitive tests have a higher sensitivity to detect cognitive differences than global 
cognitive screening tools, particularly in seemingly healthy populations. During the past 
decade, the research field has therefore gradually shifted from global tasks towards domain-
specific tasks. 
Domain-specific cognitive performance
In chapter 5, it is shown that higher 25(OH)D concentrations linearly associate with 
better executive function and tend to associate with a better information processing speed, 
reported as a cluster of multiple tests, in pre-frail and frail older adults aged ≥65 years [22]. 
Results in chapter 6 indicate that apparently healthy older adults with the upper serum 
25(OH)D quartile have a 51% lower probability of belonging to the 10% of the population 
with the worst attention and working memory as compared to those with the lowest 25(OH)D 
concentrations. Data also suggest a beneficial role for 25(OH)D concentrations in executive 
function and episodic memory, but these associations are not statistically significant. 
Recently, the first meta-analysis was published that evaluated the performance of participants 
with lower versus higher 25(OH)D concentrations on tests related to the domains episodic 
memory, information processing speed, attention and working memory, and executive 
function in older adults [24]. When comparing the performance of participants with lower 
and higher 25(OH)D concentrations, modest differences were observed with respect to 
episodic memory [24]. Moreover, persons with higher 25(OH)D concentrations completed 
177
10 10
the Trail Making Test-A (information processing speed) 4 seconds faster and the Trail Making 
Test-B (mental shifting abilities) 13 seconds faster, and performed significantly better on tasks 
related to information updating than persons with lower 25(OH)D concentrations [24]. 
Prospective data furthermore indicated a 1.25 higher odds of mental shifting impairments 
among people with lower 25(OH)D concentrations [24]. To date, trial evidence is sparse. 
The only randomized controlled trial (RCT) conducted up to now included younger adults 
and did not provide evidence for a vitamin D effect [25]. Evidence from the Women’s Health 
Initiative trial adds that 10 µg/day vitamin D3 in combination with 1000 mg calcium versus 
placebo does not beneficially affect verbal memory, visual memory, mental updating or 
incidence of mild cognitive impairment (MCI) or dementia [26]. Supplements often contain 
both vitamin D as well as calcium, in view of their interplay in relation to bone health. 
However, it has been suggested that the joint administration of vitamin D and calcium 
may be controversial when studying cognitive performance [27], as high serum calcium 
concentrations have been associated with a faster rate of cognitive decline in a population of 
Dutch older adults [28].
Dementia
None of the studies presented in this thesis were conducted in patients with dementia. 
However, several other research groups did perform studies on vitamin D in Alzheimer’s 
Disease (AD) populations. Meta-analysis of seven case-control studies, including 357 AD 
cases and 648 controls, showed that 25(OH)D concentrations were substantially lower in 
AD cases (-1.4 SD) [29]. Studies including older participants were more likely to observe 
significant associations than studies including younger participants. Therefore, it was proposed 
that the null-findings in the ‘young-old’ may be explained by the fact that these ‘young-old’ 
had 25(OH)D concentrations that still met the physiological needs of the brain, while this 
may not have been the case in the ‘older-old’ [29]. Furthermore, comparing untreated AD 
patients with AD patients treated with acetylcholinesterase inhibitors revealed that untreated 
AD patients had significantly lower 25(OH)D concentrations than treated AD patients [30]. 
However, despite these data it cannot be taken for granted that the observed associations are 
causal. In contrast to the hypothesized direction (i.e. low 25(OH)D concentrations adversely 
affect the pathological process in AD), low 25(OH)D concentrations may also be the result 
of altered outdoor behaviour, dietary intake, intestinal absorption and/or metabolism in AD. 
This last aspect can for instance be illustrated by a recent pre-clinical study that revealed that 
β-amyloid could increase calcitriol degradation and suppress VDR expression and as such 
alter vitamin D metabolism [31]. 
Depression
Estimates suggest that about 8-16% of the community dwelling older adults will face a 
depression at least once in their life [32]. These numbers are in line with the estimates in 
the populations studied in this thesis, namely 16% (chapter 4), 8% (chapter 5) and 7% 
(chapter 7). It has been suggested that the prevalence of depression may be lower in people 
with higher 25(OH)D concentrations. However, two small observational studies presented 
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in this thesis did not point towards a significant association between serum 25(OH)D and 
depression. More specifically, in the SENECA study (chapter 4) we observed a trend towards 
less depressive symptoms in participants with higher 25(OH)D concentrations (n=103) [21]. 
In the ProMuscle study (chapter 5) an opposite trend was observed (n=106) [22]. Cross-
sectional data of the B-PROOF study, including almost 3000 participants, provided more 
robust evidence, indicating an association between higher 25(OH)D concentrations and less 
depressive symptoms (chapter 7). 
So, how do these findings fit with the current literature? In chapter 1 an overview is given 
of the different observational studies that have been conducted on the association between 
25(OH)D concentrations and depression in populations of older adults. Based on this 
overview it can be concluded that the findings of the SENECA study and the B-PROOF 
study are more in line with the literature than the findings of the ProMuscle study. 
Recently, also several meta-analyses of observational studies [33, 34] and RCTs [35-37] 
have been published on this topic. Ju et al. (2013) calculated that a 25 nmol/L increase 
in serum 25(OH)D lowers the odds of having depression by 4% (pooled OR using data 
of 11 cross-sectional studies: 0.96 (95% CI 0.94-0.99). The analysis with data of five 
prospective studies provided an OR of 0.92 (95% CI 0.87-0.98) for a 25 nmol/L increase 
in serum 25(OH)D [34]. Subgroup analyses of prospective studies furthermore indicated a 
stronger risk reduction in participants aged ≥60 years (-10%) than in those <60 years (-4%) 
[34]. Although methodological disparities limit the comparison of the magnitude of the 
association, the results by Ju et al. point in the same direction as the meta-analysis conducted 
by Anglin and colleagues [33]. Schaffer and colleagues analysed data of seven RCTs, showing 
a non-significant overall mean difference in depression score of -0.14 (95% CI -0.33 to 0.05) 
in favour of vitamin D supplement use [36]. Limiting the analyses to the two RCTs including 
participants with clinically significant depressive symptoms showed a significant vitamin D 
effect, specifically a mean difference in depressive symptoms of -0.69 (95% CI -1.19 to -0.01) 
[36]. Sensitivity analyses including studies that had the lowest vitamin D concentrations at 
baseline did not suggest a stronger effect in this subgroup [36]. Spedding also conducted a 
systematic review and meta-analysis of RCTs and concluded that the methodological quality 
of the trials was high, but that eight out of 15 RCTs were limited due to shortcomings [37], 
more specifically, not measuring 25(OH)D concentrations, ineffective vitamin D dosing, 
high 25(OH)D concentrations at baseline, and/or vitamin D treatment that decreased 
25(OH)D concentrations [37].
A factor that can be added to this list of points for attention for future studies is the 
assessment of depression. In many studies, including the studies reported in this thesis, self-
report screening tools were used to identify the presence and severity of depressive symptoms. 
Validation studies report a satisfactory sensitivity and specificity of these questionnaires, but 
there are some drawbacks accompanying these tools. Specifically, higher scores indicate higher 
number of depressive symptoms, but some items relate to problems that may also exist in 
the absence of depression. For instance, the Centre for Epidemiological Studies Depression 
Scale (CES-D), used in chapter 5, also contains items on somatic problems (e.g. appetite and 
sleep) [38, 39]. Hence, non-differential misclassification may have occurred, resulting in an 
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underestimation of the associations observed. It has been proposed that the identification 
of depression using a structured clinical diagnostic interview or clinical diagnosis may 
demonstrate stronger estimates [34]. On the other hand, the GDS-15 used in chapter 
4 and 7 of this thesis, does not contain items on somatic concerns and was furthermore 
specifically designed to distinguish depressive symptoms from problems related to cognitive 
decline and dementia [39, 40]. Future studies could be refined, for instance by collecting 
data on depressive symptoms in combination with data of biomarkers for depression [41]. 
Several promising candidate biomarkers for depression have been suggested, for instance 
serum brain-derived neurotrophic factor concentrations, hippocampal volume obtained with 
structural neuroimaging, and glucose metabolism in limbic system as can be measured with a 
PET-scan [41]. It needs to be emphasized, however, that none of these candidate biomarkers 
are sufficiently tested and validated to serve as a diagnostic biomarker [41]. 
Overall it may be concluded that the current evidence is inconclusive, and as Spedding 
(2014) highlights there is a continuous need for well-designed studies to further elucidate the 
effect of vitamin D in depression and mood.
10.2.3 Evidence related to brain volume
Neuropsychological assessment has been the most informative method to differentiate between 
different types of cognitive deficits for ages. However, the field is evolving and due to imaging 
studies we now know that virtually all the cognitive domains relate to the functioning of one 
or more brain regions. In chapter 8 we showed associations between higher 25(OH)D 
concentrations, lower glucose concentrations and larger grey matter volumes. Although the 
current literature includes only a few studies that examined associations between 25(OH)D 
concentrations and structural MRI measures of the brain, these studies appraised a variety 
of brain structures, ranging from total brain volume to volumes of specific brain areas or 
structures (reviewed by Annweiler and colleagues [42]). High 25(OH)D concentrations have 
been linked with less vascular pathologies [43] and smaller ventricle bodies [44], but not with 
volumetric differences of total brain volume, hippocampus, amygdala and parahippocampal 
gyrus [43] or temporal horn volume [44]. Plasma 25(OH)D was beneficially associated with 
white matter volume, and several structures located at the medial temporal lobe (i.e. amygdala, 
thalamus and anterior cingulate gyrus) among 28 people with memory complaints [15]. In 
addition, a study among 92 healthy persons, aged 63±9 years, showed a higher atrophy rate of 
the prefrontal cortex in those with lower 25(OH)D concentrations as compared to those with 
higher 25(OH)D concentrations [45]. In 264 patients with multiple sclerosis, associations 
were observed between more abundant sun exposure and more total brain volume and grey 
matter volume [46]. Interestingly, the association remained after adjustment for 25(OH)D 
concentrations, which may insinuate that it is not vitamin D but another factor resulting 
from sunlight exposure that is responsible for the neuroprotective effect. 
10.2.4 Neuropsychological evidence versus structural MRI data
In chapter 5, we observed an association between 25(OH)D status and executive functioning. 
In chapter 6, 25(OH)D status was associated with attention and working memory. Tendencies 
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towards associations were observed for 25(OH)D status with information processing speed 
(chapter 5), executive function (chapter 6) and episodic memory (chapter 6). 
As vascular dementia is generally accompanied by deficits in executive functioning (i.e. 
mental flexibility, shifting and response inhibition) and modest recall deficits in episodic 
memory [47], our findings may suggest the involvement of a vascular pathway. Neuroimaging 
studies in vascular dementia usually show cerebrovascular pathologies (i.e. infarcts and/or 
white matter lesions), which may affect both grey and white matter [47, 48]. We observed 
associations of lower plasma glucose and higher serum 25(OH)D concentrations with more 
grey matter volume (chapter 8), but no associations between markers of glucose homeostasis 
and white matter volume were observed (chapter 8). We did not yet quantify the degree of 
cerebrovascular disease, or volumes of specific brain structures. To get more insight in the 
underlying pathways additional analyses should therefore focus on measures of white matter 
hyperintensity volume and grade, large vessel infarcts and small vessel infarcts.
AD is primarily a disease of grey matter, and in the first stage predominantly the memory, 
language and visuospatial abilities are affected [49]. Therefore, the association of 25(OH)D 
status with episodic memory and grey matter volume may also imply a pre-clinical stage of 
AD. To further explore this potential pathway, additional analyses should be conducted on 
specific regional brain volumetric measures that are involved in memory, like hippocampal 
volume. In addition, it may be interesting to explore associations between 25(OH)D 
concentrations and molecular biomarkers like plasma Aβ. Nevertheless, it needs to be stressed 
that the predictive value of these blood-based biomarkers for AD is still under investigation 
[50]. 
10.2.5 Where the shoe pinches: challenges in observational vitamin D research
Methodological issues are a common topic of debate in vitamin D research. One of the main 
reasons for lack of strong evidence is related to the fact that many studies up to now have 
been observational, particularly cross-sectional. Here it is where we start talking about the 
chicken and the egg, and what came first. Are low vitamin D concentrations the cause of 
the health issues observed, or do the health issues result in altered behaviours like outdoor 
activities and dietary habits? Insufficient adjustment for known and unknown confounders 
is another acknowledged issue in observational studies, resulting in residual confounding. 
Residual confounding may also have occurred in the studies described in this thesis, for 
instance resulting from the fact that we did not collect extensive data on the presence of 
chronic diseases. As many important methodological aspects have already been discussed 
above and in the previous chapters, they will not be discussed here. Some aspects, however, 
need some more attention and will be discussed below.
Measurement of 25(OH)D concentrations
Tens of vitamin D metabolites have been identified in the circulation [51]. Although vitamin 
D biomarker research is an on-going process [52, 53], 25(OH)D is currently considered 
as being the most optimal biomarker of vitamin D availability in the circulation [52]. 
There is quite some debate on the most optimal method to measure this marker [54]. The 
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Competitive Protein Binding Assay, as used in chapter 4, that was developed in the 70’s is 
at present labelled as having an unacceptable performance [54]. Nowadays, immunoassays 
are frequently used, which are considered to perform satisfactory. However, it has also 
been reported that these assays may have a stronger binding affinity to 25(OH)D3 than to 
25(OH)D2, which may result in misclassification, particularly in populations with a high 
vitamin D2 intake [54]. LC-MS/MS (chapter 3, 5, 6, 7, 8, 9) seems to be equipotent to 
25(OH)D3 and 25(OH)D2 and is currently considered to be the most optimal method to 
determine serum vitamin D status [54]. However, LC-MS/MS has its limitations as well 
(i.e. cross-reacting with 3-epi-25(OH)D3 [55] and less standardized procedures between 
laboratories [54]). Thus, determining serum vitamin D status remains challenging and 
continues to be refined. Differences between 25(OH)D assays hamper the comparison across 
studies, and may also hamper the interpretation of multicentre studies that determined 
vitamin D status at various locations and using different assays. A strength of the multicentre 
studies reported in this thesis is therefore that 25(OH)D concentrations were analysed in one 
central lab facility (chapter 3, 5, 6, 7, 8) using the same analysis method and protocol. 
Seasonal variation
Blood 25(OH)D concentrations are known to fluctuate throughout the year, especially at 
higher latitudes. Therefore, studies collecting samples throughout the year may be biased by 
seasonal variation [56]. Most of the data collected for the research presented in this thesis 
were collected throughout the year (chapter 3, 5, 6, 7, 8). However, we accounted for this 
seasonal variation by incorporating season of blood sampling in the statistical model, which 
is a commonly used approach. In case of studying vitamin D in categories (e.g. insufficient, 
adequate, surplus), one can also account for seasonal variation by creating season-specific or 
month-specific categories. Wang and colleagues (2009) compared the two aforementioned 
methods (i.e. adjustment for season by incorporating season in the model versus creating 
season-specific quartiles) with the true long-term vitamin D concentration. It was shown that 
using quartiles created without taking into account seasonal variation, but adjusted for season 
or month of blood collection, occasionally results in a modest bias away from the null. The 
use of season-specific or month-specific categories, however, did not result in bias away from 
the null and successfully reduced bias toward the null [56]. However, it was also emphasized 
that the approach of season-specific categories is less effective when there are large variations 
in 25(OH)D concentrations. For instance when blood samples are collected throughout the 
year, as in most of the studies presented in this thesis. 
Vitamin D, what else?
As suggested in paragraph 10.2.3, it may also be that the association between 25(OH)D status 
and brain function is explained by other factors that are tightly correlated with 25(OH)D 
status, but not captured by the measurements in our studies. Specifically, besides the fact that 
sunlight activates vitamin D synthesis, there may also be other processes that are activated by 
sunlight exposure. UV has for instance been shown to exert immunomodulary effects that are 
assumed to be independent of vitamin D [57]. In addition, UV-A has been shown to increase 
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nitric oxide concentrations [58, 59], which might be beneficial for neurotransmission as 
long as concentrations do not become too high. (Sun)light also plays an important role 
in the regulation of the circadian rhythm, which relates to the production of melatonin 
and noradrenaline [60]. A disturbed circadian rhythm has furthermore been linked with 
learning and memory deficits in hamsters [61]. In addition, similarly with diet, it cannot be 
expected that factors like vitamin D come in isolation. For instance, fish is a dietary source 
that is naturally high in vitamin D, but fish also contains zinc, selenium and omega-3 fatty 
acids that may be beneficial for brain function [62-64]. Unravelling whether the observed 
associations are actually caused by vitamin D or by one or more closely associated factors will 
be extremely difficult.
Power
Recently, several meta-analyses have been published. Although these analyses included 
relatively few studies, they are important. As the effect of vitamin D, if present, on cognitive 
performance/decline and depression will probably be subtle, combining the results of 
multiple studies may provide datasets that are more powerful to detect potential associations. 
Nevertheless, future meta-analyses can be improved. Many published meta-analyses, including 
those summarized previously, are based on data that are available from published reports, 
or summary data provided by the researchers of the individual studies. Consequently, data 
are often heterogeneous (e.g. in population, sample size, confounders taken into account, 
assessment method of the outcome). Therefore, collecting and combining the individual 
patient data from different studies may result in more detailed analyses and consequently a 
more balanced interpretation of the outcomes [65]. For instance, analyses could be stratified 
for sex, and if data are available, also for markers of glucose homeostasis.
Experimental proof
Many of the aforementioned methodological aspects can be captured in RCTs. However, 
RCTs in vitamin D and mental health research are challenging. Preferably, one would like 
to test the effects in persons that are vitamin D deficient. However, given the recognized 
role of vitamin D in bone health, not supplementing participants with a known vitamin D 
deficiency (i.e. control group) may be considered unethical. Another question relates to what 
dose of vitamin D can be expected to be effective. Additionally, what should be the minimal 
trial duration and during which months should the trial be conducted? To exclude sunlight 
effects, a trial should preferably be conducted during the winter. However, the period to 
induce a supplementation effect is probably longer than one winter season. We should 
furthermore thoroughly think about the method to assess cognitive decline and depression. 
Are the currently used methods sensitive enough to capture the effect of a single nutrient? 
Are there other, more sensitive, outcome measures available? To further study the potential 
vitamin D effect, independent of the commonly experienced limitations in human studies, 
we therefore conducted a proof of principle study in aging C57BL/6 mice (chapter 9). In the 
next paragraph the validity of this animal model is discussed. 
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10.3 Mice as a model for cognitive decline and emotional reactivity: how 
 good are they?
In chapter 9 the effect of a long-term vitamin D deficiency in male C57BL/6 mice was 
studied. Mice were fed a vitamin D adequate or a vitamin D deficient diet for one-year, starting 
at the age of 10 months (±38 years in humans) [66]. At 22/23 months of age (±64/69 years in 
humans) [66] no difference in emotional reactivity, recognition memory, spatial learning and 
reference memory was observed between the vitamin D adequate and vitamin D deficient 
group. Whether the lack of effect in our study has to be contributed to the nonexistence of 
a causal relationship between vitamin D and brain health, and/or methodological issues, can 
be debated. When discussing this study, there is one question that always comes up: “Using 
animal species as a model for human aging, how valid is that?” Undeniably, the best model to 
study human disease is of course the human itself. Due to ethical as well as practical issues, 
however, the human is not always included in the list with optional models. In view of this 
knowledge and as 96% of the genes of men and mice show major resemblances [67], using a 
mouse model may actually be a good solution to get a better understanding of human disease 
processes. Obviously, physiological differences between mice and men do exist and as such 
it is not all moonlight and roses. Van der Staay (2006) wrote: “It is the task of the scientist 
to identify shortcomings of animal models, to refine them, and to develop tools that allow a 
better understanding of the human condition. (…) It is only by identifying the weaknesses 
and errors of models that improvements can be made.” [68] Therefore, this paragraph will 
provide a critical evaluation of the mouse model used in chapter 9, guided by the model 
evaluation approach as proposed by Van der Staay, Arndt and Nordquist [69]. 
10.3.1 Reproducibility
Reproducibility refers to the comparability of a model for the disease being modelled, 
obtained from independent experiments that are similar in methodology and biology. 
Multiple experiments indicate that C57BL/6 mice have a relatively long life-span (e.g. mean 
age of death of males: 26.6 months [70]) and a reasonably low tumour incidence up to 
the third life year [70-72], which suggests that C57BL/6 may be a suitable strain for aging 
research. In addition, several studies have shown age-related impairments in spatial learning 
as measured in the Morris Water Maze (MWM) [73-76] and decreases in explorative activity 
as measured by Open Field Test (OFT) and Elevated Plus Maze (EPM) performance [77, 
78]. Studies on the effect of aging on recognition memory, as assessed with the ORT, are less 
definite [73, 78] and it has been suggested that effects may only be detectable in the oldest-
old [78]. Thus, already several experiments showed that age-related cognitive impairment and 
emotional reactivity can be observed in aging C57BL/6 mice.   
10.3.2 Internal validity
With respect to the internal validity there are two important confounding factors of 
behavioural assessment that need to be considered, specifically motor performance and 
vision. With respect to motor performance it can be reported that in vivo and ex vivo muscle 
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measurements in this study did not point towards significant differences between treated 
and non-treated animals, and therefore it is considered unlikely that differences in motor 
performance affected the internal validity. Another factor that may have confounded the 
behavioural assessment is vision [79]. Although vision was not quantified in our study, no 
differences in the behavioural outcomes were observed between treatment groups. Hence, 
we do not assume that vision confounded the results of our study. Nevertheless, for future 
studies the assessment of vision is recommended.
10.3.3 Face validity
The next question that should be raised is how well the model used in chapter 9 mimics the 
behavioural phenotype observed in cognitive decline and depression in humans. Comparing 
behavioural features of depression and cognitive decline in humans with behavioural 
dysfunction in mice is challenging, and for some aspects even impossible (e.g. mood, feelings 
of worthlessness, concentration problems). Nevertheless, several characteristics of cognitive 
decline and depression in humans have been observed, including age-related working 
memory deficits [76, 80], impairments in spatial memory/executive functioning [73, 74, 76, 
81, 82] and increases in anxiety/depressive symptoms [81, 83]. Thus, face validity has been 
shown for some of the characteristics of cognitive impairment and depression, but not for all. 
However, as argued by others, given the condition being modelled, requiring complete face 
validity is unrealistic [69, 84].
10.3.4 Predictive validity 
With regard to the predictive validity of an animal model Van der Staay, Arndt and 
Nordquist (2009) refer to: “ (…) the extrapolation of the effect of a particular experimental 
manipulation from one species to other species (…)” and “(...) the ability of a drug screening 
or an animal model to correctly identify the efficacy of a putative therapeutic” [69]. As 
already addressed in chapter 1, effective treatment for cognitive decline/dementia is lacking. 
To date, pharmacological treatment in cognitive decline/dementia is symptomatic and not 
curative. Nevertheless, several preclinical studies have shown that the commonly prescribed 
acetylcholinesterase inhibitors [85-87] and NMDA-antagonist memantine [88] in AD patients 
also improve cognitive performance in C57BL/6 mice. Depression is commonly treated with 
antidepressants, which act to increase the availability of serotonin and noradrenalin in the 
brain. Several studies have shown that C57BL/6 mice are also responsive to antidepressants 
as serotonin reuptake inhibitors and selective-noradrenaline reuptake inhibitors [89-91]). 
10.3.5 Construct and aetiological validity
The next aspect of attention in the evaluation of the validity of the animal model is the 
construct and aetiological validity. In view of this criterion two aspects are highlighted: 1) the 
similarity in the potential role of vitamin D in brain functioning in rodents and humans, and 
2) the similarity in mechanisms of age-related cognitive decline and depression as observed 
in rodents and humans. 
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With respect to the first aspect, although evidence is sparse, it seems that there are several 
important similarities in vitamin D metabolism/action in rodents and humans. Specifically, 
resemblances have been shown in VDR distribution in the brain, circulating concentrations 
of vitamin D binding protein and apoptotic properties of calcitriol on brain glial cells. 
Additionally, alike humans, rodents have the ability to synthesize vitamin D under the 
influence of ultraviolet radiation (reviewed in [92, 93]). 
Several parallels in the aetiology of cognitive decline and depression of normal aging 
mice and humans have been suggested as well, including impaired connectivity [76, 94-
96], morphological changes [49, 95] and homology in regions involved in stress, fear and 
depression (e.g. amygdala, hypothalamus, hippocampus) [97, 98]. However, it is also known 
that the normal ageing C57BL/6 mouse, as used in chapter 9, does not spontaneously develop 
plaques and tangles [95]. Hence, the proposed effect of vitamin D to prevent or slow-down 
plaque and tangle formation [13, 14] is not reflected in our model. Several transgenic mouse 
models for studying Aβ – and/or tau pathologies have been developed [95], which could 
be used to address this specific hypothesis in future studies. A comparative study of three 
inbred mice strains, furthermore, indicates that BALB/c and C3H:He mice tend to be more 
susceptible to chronic stress than C57BL/6 mice. Hence, these mouse strains may be more 
suitable to study chronic stress-related pathology like depression than the C57BL/6 strain 
[99]. 
Although many researchers consider construct validity to be the most important criterion 
to evaluate validity, it needs to be emphasized that animal models usually selectively model 
only a subset of the disease symptomatology. It is probably impossible to create a (rodent) 
model that captures all the known features of a specific pathological process. In addition, the 
assessment of construct validity of the aging vitamin D deficient C57BL/6 mouse model is 
restricted by the fact there are still many unidentified aetiological factors. Thus, although the 
current evidence suggests important similarities, there is insufficient evidence to determine 
the construct validity of the aging vitamin D deficient C57BL/6 mouse model. 
10.3.6 External validity
External validity refers to whether the experimental results can be generalized across 
populations, and species. Only a few other studies investigated the impact of a vitamin D 
deficiency developed later in life on behaviour in rodents. In a recent study on adult vitamin 
D deficiency in 16 to 20-week-old Sprague-Dawley rats - receiving a vitamin D deficient 
diet from 10 weeks of age onwards - it was concluded that animals did not exhibit major 
impairments in behaviour, but subtle vitamin D effects seemed to be present as observed in 
tasks of attentional processing [100]. Another study that investigated the effect of a vitamin 
D deficient diet for 10 weeks showed behavioural and neurochemical changes in 20-week old 
vitamin D deficient BALB/c mice, but no convincing patterns in 20-week old C57BL/6 mice 
[101]. Several human studies also examined the effect vitamin D on cognitive processes and 
depression, but - as already summarized earlier in this chapter - the results are inconclusive. 
Overall we conclude that the current evidence-base is insufficient to judge the validity of the 
model used in chapter 9. However, as no notable effects of a long-term vitamin D deficiency 
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on various measures of emotional behaviour and cognition were observed in aged male 
C57BL/6 mice, this study does suggest that there is no causal relationship between adult 
vitamin D deficiency and cognitive decline and depression in C57BL/6 mice. 
10.4 Vitamin D and the brain: A role for glucose homeostasis?
As mentioned in paragraph 10.2.1, vascular risk factors may play a role in the link 
between vitamin D and brain function, including glucose intolerance and diabetes [19, 
102]. Pre-clinical studies and epidemiological studies have associated hyperglycaemia and 
hyperinsulinaemia with macrovascular and microvascular brain changes, increased Aβ 
secretion, decreased Aβ degradation, insufficient energy supply of neurons and significant 
alterations in glucose metabolism in the brain [19, 102]. 
10.4.1 Is there effect modification by the degree of glucose tolerance?
We postulated that vitamin D deficiency makes the brain more vulnerable to other stressors 
[29, 100], like glucose intolerance and diabetes. Byrne and colleagues illustrated this 
hypothesis by referring to a study on vitamin D and post-stroke effects. Mice that had a low 
vitamin D concentration pre-stroke appeared to have a slower and worse recovery after being 
‘hit’ by an experimentally induced stroke than animals that had a vitamin D adequate status 
[100]. However, this ‘second hit’ hypothesis was not supported by the research presented 
in this thesis. Namely, stratification by low and high fasting plasma glucose did not point 
towards substantial differences in cognitive function in Dutch pre-frail and frail older adults 
(chapter 5) [22], or in a population of Dutch older adults with mildly elevated homocysteine 
concentrations (chapter 6). Also, no interaction with glucose homeostasis could be established 
in the association between 25(OH)D concentration and the number of depressive symptoms 
(chapter 8). It needs to be emphasized, however, that the population size in chapter 5 was 
relatively small to conduct stratified analyses. Moreover, data on glucose tolerance used in 
chapter 6 were not obtained completely fasting, as participants were allowed to consume a 
restricted breakfast. In addition, in chapter 9 no interaction was observed between a long-
term adult vitamin D deficiency and a pre-diabetic metabolic state in relation to cognitive 
decline and emotional reactivity in aged C57BL/6 mice. Data in chapter 9, however, are 
limited by the fact that we only induced a modest glucose intolerance, which may not have 
been sufficient to adversely affect brain function in such a way that it is measureable with 
a behavioural test battery. To the best of our knowledge, only one small cross-sectional 
study can be added to our findings. In this study higher 25(OH)D concentrations were 
significantly associated with lower cognitive function in 165 type 2 diabetes patients (<71 
years), independent of age, sex and years of education [103]. However, as this study did 
not include non-diabetics, the interpretation with respect to a potential interaction between 
vitamin D and type 2 diabetes is limited. 
10.4.2 Is there mediation by the degree of glucose tolerance?
Secondly, as vitamin D has been proposed to beneficially influence glucose intolerance, and 
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glucose intolerance and diabetes are considered to be a potential risk factor for cognitive 
decline/dementia and depression, we also hypothesized that an impaired glucose tolerance 
serves as an intermediate in the pathway between vitamin D and brain health. The research 
in this thesis, however, did not provide evidence to support this second hypothesis on the 
interplay between vitamin D and glucose homeostasis. This potential mediation effect of 
glucose homeostasis in the association between vitamin D and mental health has been 
explored in three other observational studies. Data of the European Male Aging Study [104] 
and the InCHIANTI Study [105] did also not support a potential mediation effect of glucose 
in the association between 25(OH)D concentrations and cognitive performance. In the 
NHANES study there seemed to be partial mediation by the presence of diabetes mellitus, as 
incorporation of diabetes in the model slightly attenuated the association [106]. 
Thus, evidence for an interaction or mediation effect by glucose homeostasis in the association 
between vitamin D and mental health can be considered sparse and limited due to several 
methodological constraints. Given the biological plausibility of an interplay between vitamin 
D and glucose intolerance, concomitantly with the limited human studies up to now, it can 
be concluded that further studies on this aspect are needed.
10.5 Vitamin D: hype or high potential? 
In the first paragraph of this discussion an overview is given of the recommendations that 
emerged from an expert meeting that took place in 2011 in Ede [1]. Meanwhile, the scientific 
evidence substantially increased and several reviews and meta-analyses on non-skeletal health 
outcomes have been published [107]. The previous paragraphs have shown that several studies 
point towards a beneficial effect of vitamin D in relation to brain health. Whether the current 
evidence-base is sufficient to conclude that vitamin D is causally related to cognitive decline 
and depression can be evaluated using nine criteria for causality as proposed by Bradford 
Hill (1965) [108]. Below these criteria will be used to summarize the conclusions that can be 
drawn from the evidence resulting from this thesis, as well as the emerging evidence provided 
by colleagues in the field.
 
10.5.1 Bradford-Hill’s criteria for causality
Strength of the association 
The cross-sectional association between 25(OH)D and global cognitive performance has been 
widely examined. A recent meta-analysis suggests a potential beneficial role for vitamin D in 
global cognitive performance, as assessed with a brief screening tool (MMSE) (paragraph 
10.2.2). In addition, despite the limited number of studies, observational evidence on vitamin 
D and domain-specific cognitive performance is promising, especially for tasks related to 
executive function (paragraph 10.2.2). Also several studies, but not all, have shown cross-
sectional associations between 25(OH)D and depression in older adults (paragraph 10.2.2). 
Large heterogeneity in methodologies, however, limit the comparison of the magnitude of 
the associations observed across these studies. 
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Consistency of the evidence 
Whereas several observational studies point towards associations between vitamin D and 
cognitive performance, and depressive symptoms, others do not. Thus, observational data 
are inconclusive, and therefore the current evidence-base does not reach a sufficient level of 
consistency yet. 
Specificity
The etiology of cognitive decline/dementia and depression is undoubtedly complex, and it is 
unlikely that these conditions are the result of one single factor. Most observational studies 
accounted for a substantial number of confounding factors. However, the occurrence of 
residual confounding cannot be excluded.
Temporality 
Reverse causation is a commonly raised concern in the field of vitamin D research. Besides 
the possibility that vitamin D deficiency precedes the onset of functional disabilities, it may 
well be that functional limitations precede the development of vitamin D deficiency. To date, 
prospective studies and RCTs examining the link between 25(OH)D concentrations/vitamin 
D and cognitive performance and depression are sparse. Therefore, the possibility that the 
observed associations are the result of an artefact resulting from reverse causation rather than 
a true biological link cannot be rejected yet. 
Biological gradient 
Most observational studies that observed an association between 25(OH)D status and 
mental health do suggest a dose-response gradient, where higher 25(OH)D concentrations 
associated with a better cognitive performance, less depressive symptoms and larger brain 
volumes. 
Biological plausibility
Up to now, numerous studies provided biological evidence linking vitamin D with brain 
function, and new evidence continues to be added (paragraph 10.2.1). Hence, these studies 
do suggest a role for vitamin D in brain functioning. 
Experimental evidence 
Trials examining the effect of vitamin D on cognitive performance (paragraph 10.2.2), and 
depression (paragraph 10.2.2) in populations of older adults are sparse and the ‘biological 
quality’ of these trials has been questioned. Hence, much more evidence is warranted before 
we can judge on the causality of the association between vitamin D and cognition.
Coherence 
As shown in this thesis, several approaches can be used to study brain health, like pre-clinical 
research (paragraph 10.2.1), neuropsychological research (paragraph 10.2.2) and imaging 
research (paragraph 10.2.3). Mechanistic studies support a role of vitamin D in brain processes. 
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Whereas several observational studies on 25(OH)D concentrations that studied either 
cognitive function, depression or brain volumetric measures show promising associations, 
others do not support that evidence. Only a few animal and human trials examined the effect 
of low vitamin D concentrations on cognitive function; results are inconclusive. 
Analogous evidence
As already discussed previously (paragraph 10.2.5), it is likely that 25(OH)D status is 
correlated with other factors that result from exposure to sunlight, and these correlated 
factors may be beneficial for brain functioning independent of the vitamin D synthesis in the 
skin. As vitamin D obtained from dietary sources does also not come in isolation, for vitamin 
D intake the same idea applies. Studies aiming to untangle the effect of vitamin D from other 
potentially correlated factors are therefore warranted. 
10.5.2 Conclusions
Thus, it can be concluded that the evidence-base to recommend vitamin D supplementation 
in order to enhance cognitive performance, slow down cognitive decline and brain atrophy, 
or prevent/counteract depression is currently insufficient to justify the revision of the vitamin 
D recommendations. However, given the established role of vitamin D in bone health and 
the high prevalence of vitamin D deficiency, we do call for dietary strategies to increase 
vitamin D intake, particularly during the winter months. Although there are probably a 
limited number of options to counteract vitamin D deficiency in the general population, 
several dietary strategies have been put forward, that is promoting the intake of food products 
that are naturally high in vitamin D, increasing the number of foods fortified with vitamin 
D, and encouraging supplemental vitamin D intake [109]. 
10.6 Future perspectives
Thus, founded on the current evidence-base it can be concluded that there is a continuous 
need for well-designed prospective observational studies and RCTs. We all know that this is 
easier said than done. Throughout this discussion several suggestions for refinement of studies 
have been given; they are summarized in the box on the next page. In short, the prevalence 
of vitamin D deficiency is high, which is concerning given the known effects of vitamin D 
on bone health. It should be examined how the effectiveness of strategies aiming to ensure 
an adequate vitamin D status can be improved. In addition, in the design of future studies, 
we must pay more attention to the biology of the associations studied. For instance, trials in 
populations that have an adequate vitamin D status, or do not show any variation in outcome 
measures studied, are unlikely to provide conclusive evidence. Furthermore, prospective 
studies and trials are needed to replicate previous data and subsequently, individual patient 
data meta-analyses should provide us with the cherry on the pie. We also need to continue 
research on potential underlying mechanisms. This could for instance be via including 
parameters that are related to vascular brain health and by including biomarkers of Alzheimer 
pathology, and depression. To adequately address vitamin D related mechanisms that 
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cannot be studied in humans, (aging) models of vitamin D deficiency should be developed, 
systematically evaluated, and, if considered valuable, further refined.
Suggestions for future research
• The high prevalence of vitamin D deficiency calls for research on effective approaches 
to ensure an optimal vitamin D status. 
• More evidence is warranted to establish whether the current vitamin D 
recommendations cover the optimal concentrations needed for brain health. Thus, 
there is a continuous need for prospective and well-designed randomized controlled 
trials.
• To provide more conclusive data, results of individual studies should be combined in 
individual patient data meta-analyses.
• Dose-response analyses (observational) and designs (trials) are warranted to 
establish the optimal 25(OH)D concentrations for brain health (if causality exists).
• In the design of trials one should thoroughly consider the target population. For 
instance: What should be the maximum 25(OH)D concentration at the time of 
inclusion? Is the expected variation in the level of cognitive performance and/or the 
prevalence of depressive symptoms in the population sufficient to expect/measure 
an effect?
• Although diagnostic biomarkers of cognitive impairment and depression are lacking, 
the use of biomarkers may be helpful to corroborate neuropsychological findings 
and to generate hypotheses on the underlying pathways.    
• It might also be interesting to further explore the vascular hypothesis in the 
association between vitamin D and brain health, for instance by including measures 
of white matter hyperintensities and infarcts. 
• To further explore the potential role of vitamin D in AD pathology, it may be 
valuable to include measures on for instance hippocampal volume and CSF/blood-
based biomarkers like Aβ. 
• Examining associations between common single-nucleotide polymorphisms (SNPs) 
related with 25(OH)D concentrations and disease outcomes highlights another 
potential interesting field of study (chapter 3 and chapter 7).
• To further study the underlying vitamin D pathways in brain function, currently used 
animal models should be critically evaluated for their relevance. For example, for 
the C57BL/6 mouse the question whether there is sufficient comparability in the 
vitamin D mediated mechanisms when compared to ‘the human being’ is still largely 
unanswered.
• Finally, as vitamin D status may be closely linked with other factors resulting from 
sunlight or diet it may be valuable to think about study techniques to disentangle 
these factors. 
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According to recent estimations approximately 35.6 million people have dementia worldwide. 
Globally, 350 million people experience one or more depressive episodes during their life. 
As the therapeutic options for dementia and depression are limited, these conditions form 
a major challenge for public health and society. More and more researchers have initiated 
research on potential preventive factors for dementia and depression, including the potential 
effects of nutritional factors. The aim of this PhD-project was to study the role of vitamin D 
and its potential interplay with glucose homeostasis, in the development of cognitive decline 
and depression, using epidemiological data as well experimental animal data.
Chapter 2 recapitulates a debate between vitamin D experts that was organized to make a 
step towards the harmonization on the formulation of optimal vitamin D intake levels and 
serum 25(OH)D concentrations across Europe. It was concluded that based on the current 
evidence-base 25(OH)D concentrations ≥50 nmol/L are sufficient with respect to optimal 
bone health. For health outcomes beyond bone health evidence was considered insufficient 
to formulate optimal levels. In order to achieve and maintain a 25(OH)D concentration ≥50 
nmol/L, older adults aged ≥65 years were recommended to adhere to a vitamin D intake of 
20 µg/day.
Chapter 3 shows that there is a high prevalence of 25(OH)D inadequacy in a population 
of Dutch older adults that participated in the B-PROOF study (n=2857), namely 45% had 
25(OH)D concentrations <50 nmol/L. Mean vitamin D intake was 4.9±2.9 µg/day and only 
20% of the participants reported to use vitamin D containing supplements. Exploration 
of the determinants of 25(OH)D status showed significant associations between vitamin 
D ‘raising’ SNPs (n=2530), higher sun exposure (n=1012), vitamin D intake (n=596) and 
higher 25(OH)D concentrations. Including all the potential relevant and measured predictors 
in one model explained 35% of the variance in 25(OH)D status (R2=0.35).
In chapter 4 the associations between 25(OH)D status and global cognitive performance 
(n=116), depressive symptoms (n=118), and surrogate markers of glucose intolerance (n=593) 
were evaluated using data of European adults aged 70-75 years. None of the associations 
reached significance. 
Studying the potential role of vitamin D in domain-specific cognitive performance and 
depression in 127 Dutch pre-frail and frail older adults aged ≥65 years (chapter 5), showed 
an association between 25(OH)D concentration and executive functioning, and a tendency 
towards an association with information processing speed. Stratification for ‘low’ and ‘high’ 
fasting glucose concentrations did not suggest an interaction between vitamin D and glucose 
homeostasis in the association with domain-specific cognitive performance. Moreover, adding 
fasting glucose or insulin did not substantially influence the associations between 25(OH)D 
status and domain-specific cognitive performance, and hence a mediation effect of glucose 
homeostasis was considered unlikely.
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We furthermore observed associations of 25(OH)D status with attention and working 
memory (n=787) (chapter 6), depression (n=2839) (chapter 7) and grey matter volume 
of the brain (n=217) (chapter 8) in a population community-dwelling Dutch older adults 
aged ≥65 years. Again, these studies did not provide evidence that the associations were 
modified or mediated by glucose intolerance. However, it should be emphasized that glucose 
intolerance in these three chapters was defined sub-optimally, specifically using blood samples 
that may have been collected in a non-fasting state, or by using self-reported diabetes data. 
Hence, the mediation and interaction effects should be interpreted cautiously.
Finally, chapter 9 shows the results of a proof of principle study on the effect of a long-term 
vitamin D deficiency on cognitive decline and emotional reactivity in old C57BL/6j mice. 
Modest tendencies were shown for a relation between vitamin D and spatial learning, but 
these tendencies did not reach significance. Vitamin D deficiency did not affect recognition 
memory, spatial memory or emotional reactivity. Mice that received a higher dietary fat load, 
which was given to induce an impaired glucose tolerance, did not respond differently to a 
vitamin D deficiency than mice that received a low fat diet did.
Overall, it is concluded that the evidence for an effect of vitamin D on cognitive performance/
decline, depression or brain volume is insufficient to formulate disease specific cut-off values 
for vitamin D intake or 25(OH)D status. However, given the high prevalence of 25(OH)D 
concentrations <50 nmol/L we do call for a more active promotion of the current vitamin D 
intake recommendations.

Samenvatting
S A M E N VAT T I N G
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Volgens recente schattingen zijn er wereldwijd ruim 35 miljoen mensen met dementie. Daarbij 
maken circa 350 miljoen mensen minimaal eens in hun leven een depressieve periode door. 
De behandeling van dementie richt zich momenteel met name op symptoombestrijding; 
een curatieve behandeling is helaas nog niet voor handen. Depressies kunnen effectiever 
behandeld worden, maar deze behandeling gaat regelmatig gepaard met vervelende 
bijwerkingen en/of treedt er op termijn toch weer recidief op. Onderzoek naar factoren die 
een bijdrage kunnen leveren aan de preventie van deze aandoeningen is daarom belangrijk. 
Het doel van dit promotieproject was om te onderzoeken of vitamine D - ook wel bekend 
als de zonlichtvitamine - van belang kan zijn voor de preventie van dementie en depressie. 
Ten tweede wilden we weten of glucose homeostase een rol speelt in deze veronderstelde 
associaties. Om meer inzicht te krijgen in deze processen hebben we in het kader van dit 
promotietraject zowel epidemiologisch als dierexperimenteel onderzoek uitgevoerd.
Hoofdstuk 2 geeft een overzicht van de resultaten van een bijeenkomst van vitamine 
D experts. Het doel van deze bijeenkomst was om inzicht te krijgen in de huidige 
wetenschappelijke stand van zaken omtrent de rol van vitamine D in relatie tot gezondheid 
en ziekte, en om te bediscussiëren of het op basis van deze informatie mogelijk is om een 
gezamenlijke Europese richtlijn op te stellen aangaande de optimale vitamine D inname 
en vitamine D waarde in het bloed. De experts stelden dat er voldoende wetenschappelijk 
bewijs is om te concluderen dat een serum/plasma vitamine D niveau van ≥50 nmol/L van 
belang is voor de botgezondheid. Voor andere gezondheidsuitkomsten, zoals bijvoorbeeld 
spierfunctie, cognitieve functie en diabetes, is er onvoldoende wetenschappelijk bewijs om 
een afkapwaarde te definiëren. Om een serum/plasma vitamine D niveau van ≥50 nmol/L te 
bereiken en te behouden luidt het advies voor ouderen met een leeftijd van ≥65 jaar om te 
streven naar een vitamine D inname van 20 µg/dag.
In hoofdstuk 3 zien we dat 45% van een Nederlandse ouderen populatie (n=2857) een 
serum vitamine D niveau heeft dat onder de 50 nmol/L grens ligt. De gemiddelde vitamine 
D inname in deze populatie was 4.9±2.9 µg/dag; slechts 20% van de deelnemers rapporteerde 
gebruik te maken van supplementen die vitamine D bevatten. Deze onderzoeksgegevens 
toonden verder aan dat het serum vitamine D niveau significant hoger is in deelnemers met 
bepaalde vitamine D gerelateerde single nucleotide polymorphisms (SNPs) (n=2530), een 
hogere mate van zonlichtblootstelling (n=1012) en een hogere vitamine D inname (n=596). 
Met behulp van regressie analyse met alle mogelijk relevante en gemeten determinanten van 
vitamine D status bleken we 35% van de variatie in vitamine D status te kunnen voorspellen 
(R2=0.35).
In hoofdstuk 4 zijn de mogelijke associaties tussen vitamine D status en cognitief 
functioneren (n=116), depressieve symptomen (n=118) en markers voor glucose tolerantie 
(n=593) onder de loep genomen. Voor deze analyses is gebruikgemaakt van data afkomstig 
van een Europees ouderen  cohort (leeftijdsrange: 70-75 jaar) genaamd de SENECA studie. 
Geen van de associaties in deze studie behaalde het statistische significantieniveau. 
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Bij het bestuderen van de associatie tussen vitamine D en domein specifieke cognitieve functie 
in een groep van 127 kwetsbare Nederlandse mannen en vrouwen ≥65 jaar (hoofdstuk 5), 
bleek serum vitamine D wel significant geassocieerd te zijn met het cognitieve functioneren, 
namelijk het executief functioneren. Een bijna significante associatie werd geobserveerd tussen 
serum vitamine D en informatieverwerkingssnelheid. Stratificatie duidde niet op belangrijke 
verschillen in de associaties tussen serum vitamine D en cognitief functioneren bij mensen 
met ‘lage’ of ‘hoge’ nuchtere glucose waarden, hetgeen suggereert dat verschillen in glucose 
homeostase geen of weinig invloed hebben op de bestudeerde associaties in deze populatie. 
Ook wanneer nuchter glucose en nuchter insuline als co-variabele werden toegevoegd aan 
het statistische model had dit geen of slechts een geringe invloed op de uitkomsten van 
dit onderzoek, hetgeen verder suggereert dat deze variabelen niet fungeren als belangrijke 
intermediairs in de bestudeerde associaties.
Vitamine D status bleek ook significant geassocieerd te zijn met het cognitieve domein 
aandacht en werkgeheugen (n=787) (hoofdstuk 6), depressie (n=2839) (hoofdstuk 7) en 
het grijze stof volume van de hersenen (n=217) (hoofdstuk 8) in een groep Nederlandse 
ouderen in de leeftijdscategorie van 65 jaar en ouder. Ook in deze studie was er geen bewijs 
dat de associaties substantieel beïnvloed werden door verschillen in glucose homeostase. 
Het moet echter wel genoemd worden dat glucose homeostase in deze onderzoeken niet 
op een optimale wijze gedefinieerd is; ofwel is er gebruik gemaakt van zelfgerapporteerde 
data, ofwel is er gebruik gemaakt van bloedmonsters die mogelijk zijn afgenomen terwijl 
mensen een licht ontbijt geconsumeerd hadden. Het mag daarom duidelijk zijn dat we deze 
gegevens met betrekking tot de rol van glucose homeostase met enige voorzichtigheid dienen 
te interpreteren.
Tot slot, in de studie gepresenteerd in hoofdstuk 9 is onderzocht of een algehele en langdurige 
vitamine D deficiëntie invloed heeft op de cognitieve achteruitgang en emotionaliteit 
van oude C57BL/6j muizen. De conclusie van dit onderzoek is dat vitamine D geen tot 
weinig invloed lijkt te hebben op cognitieve achteruitgang en emotionaliteit in deze dieren. 
Mogelijkerwijs heeft vitamine D enigszins een effect op het ruimtelijke leervermogen, maar 
de geobserveerde trends waren niet statistisch significant. Muizen gevoed met een gematigd 
vet dieet (20 En% vet), met als doel het induceren van een glucose intolerantie, reageerden 
cognitief en emotioneel niet anders op het vitamine D deficiënte dieet dan de met laag vet (9 
En% vet) gevoede muizen.
Samenvattend kan geconcludeerd worden dat er momenteel onvoldoende bewijs is om te 
kunnen stellen dat vitamine D van belang is voor de gezondheid van ons brein. Het is daarom 
nog te vroeg om ziekte specifieke afkapwaarden te formuleren voor vitamine D in relatie 
tot cognitieve functie en depressie. Echter, gezien de hoge prevalentie van serum vitamine 
D waarden <50 nmol/L en de bewezen rol van vitamine D in relatie tot de botgezondheid, 
adviseren we wel om meer aandacht te besteden aan de promotie van de huidige vitamine D 
aanbevelingen.
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Overview of completed educational activities
Discipline specific activities
• Conference: Nutrition for the Ageing Brain (Milan, Italy, 2014)
• Conference: Vitamin D and Human Health (London, United Kingdom, 2014) 
• Conference: AgeingResearch@NL (Rotterdam, The Netherlands, 2013) 
• Conference: Gezonde voeding, gezond ouder worden (Wageningen, The Netherlands, 2013) 
• Course: Synapses, Neurons and Brains, www.coursera.org, 2013  
• International Conference on Nutrition and the Brain (Washington, United States, 2013)
• Alzheimer's Association International Conference (Boston, United States, 2013) 
• Workshop: Introduction Canoco (Wageningen, The Netherlands, 2013) 
• 11th Dutch Endo-Neuro-Psycho Meeting (Lunteren, The Netherlands, 2013) 
• International Conference on Aging & Cognition (Dortmund, Germany, 2013) 
• Masterclass: Longitudinal data analysis (Wageningen, The Netherlands, 2013)  
• Masterclass: Analysis in R (Wageningen, The Netherlands, 2012)  
• Conference: Annual NWO nutrition days (Deurne, The Netherlands, 2011) 
• Vitamin D expert meeting (Ede, The Netherlands, 2011)  
• 4th International Congress on Prediabetes and the Metabolic Syndrome (Madrid, Spain, 2011) 
• Course: Epigenesis & Epigenetics (Wageningen, The Netherlands, 2011) 
• Course: Nutrition and Lifestyle Epidemiology (Wageningen, The Netherlands, 2010) 
• Masterclass: Linear and logistic regression (Wageningen, The Netherlands, 2010)  
• Course: Laboratory animal science, article 9 (Wageningen, The Netherlands, 2010) 
        
General activities
• Course: Career perspectives (Wageningen, The Netherlands, 2013)  
• Course: Scientific Writing (Wageningen, The Netherlands, 2013)
• Course: Wet- en regelgeving van klinisch onderzoek (Ede, The Netherlands, 2011)
• Course: Supervising MSc-students (Wageningen, The Netherlands, 2011)  
• Workshop: How to write a world-class paper (Wageningen, The Netherlands, 2011) 
• Workshop Mindmapping (Wageningen, The Netherlands, 2011)  
• NWO talent day: onderhandelen en netwerken (Utrecht, The Netherlands, 2010) 
• VLAG PhD-week (Venlo, The Netherlands, 2010)     
 
Optionals
• Preparation research proposals      
• Literature study program Oldsmobiles/Paperclip/EPIC, 2010-2014, Wageningen 
• PhD study tour, Mexico / United States, 2011 
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